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Chapter 1 2
Chapter 1: Introduction
1. The genetic basis of leukaemogenesis
1.1. General aspects of leukaemia
Haematopoiesis is the formation of different types of blood cells, and is essential for the
development and survival of a normal individual. Despite the extreme structural and functional
differences among blood cells, strong evidence exists that all of the blood cells are the progeny
of a single type of cell, the haematopoietic stem cell. These haematopoietic stem cells proliferate
to produce more stem cells or differentiate into myeloid or lymphoid progenitors and further
along the line produce mature erythrocytes, platelets, granulocytes, monocytes, B and T
lymphocytes (Figure 1). Abnormalities in the normal developmental program for blood cell
formation result in haematological diseases including leukaemia.
Figure 1: The haematopoietic system: from pluripotent stem cell to mature erythrocytes,
platelets, monocytes, granulocytes, B- and T-lymphocytes
In the case of leukaemia, certain blood cell types are abnormally expanded. This is due to altered
growth, maturation stop and deficiency of apoptosis. Historically, leukaemias have been broadly
divided according to the progression of the disease into (1) acute leukaemia, which without
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treatment is fatal within weeks or months, and (2) chronic leukaemia, which is less aggressive
and generally associated with longer survival. Further classification is based upon the
haematopoietic cell in which the leukaemic transformation occurred, with differentiation between
myeloid, lymphoid and plasma cell leukaemia.
In acute leukaemias there is both an increase in the number of circulating blast cells and a defect
in their normal maturation and function. However, some ‘pre-leukaemic’ haematological disorders
display either only growth expansion (myeloproliferative syndromes) or stop of differentiation
(myelodysplasia). Yet, progression to acute leukaemia occurs in these haematological
malignancies, and is associated with both differentiation block and excess of growth (Sawyers et
al., 1991).
1.2. Chromosomal defects as a hallmark of cancer
Theodor Boveri was the first who proposed in 1914 the concept of chromosomal instability as a
cause of abnormal growth and cancer, and postulated the existence of ‘growth-stimulatory
chromosomes’ and ‘inhibitory chromosomes’ (Boveri, 1914). Boveri’s theory was based upon his
observation that sea-urchin eggs with mitotic abnormalities showed abnormal growth.
More detailed insights into the genetic basis of cancer were obtained in the 1950s and 1960s,
when improved cell culture and slide preparation techniques made it possible to accurately
enumerate the number of human chromosomes as 46 (Tjio and Levan, 1956). During this period,
it was demonstrated that the chromosomes of cancer cells were often abnormal: some
chromosomes were present in three or four copies, whereas others had structural abnormalities
(Levan, 1967). These chromosomal abnormalities assumed particular importance when some
were recognised to occur regularly in certain types of cancer. Such regularity implies that genes
affected by these rearrangements might be instrumental in the genesis of the associated
tumours. The discovery of a small aberrant chromosome, called Philadelphia chromosome, in
patients with chronic myeloid leukaemia was proverbial in this respect (Nowell and Hungerford,
1960).
A second major breakthrough in cytogenetics was the development of microscopic staining
techniques, generating a banding pattern along the length of the chromosomes (Caspersson et
al., 1970). With this banding pattern, all individual chromosomes could be identified and
structural changes could be characterised in much greater detail. From then on, chromosome
rearrangements such as translocations and inversions, deletions and insertions could be readily
detected, as well as homogeneous staining regions (hsr) and small extrachromosomal elements
(dmin). Further increase of resolution of cytogenetic analysis was obtained through cell cycle
synchronisation of short term cultures which produced less contracted (pro-)metaphase
chromosomes with improved morphology (Yunis, 1976).
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The development of the recombinant DNA technology in the early 1970s, opened the way to the
study of genes and the regulation of their expression in cancers (Turkington, 1972; Bishop, 1987;
Friend et al., 1988). A revolutionary series of DNA transfection experiments provided the first real
evidence of a causal role for genetic alterations in cancer (Shih et al., 1979). Varmus and Bishop
reported the discovery of proto-oncogenes defined by dominant gain of function in cancer
(Stehelin et al., 1976; Bishop, 1981). The evidence for the existence of tumour suppressor genes
was derived from the observation that some tumour types, i.e. retinoblastoma occurred both in a
sporadic and a hereditary form. On the basis of epidemiological analyses of the age-specific
incidences, Knudson reported the two hit hypothesis needed for loss of function of tumour
suppressor genes, which results in the development of retinoblastoma (Knudson, 1971). Cavenee
and co-workers proved Knudson’s hypothesis by demonstrating the loss of the tumour suppressor
gene at the RB1 locus in retinoblastoma cells (Cavenee et al., 1983).
Now more than 20 years later, general patterns of genetic abnormalities leading to distortions of
cellular pathways controlling normal cell behaviour, are emerging. Essentially, cancer occurs
when gene alterations (mutations) distort the various normal controls in the cell, resulting in
invasive growth. It is believed that cancer is the result of at least six essential alterations in cell
physiology: i.e. self sufficiency in growth signals, insensitivity to anti-growth signals, evading
apoptosis, acquired invasive and metastatic properties, limitless replication potential, and
sustained angiogenesis (Hanahan and Weinberg, 2000). The genes involved in these processes
include cellular oncogenes, tumour suppressor genes, DNA mismatch repair genes, and genes
associated with cell ageing or apoptosis.
2. Cytogenetic analysis in haematological malignancies
2.1. The role of cytogenetic analysis in basic research of leukaemogenesis
The impact of cytogenetics is highly significant in basic research of haematological neoplasms.
The identification of chromosomal breakpoints involved in specific chromosome aberrations
indicates the position of the genes that as a result of chromosomal rearrangements are important
in leukaemogenesis. Thus, cytogenetic analysis is often the first step towards the identification of
leukaemia-associated genes, and has to be followed by candidate gene approaches, or positional
cloning strategies. This scientific knowledge is further used to design molecular or molecular
cytogenetic analyses used in diagnosis and follow-up of the patients. Basic research of recurrent
rearrangements further provides intriguing clues about the molecular events underlying
leukaemogenesis. The cloning and functional analysis of genes whose structure or expression is
altered as a result of chromosomal rearrangements is yielding unprecedented insights into the
mechanisms of neoplastic transformation and normal cell function and development.
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2.2. The role of cytogenetics in the diagnosis, prognosis and treatment of
haematological neoplasms
Early observations showed that many leukaemic subtypes are associated with specific cytogenetic
changes. As an increasing number of leukaemia patients underwent cytogenetic analysis, it
became apparent that the chromosome abnormalities were useful diagnostic and prognostic
indicators. An extensive list of publications documents the prognostic significance of recurrent
chromosomal abnormalities in acute myeloid leukaemia (AML), acute lymphoblastic leukaemia
(ALL), myelodysplastic syndrome (MDS), chronic myeloid leukaemia (CML) and chronic
lymphocytic leukaemia (CLL) (for reviews see: Faderl et al., 1998; Pui and Evans, 1998; Faderl et
al., 1999; Lowenberg et al., 1999; Rowley, 1999; Sawyers, 1999; Dohner et al., 2000; Rossi et
al., 2000).
This information is increasingly used for the stratification of patients for therapy. The most
intensive treatment regimens are withheld in patients with a good prognosis, while patients with
very poor prognosis may be treated more intensively, for example with bone marrow
transplantation or with more experimental chemotherapeutic regimens. For example, in
paediatric B-cell acute lymphoblastic leukaemia (B-ALL), TEL/AML1 fusion and hyperdiploidy are
associated with a favourable outcome, whereas hypodiploidy, BCR/ABL1 fusion, and MLL
rearrangements are associated with a poor prognosis (Pui and Evans, 1998). B-ALL patients with
E2A/PBX1 fusion were initially found to be at high risk for treatment failure. The application of
more aggressive combinations of chemotherapy has resulted in long-term cure rates comparable
to those of children with standard-risk ALL (Pui and Evans, 1998). This risk-adjusted therapy
together with novel chemotherapeutics have led to an increased patient's outcome and resulted
in an overall survival of more than 85% in childhood ALL.
For some translocations the functional consequences are understood and rational targeted
therapeutic approaches can be utilised when this particular rearrangement is found in a patient.
A classical example is the t(15;17)(q22;q11-21), resulting in PML/RARA fusion and associated
with acute promyelocytic leukaemia. Acute promyelocytic leukaemias with t(15;17)(q22;q11-21)
have proven to respond to the differentiating action of all-trans-retinoic acid. This therapeutic
approach does not involve chemical or physical agents to eradicate the tumour by killing the
neoplastic cells, but rather induces the cells to differentiate normally (Melnick and Licht, 1999).
Some cytogenetic abnormalities are associated with a specific subtype of leukaemia or lymphoma
and can therefore be used to confirm the diagnosis. Examples are the t(15;17)(q22;q12-21) and
t(8;14)(q24;q32), that may confirm the diagnosis of AML-M3 and Burkitt’s lymphoma,
respectively (Borrow et al., 1992; Akasaka et al., 2000).
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2.3. The Philadelphia story: from chromosome defect to novel therapeutic strategy
The first consistent chromosome abnormality in a human cancer was demonstrated by Peter
Nowell and David Hungerford in 1960, before banding techniques became available (Nowell and
Hungerford, 1960). They identified the presence of a small marker chromosome in bone marrow
of patients with chronic myeloid leukaemia (CML). This small chromosome was called the
Philadelphia chromosome, after the city in which it was discovered, and was for more than 10
years thought to be the result of a deletion. However, the use of chromosome banding
demonstrated that the Philadelphia chromosome was a derivative chromosome 22 resulting from
a reciprocal translocation with chromosome 9 (Rowley, 1973). The Philadelphia chromosome is
observed in the majority of patients with CML, and detection of this defect, either by cytogenetic
or molecular techniques (see below), is important for differential diagnosis with e.g. transient
lymphocytosis (Sawyers, 1999). Although initially found in CML, the Philadelphia chromosome
also occurs in 25-30% of adult ALL, in 5% of childhood ALL, and in rare cases of AML.
Following the cloning of the t(9;22)(q34;q11) breakpoints, it was shown that the molecular
consequence was fusion of ABL1 and BCR, forming a chimeric BCR/ABL1 gene (Heisterkamp et
al., 1983). The NH2-terminal encoding part of the BCR gene is fused to the ABL1 gene previously
characterised as the human homologue of the Abelson murine leukaemia retrovirus oncogene.
Breakpoints at the BCR cluster are located within two regions, the major breakpoint cluster (M-
BCR) which produces a 210 kDa protein and the minor breakpoint cluster region (m-BCR) which
produces a 190 kDa protein. Almost all patients with CML present the major fusion protein. Either
type of product can be observed in ALL, although, in contrast to CML, the 190 kDa protein
predominates (Melo, 1996). From 1984, it was shown that CML cells express an altered form of
ABL1 with increased tyrosine kinase activity, indicating a mechanism of action of this oncogene
(Konopka et al., 1984; Daley et al., 1990; Lugo et al., 1990). This understanding led to the
development of a novel therapeutic drug that inhibits tyrosine kinase activity, i.e. STI571
(formerly CGP57148, now Glivec or Gleevec, [Novartis, Basel, Switzerland], or imatinib mesylate)
(Druker et al., 1996). In the first clinical trials with STI571, patients with Philadelphia-positive ALL
and CML showed efficient clinical and cytogenetic responses (Druker et al., 2001a; Druker et al.,
2001b; Kantarjian and Talpaz, 2001). This example is proof of the principle that understanding
the functional consequences of genetic changes can lead to targeted drug treatment. This
success should encourage researchers to further characterise recurrent and novel translocations
in order to understand its biological consequences as one of the possible entries towards more
effective and less toxic drugs.
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2.4. Genes involved in leukaemogenesis
Following the discovery of the Philadelphia chromosome, an increasing number of recurrent
cytogenetic abnormalities in malignant cells have been described. These have been documented
in the serial editions of Mitelman’s catalogue of chromosome aberrations and are now available
online (Mitelman, 2002).
Chromosomal rearrangements, predominantly translocations, cause alteration of gene function
through either: 1) inappropriate activation or expression of certain genes by juxtaposition to
strong enhancers/promotors, thereby providing oncogenic stimulus and 2) the formation of
chimeric fusion genes with transforming properties (Rabbitts, 1994). The first mechanism is often
the result from illegitimate recombination of either the immunoglobulin genes (IGH at 14q32, the
light chain gene  at 2p12, or  at 22q11), or the T-cell receptor genes (TCRAD at 14q11.2,
TCRB at 7q35, or TCRG at 7p15). Another example is the inv(3)(q21q26) with RPN1 mediated
ectotropic expression of EVI1. More recently, altered expression of the homeobox gene GSH2 at
4q11-q12 and the growth factor gene IL3 at 5q31 has been observed in translocations involving
the 5’ end of ETV6 (Cools et al., 2002). Beside translocations and inversions, deregulated
expression of oncogenes has also been observed in microdeletions at 1q32 in 25% of T-ALL,
resulting in activation of TAL1 by juxtaposition to the promotor region of SIL (Aplan et al., 1990;
Brown et al., 1990).
The second type of molecular event resulting from translocations in leukaemia is the generation
of chimeric fusion proteins. Molecular studies of these chimeric fusion products showed that
certain genes are involved in many different translocations. Figure 2 illustrates the network of
genes frequently translocated in leukaemia. The key genes that are known to be fused to a
variety of partner genes are most prominently ETV6, MLL, RARA, ALK, NUP98, AML1 and to a
lesser extent ABL1, MDS/EVI1, BCR, PDGFR, JAK2, ZNF220, FGFR1, NPM1, CBP, E2A, NUP214,
MOZ and MLLT10.
The ETV6 gene is located at 12p13 and involved with more than 41 different putative partner
genes. Fifteen of these breakpoints and the corresponding partner genes have already been
cloned (Cazzaniga et al., 1999; Rowley, 1999; Salomon-Nguyen et al., 2000; Beverloo et al.,
2001; Cazzaniga et al., 2001). These studies revealed that different domains of ETV6 are fused
with partner genes encoding either kinases or transcription factors. Fusion of the
homodimerisation domain of ETV6 to ABL1, ABL2, JAK2, and PDGFR results in increased tyrosine
kinase activity. The same elevated tyrosine kinase activity is also obtained by fusion of the
homodimerisation domain of BCR in BCR/ABL1, BCR/JAK2, and BCR/FGFR1 fusion genes
(Sawyers, 1999; Bohlander, 2000; Demiroglu et al., 2001).
The most frequently observed partner of ETV6 is AML1 (Romana et al., 1995). In the resulting
ETV6/AML1 fusion, the ETV6 homodimerisation domain activates the transcription factor AML1.
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AML1 has been identified as the fusion partner of CBFA2T1 in the t(8;21)(q22;q22) (Erickson et
al., 1992), MTG16 in the t(16;21)(q24;q22) (Gamou et al., 1998), and as partner with MDS1,
EVI1 or EAP in t(3;21)(q26;q22) (Nucifora et al., 1993; Mitani et al., 1994). MDS1/EVI1 has been
reported in different fusion products and fuses also in rare cases with ETV6 (Raynaud et al.,
1996; Peeters et al., 1997).
Figure 2: Schematic illustration of the network of genes translocated in leukaemia. Genes known
to form fusion genes are connected by lines
The second most promiscuous gene involved in both acute lymphoblastic leukaemia and acute
myeloid leukaemia, is the MLL gene. To date, 30 fusion genes have been identified (Huret et al.,
2001). MLL partner proteins appear to fall into two functional categories: signalling molecules
that normally localise to the cytoplasm/cell junctions or nuclear factors implicated in various
aspects of transcriptional regulation (Ayton and Cleary, 2001). Translocations with MLL result in
the production of a chimeric protein in which the amino-terminal portion of MLL is fused to the
carboxy-terminal portion of the partner genes. This has led to models of leukaemogenesis in
which the MLL fusion protein may either confer gain of function or may interfere with normal MLL
function (with the MLL translocation representing a dominant-negative gene). Apart from these
fusion genes, MLL can be self-rearranged (MLL partial tandem duplication) or amplified
(Schichman et al., 1995; Caligiuri et al., 1997; Allen et al., 1998; Avet-Loiseau et al., 1999;
Michaux et al., 2000; this study). These alternative classes of MLL rearrangements presumably
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promote leukaemogenesis without the concomitant need for fusion of MLL to a partner gene,
suggesting that alteration of MLL function alone, in some circumstances, is sufficient to promote
leukaemogenesis (Ayton and Cleary, 2001).
Among the MLL partners are also promiscuous genes. For example, the MLLT10 gene fuses to
MLL in the recurrent t(10;11)(p13;q23) (Chaplin et al., 1995a; Chaplin et al., 1995b), but an
apparently similar 10;11 rearrangement can also result in MLLT10/CALM fusion (Dreyling et al.,
1996). One report describes an MLL/RARA fusion (Redner et al., 1999). The RARA gene is
typically translocated in acute promyelocytic leukaemia and fuses with PML, PLZF, NuMa, STAT5b
or NPM1 (Melnick and Licht, 1999; Jansen and Lowenberg, 2001).
Besides translocations and inversions, deletions also play an important role, observed as either
whole chromosome losses or loss of part of a chromosome. Frequent recurrent deletions are –5,
-7, del(5q), del(7q), and del(20q) in AML and MDS (Grimwade et al., 1998), del(13)(q14),
del(11)(q22-q23), del(17)(p13) and del(6)(q21) in CLL (Dohner et al., 2000), and del(6q) and
del(9p) in ALL (Pui and Evans, 1998). Chromosome deletions are a good indication for the
presence of a tumour suppressor gene, whose loss is important for leukaemogenesis. Inactivation
of a tumour suppressor gene is possible through several mechanisms, but mainly involves
deletion of one allele and mutation or hypermethylation of the tumour suppressor gene of the
second allele. Tumour suppressor genes affected by common chromosome aberrations are p53 in
cases with 17p deletion (Sugimoto et al., 1993; Baldini et al., 1994; Bi et al., 1994), and ataxia
telangiectasia mutated (ATM), which is mutated in a subset of cases with 11q22-q23 aberrations
(Stankovic et al., 1999; Schaffner et al., 2000). More recently, the B-cell neoplasia-associated
gene with multiple splicing (BCMS) has been identified as candidate for the tumor suppressor
gene in 13q14 involved in the leukaemogenesis of B-CLL (Wolf et al., 2001)
The most common acquired trisomy is +8 seen in AML, MDS and CML in blast transformation
(Mitelman, 2002). Trisomy 12 is the most common numerical abnormality found in CLL, present
in 30% of all cases (Juliusson et al., 1990). In contrast to most other chromosome changes, the
contribution of a whole chromosome gain to the leukaemia phenotype is poorly understood. It
may result in an extra copy of mutated proto-oncogenes as described for the MET proto-
oncogene in hereditary papillary renal cell cancer (Zhuang et al., 1998). Amongst others,
expression profiling might shed light on the biological consequences of whole chromosome gain
(Virtaneva et al., 2001).
Chromosomal rearrangements seem to play an important role in the development of leukaemia.
However, important additional defects can occur that are not cytogenetically detectable or
cytogenetically normal leukaemias may contain molecularly detectable defects. Genes typically
affected by molecular alterations (e.g. point mutations, partial duplications) are TP53, FLT3,
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AML1, and RAS (Imai et al., 2000; Stirewalt et al., 2001). The role of the latter gene in leukaemia
is described in further detail (section 3.4.).
It appears that only a relative small number of genetic events are involved in leukaemogenesis.
This observation offers hope that only a limited number of pathways are altered and that the
understanding of the crucial differentiation and proliferation pathways could lead to very specific
and effective treatments in leukaemia.
3. Malignant transformation of haematopoietic cells
The disease process in leukaemia is characterised by maturation arrest and uncontrolled
proliferation of blood cells, and results from at least three events. The haematopoietic cells must
lose their capacity to differentiate, escape apoptotic cell death and initiate proliferation (Saha et
al., 1998). The cellular pathways responsible for these events are tightly controlled and
regulated. The identity and functional importance of many of these pathways are now becoming
clear, and offer new potential targets for therapeutic intervention.
3.1. HOX gene expression and maturation stop
The human homeobox-containing HOX genes play a central role in early stages of haematopoietic
development and in the differentiation of the haematopoietic cells (Look, 1997; van Oostveen et
al., 1999). Human cells contain 39 major HOX genes organised in clusters on four different
chromosomes. The expression of HOX genes, is characteristic for a particular cell lineage at a
specific stage of differentiation, but shows a general down-regulation as the progenitor
differentiates into a mature blood cell. Recent findings showed that several HOX genes
participate in development of human leukaemia either as fusion protein with the nucleoporin
NUP98, or due to over-expressed proteins (Borrow et al., 1996; Nakamura et al., 1996a;
Thorsteinsdottir et al., 1997). In addition, several of the HOX co-factors, like for example PBX1,
are rearranged in leukaemia (Nakamura et al., 1996b; Kroon et al., 1998). Since several
oncoproteins generate major changes to HOX gene expression, a predominant role of HOX genes
in human leukaemia has been proposed. HOX gene expression is regulated by dose-dependent
interaction between two groups of transcription factors: trithorax (TrG) group of proteins
required for the maintenance of HOX gene expression and polycomb (PcG) group of proteins,
which oppose the effects of TrG proteins and repress HOX gene expression (Simon, 1995). MLL,
the human homologue of the Drosophila trithorax gene, has been implicated in the maintenance
of HOX gene expression. The leukaemic genes ETV6, AML1, CBFB and RARA are upstream
regulators of the TrG, which may act on HOX gene expression and in this way block maturation
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(Saha et al., 1998). Figure 3 illustrates the model showing leukaemia-associated proteins that are
involved in the regulation of HOX gene expression.
Figure 3: Schematic representation of the leukaemia-associated proteins that are involved in HOX
gene expression controlling the normal development of haematopoietic cells. At the centre of the
model is the balanced interaction between two groups of transcription factors: trithorax (TrG)
group of proteins required for the maintenance of HOX gene expression and polycomb (PcG)
group of proteins, which repress HOX gene expression. To the left of the diagram are genes that
interact with each other and that are upstream regulators, which may act on HOX gene
expression (adapted from Saha et al., 1998)
3.2. Histone deacetylase and chromatin remodelling
Dynamic histone acetylation/deacetylation plays an important role in several cellular processes
like replication, gene silencing and differentiation. The acetylation of lysine residues on histones
is associated with chromatin expansion and gene expression, while histone deacetylation is linked
to chromatin compaction and transcriptional repression (Grunstein, 1997). Some of the genes
targeted by chromosome translocations are connected to this process of acetylation and
deacetylation. For example, PML/RARA, PLZF/RARA and AML1/CBFA2T1 heterodimers repress
transcription through histone deacetylation by recruiting nuclear receptor co-repressors, Sin3A or
Sin3B, which in turn form complexes with histone deacetylase (HDAC1 or 2), thereby resulting in
nucleosome assembly and transcriptional repression (Grunstein, 1997; Gelmetti et al., 1998;
Lutterbach et al., 1998; Wang et al., 1998). Other leukaemia-associated genes as p300, CBP,
MOZ, and TIF2 are important to catalyse histone acetylation (Chen et al., 1997; Torchia et al.,
1997; Carapeti et al., 1998; Giles et al., 1998; Martinez-Balbas et al., 1998; Champagne et al.,
2001). However, histones are not a sole target of acetyl transferases and deacetylases, as the
protein p53 is acetylated by its co-activator p300 (Sterner and Berger, 2000). Inhibition of
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histone deacetylation is of therapeutic interest to regain normal gene expression and
transcription. Several classes of histone deacetylase inhibitors (HDACI) have been identified
including short chain fatty acids and organic hydroxamid acids (Richon et al., 1998). Recent
reports indicate that HDACIs invariably exerted growth inhibitory, pro-apoptotic and
differentiating activities in various cancer cells and that they may be useful for therapy of other
cancers and leukaemia (Pandolfi, 2001).
3.3. JAK-STAT pathway and leukaemia
Fusion products with elevated tyrosine kinase, constitutively phosphorylate certain cellular
pathways controlling cell growth and differentiation. It has been recently demonstrated that the
oncogenic potential of both ETV6/JAK2 and BCR/ABL1 depends on the proper function of
transcription factors of the STAT family as in the absence of STAT5a and STAT5b the
leukaemogenic activity of the fusion protein is markedly repressed (Garcia and Jove, 1998; de
Groot et al., 1999; Ho et al., 1999; Nieborowska-Skorska et al., 1999; Schwaller et al., 2000).
Alternatively, constitutive phosphorylation of STAT5 transcription factor contributes to malignant
transformation (Takemoto et al., 1997). STAT5 overexpression also activates the repair gene
RAD51, which represses apoptosis by an increased DNA repair. It has been reported that RAD51
is also activated through constitutive phosphorylation and block of caspase 3 by the BCR/ABL1
fusion product (Slupianek et al., 2001) (Figure 4). Based on these findings, it is logical to
hypothesise that a therapeutic approach aimed at specifically blocking STAT5a and STAT5b
function should be extremely beneficial in these leukaemias (Meydan et al., 1996; Ward et al.,
2000).
Figure 4. Schematic representation of the different ways mediated by BCR/ABL1 to activate
RAD51: i.e. increasing its expression, decreasing its degradation, activation through post-
transcriptional modifications (adapted from Brooksbank, 2001)
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3.4. Role of RAS activation in haematologic malignancies
The constitutive activation of RAS appears to be an important factor in cancer and haematologic
malignancies. RAS is a member of the superfamily of G-proteins regulated by a GDP/GTP cycle.
RAS is active when bound to GTP, and inactive when bound to GDP. GTP bound RAS recruits and
activates RAF. RAF initiates a cascade of protein phosphorylation by first phosphorylating MEK.
Phosphorylated MEK in turn phosphorylates ERK, which moves to the nucleus, where it
subsequently phosphorylates a number of transcription factors including ELK1 (Elion, 1998). In
this way, RAS activation causes elevated cell cycle progression and inhibition of apoptosis. The
oncogenic forms of RAS always have GTP bound, and are therefore always active. In about one-
third of the myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML), RAS genes
are mutationally activated (Reuter et al., 2000). In addition to activation by mutation, RAS is
deregulated by constitutive activation of proto-oncogenes or translocations involving receptor
tyrosine kinases (Sawyers and Denny, 1994; Hunter, 1997).
4. Molecular cytogenetics
As described above, cytogenetic analysis is helpful in determining the diagnosis, assessment of
prognosis and choice of therapy in haematological malignancies. Moreover, cytogenetics remains
a vital tool in the discovery of new recurrent abnormalities significant in haematological
malignancies. As explained above, the finding of recurrent chromosomal changes has led to the
identification of genes that play a critical role in the malignant process and the understanding of
the pathways involved in the malignant process. In its turn, the identification of these genes can
be used at diagnosis and follow-up. Standard banding analysis has the advantage that the entire
genome is screened for abnormalities. However, standard karyotyping has a limited resolution (>
10 Mb) and dividing cells are required in order to obtain chromosomes for analysis. Moreover, the
interpretation of chromosomal banding patterns requires highly skilled personnel, and is labour-
intensive. Although automated karyotyping systems became available, analysing metaphase
spreads remains time-consuming. PCR analyses have the advantage to be more sensitive, and to
screen for a specific chromosome aberration without the need for dividing cells. However, the
molecular analyses are limited to known fusion genes, and do not allow the screening of the
whole genome for other (secondary) alterations.
Molecular cytogenetic techniques have been developed to bridge the gap between classical
cytogenetics and molecular DNA techniques. The major breakthrough for in situ hybridisation
(ISH) came with the application of biotinylated DNA probes in 1986 (Cremer et al., 1986; Pinkel
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et al., 1986). Like the radio-active ISH, fluorescence in situ hybridisation (FISH) is based upon
the annealing of single-stranded probe DNA to the complementary DNA sequences, present in
their natural position on the chromosomes (in situ hybridisation). In FISH however, the probe is
coupled to a reporter molecule that fluoresces when excited by a particular wavelength, and
visualised using a fluorescence microscope. Initially, probes were used to detect repetitive
sequences or small unique DNA targets. Rapid development of new types of probes such as
cosmids, P1, PAC, BAC, YAC, micro-dissected chromosome regions, and whole chromosome
libraries, dramatically increased the possible applications for FISH. The development of FISH
opened venues to novel applications, and consequently, even more information about
cytogenetic abnormalities can now be obtained.
4.1. Applications of molecular cytogenetics in haematological neoplasms
FISH is particularly useful for screening of specific gene rearrangements in metaphase spreads
and interphase nuclei. For this purpose, DNA probes covering the chromosomal breakpoints can
be used at diagnosis. These probes can specifically identify the genes involved in the
chromosome alterations without the need for dividing cells. The same FISH experiments can
subsequently be used to assess the efficacy of therapeutic regimens and to detect residual
disease with a rather limited sensitivity of 0.5-5%.
FISH is also very useful for the detection of gene rearrangements involving multiple partners. For
example, a dual colour FISH probe has been developed with probes at either side of the MLL
gene breakpoint, resulting in separation of the normally co-localising signals if the MLL gene is
rearranged. The advantage of this system is that it can detect all recurrent and possibly novel
MLL rearrangements in a single experiment.
The application of FISH further provides increased sensitivity, in that chromosomal abnormalities
have been detected in samples that appeared to be normal by conventional cytogenetic analysis.
The difficulty in detecting these chromosome abnormalities lies in the fact that there is a
reciprocal exchange of chromosome ends or chromosome material with similar banding pattern
and size. The presence of these cryptic or hidden translocations, has been evidenced for the first
time in 1995 with the discovery of the t(12;21)(p13;q22), resulting in ETV6/AML1 fusion
(Romana et al., 1995). Molecular cytogenetic investigations with probes specific for this gene
rearrangement revealed the translocation to be present in 25% of all paediatric B-ALLs. Another
cryptic t(5;14)(q35;q32), resulting in HOX11L2 expression has been observed in 20% of T-ALLs
(Bernard et al., 2001). The genes involved in the latter translocation are located at the
subtelomeric ends of the chromosomes 5 and 14. Therefore, G-banding analysis and FISH with
whole chromosome libraries for 5 and 14 fail to observe this translocation. However, FISH with
locus-specific probes or molecular methods can be used to detect this translocation.
Chapter 1 15
Very small interstitial deletions are at the limits of optical resolution, often involving only a single
band of the extended chromosome karyotype, and are difficult or even impossible to detect by G-
banding analysis. A possible way to screen for these deletions is by FISH using specific DNA
probes. If the target hybridisation site on a chromosome has been lost by deletion of material
from that chromosome, then a probe cannot bind to the chromosome and no fluorescent signal
will be observed.
Apart from the diagnostic approaches, FISH can be used as a research tool to refine the
breakpoint regions of novel chromosome abnormalities, which is often an essential step in the
identification of new (partner) genes involved in leukaemogenesis. Recent progression of the
Human Genome Project has facilitated the characterisation of the translocation breakpoints using
FISH. PAC/BAC resources, covering the entire genome are available and can be easily found
using the databases of the University of California, Santa Cruz (UCSC), and the National Center
for Biotechnology Information (NCBI) (http://genome.ucsc.edu/, http://www.ensembl.org/,
http://www.ncbi.nlm.nih.gov/genome/guide/human/). These clones can be used to determine
more precisely the breakpoint regions and to search for genes involved in the translocations.
4.2. FISH based technologies
Over the years, new FISH-based technologies have been developed, that mark a new era in
cytogenetics and provide an enormous potential to detect gene and chromosome alterations in
cancer cells.
Multi-colour FISH is a powerful and sensitive technique that enables the simultaneous study of
multiple targets, labelled in different colours, with a reported resolution between 320 kb and 2.6
Mb (section 5).
Comparative genome hybridisation (CGH) is a FISH technique, which can be used on all types of
malignant tissue and whereby the whole genome is tested to determine changes in DNA
sequence copy number with a resolution of 5-10 Mb. The procedure involves labelling tumour
genomic DNA and normal DNA with different fluorochromes. The two genomic DNA samples are
then simultaneously hybridised to normal metaphase chromosomes. The ratio of fluorochrome
intensity along the length of a chromosome is proportional to the ratio of tumour and control
DNA hybridised at each point. The major advantage of CGH is that it allows to perform a genome
wide scan for gains and losses in one experiment from archived tumour material. However,
balanced translocations are not detectable since they do not lead to a relative difference in DNA
content between tumour and normal reference (Van Gele et al., 1997; Vandesompele et al.,
1998; James, 1999; Lichter et al., 2000). More recently, CGH-arrays or DNA micro-arrays, in
which small spots of cloned DNA from specific regions of the genome are attached to a glass
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support, has increased the sensitivity and efficiency to screen for microdeletions and
amplifications (Pinkel et al., 1998; Pollack et al., 1999).
Simultaneous fluorescence immunophenotyping and interphase cytogenetic analysis (termed
'Fluorescence immunophenotyping and Interphase Cytogenetics as a Tool for Investigation Of
Neoplasms (FICTION)'), allows selective evaluation of hybridisation signals of a particular cell
population (for example CD30+ in Hodgkin’s disease) (Weber-Matthiesen et al., 1995).
FISH can also be performed on extended DNA fibres, obtained from e.g. fixed cells and
chromosomes. The so-called fibre-FISH opened new possibilities for high-resolution genome
mapping. The probes can be hybridised to the strands in order to map and order adjacent and
overlapping probes as well as for the characterisation of long-range genomic contigs within the
range of 5-10 kb (Florijn et al., 1995; Heiskanen et al., 1995; Rosenberg et al., 1995; Speleman
et al., 1997). Effective utilisation of these techniques facilitates physical mapping and positional
cloning efforts.
5.  Multi-colour FISH
5.1. Methodologic aspects of multi-colour FISH
Several groups have worked to extend the potential of FISH by simultaneously detecting multiple
genomic targets in different colours. With the availability of an increasing number of spectrally
distinct fluorochromes that can be used for direct and indirect labelling of nucleic acid probes,
more targets can be visualised in parallel by simply mixing differentially labelled probes for a
given target. There are two strategies that allow an increase in the number of detectable targets
beyond the number of fluorochromes, i.e. combinatorial or ratio labelling. In the first approach,
the probe is stained with equal amounts of each fluorochrome. The theoretical number of
targets, which can be discriminated in this manner is 2n-1, with the number of fluorochromes
being ‘n’ (Ried et al., 1992). Therefore, a combination of only 5 fluorochromes allows the
detection of 31 targets, which is sufficient to differential staining of all 24 human chromosomes.
Ratio labelling uses different amounts of each fluorochrome to label the probes, allowing more
than one target to be distinguished for each combination of fluorochromes (Dauwerse et al.,
1992; Nederlof et al., 1992). Ratio labelling has thus the potential to identify more DNA targets
simultaneously with less fluorochromes than combinatorial labelling. However, ratio labelling
requires a correct quantitative incorporation of the fluorochromes and accurate measurement of
the fluorochrome intensity to differentiate targets stained with different ratios of the same labels.
The starting point of multi-colour FISH was the simultaneous detection of more than three target
sequences, reported by Nederlof and co-workers (Nederlof et al., 1989; Nederlof et al., 1990).
The use of three or more spectrally separable fluorochromes provided the basis for 7 and 15
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colour detection (Dauwerse et al., 1992; Ried et al., 1992; Wiegant et al., 1993). Extending the
number of fluorochromes consequently led to painting all 24 human chromosomes in different
colours in one hybridisation experiment (Schröck et al., 1996; Speicher et al., 1996).
5.1.1. Multiplex FISH (M-FISH)
The approach of M-FISH, developed by Speicher and co-workers, is a filter based multi-colour
karyotyping technology. Combinatorial labelling was performed on micro-dissected DOP-PCR
amplified chromosome DNA, using fluorescein, Cy3, and Cy5 for direct detection, and biotin and
digoxigenin for indirect detection with Cy3.5 and Cy7 coupled to avidin and anti-digoxigenin
conjugates. Equipment needed includes a set of narrow band pass filters spaced across the
spectral interval 350-770 nm that gives a high degree of discrimination between all
fluorochromes and a highly sensitive cooled charged coupled device (CCD) camera. The 5
fluorochromes and DAPI counterstain are captured separately. Computer software merges the
separate images into a composite, and distinguishes each chromosome by a distinct colour based
on its unique spectral signature (Speicher et al., 1996) (Figure 5).
Figure 5: Schematic representation of the multiplex-FISH (source: MetaSystems)
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Since the introduction of M-FISH, a number of changes or modifications were introduced in (1)
newly developed motorised fluorescent microscopes for fast image acquisition without noticeable
pixel shift (Eils et al., 1998; Azofeifa et al., 2000), (2) improved software with sophisticated
algorithms for increased image analysis (Eils et al., 1998; Saracoglu et al., 2001), and (3) new
probe generation set with other fluorochromes (Eils et al., 1998; Roberts et al., 1999).
5.1.2. Spectral karyotyping (SKY)
Schröck and co-workers developed the multi-colour spectral karyotyping (SKY), based on a
spectral imaging approach, which combines Fourier spectroscopy, charged coupled device (CCD)
imaging, and optical microscopy to measure simultaneously the emission spectra of all
fluorochromes. Chromosome-specific libraries generated by polymerase chain reaction from flow-
sorted human chromosomes were directly labelled with five different fluorochromes (Cy2,
SpectrumGreen, Cy3, TexasRed, and Cy5). In contrast to conventional microscopy, colour
separation is not achieved by using multiple fluorochrome-specific filters. Instead, a triple-band
pass filter is used for simultaneous excitation and emission of all fluorochromes, and spectral
imaging generates a spectral response ranging from 400 to 800 nm in all pixels. The computer
then processes the resulting image and the chromosomes are distinguished from one another
based on the differences in their spectra. As above, the computer program software is used to
assign false colours to each chromosome and to produce a 24 colour karyotype (Schröck et al.,
1996).
The main advantage of SKY is that it needs only one extended exposure with a triple band-pass
filter to capture an image of a metaphase spread. However, SKY does not take into account the
individual fading characteristics of the fluorochromes. M-FISH uses five different but short
exposures to create a multi-colour image. In this way, the exposure time can be adjusted to each
individual fluorochrome, and the quality of the separate images for each label can be inspected.
5.1.3. Combined Binary Ratio Labelling (COBRA)
Following the initial reports of M-FISH and SKY, further developments or strategies for multi-
colour karyotyping were reported. In 1999, Tanke and co-workers described COBRA or ‘combined
binary ratio labelling’, which is based on the use of both ratio- and combinatorial labelling (Tanke
et al., 1999). Three fluorochromes are used pair-wise for ratio labelling of a set of 12 probes. The
second set of 12 probes is labelled identically but is also given a binary label. Thus, all human
chromosomes are stained using 4 spectrally distinguishable fluorochromes. Additional
fluorochromes, multiply the number of discernible targets from 24 (4 fluorochromes), to 48 (5
fluorochromes), to 96 (6 fluorochromes), etc. Mathematically, the number of targets is given by
(n+(r x n!)/2(n-2)) x 2m, with n: the number of fluorochromes used for ratio labelling, r: the
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number of ratios, and m: the additionally binary colours. COBRA requires a very accurate
labelling and fluorescence intensity measurement. Commercial probe-sets and software are
essential for a broad distribution of the technique.
5.1.4. Colour-changing Karyotyping (CCK)
Colour-changing karyotyping (CCK) is a technique that only requires three spectrally distinct
fluorochromes and adapted optical filters to perform 24 colour FISH (Henegariu et al., 1999).
Three fluororescent and three hapten-labelled nucleotides are used for combinatorial probe
labelling. After hybridisation, the directly labelled fluorochromes are visualised. After recording of
the coordinates, the indirectly labelled probes are developed with the same three fluorochromes.
The previously recorded metaphases are again captured in the three channels. To distinguish
between the signals from the first and the second recording, CCK takes advantage of the
difference in signal strength between directly and indirectly labelled probes. Both images are
merged and software is used to define the karyotype. This approach is the cheapest but requires
two washing steps and as image analysis is not automated it increases the workload and is time-
consuming.
5.2. Further developments of multi-colour FISH
5.2.1. Novel probe-design and software to increase classification accuracy
The major limitation of standard combinatorially labelled probes, is the inaccuracy at the
breakpoints because colour combinations in the regions of overlap are ambiguous, caused by the
blending of colours. The correct identification of small structural rearrangements also depends on
factors such as chromosome condensation, size of the translocated or inserted segment, and the
number and combination of fluorochromes used for probe labelling (Saracoglu et al., 2001).
However, this limitation can be partly resolved by a conceptual change in probe labelling and
image analysis. If each chromosome is labelled with the same number of fluorochromes, flaring
from one rearranged chromosomal region into a different chromosome results in a new colour
combination (Azofeifa et al., 2000; Saracoglu et al., 2001). Thus, an optimal probe design
employs 8 fluorochromes using double combinations. The detection of possible 3 and 4-
fluorochrome overlaps at the translocation sites can then be unequivocally assigned to flaring.
Image analysis based upon a novel approach, termed goldfishTM combines direction in colour
space with spatial information for classification (Saracoglu et al., 2001). This method improves
classification accuracy of the traditional M-FISH approach and offers an accurate and fully
automated analysis of differentially labelled probes. The classification strategy in colour space is
based on the idea that pixels belonging to the same chromosome and thus the same colour class
correspond to a conical cluster of points with a characteristic direction in the colour space.
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Despite these improvements, the identification of small interstitial rearrangements remains
ambiguous and some results need to be verified by single or dual colour FISH.
5.2.2. Multi-colour FISH approaches to detect intrachromosomal abnormalities
Another limitation of multi-colour FISH with whole chromosome painting probes is that it does
not allow the detection of intrachromosomal rearrangements since they do not result in a colour
change along the chromosome. However, three recently developed multi-colour techniques try to
give an answer to this problem.
IPM-FISH (or IRS-PCR multiplex FISH) generates, next to the 24 colours, an R-banding pattern.
This R-banded pattern is obtained by the use of ‘interspersed polymerase chain reaction’ painting
probes for combinatorial labelling (Aurich-Costa et al., 2001). This not only allows recognition of
the origin of chromosomal fragments, but also definition of the breakpoints. Moreover, IRS-PCR-
derived probes provide stronger hybridisation signals at the subtelomeric ends of the
chromosomes than DOP-PCR-derived probes, increasing the possibility to detect cryptic
translocations (see 5.2.3.)
The ‘cross species colour banding’ or Rx-FISH approach takes advantage of the fact that humans
and gibbons have evolved from a common ancestor. The DNA of two gibbon species is
combinatorial labelled with 3 fluorochromes to generate 7 different colours. These probes
hybridise to different loci in the human genome and generate a pattern of 7 different colours. An
attractive feature of this technique is that the segments have precise boundaries that are defined
by evolutionary translocations (Muller et al., 1997) (Applied imaging, http://www.aicorp.com/).
The third technique, ‘high resolution multi-colour banding’ has been described by Chudoba et al.
(1999), and is based on the use of differentially labelled overlapping micro-dissected
chromosome regions. The fluorescence intensity ratios along the chromosomes are used to
assign different colours to specific chromosome regions. Using this approach, 23 bands were
obtained for chromosome 5 (Chudoba et al., 1999). Similar banding patterns have been
developed for the chromosomes 1, 2, 3, and 7 (http://www.metasystems.de/).
5.2.3. Multi-colour subtelomeric probes
One of the major challenges for new FISH technologies is to identify subtelomeric
rearrangements, which are typically undetectable by conventional cytogenetics.
As described above, the most innovative part of IPM-FISH technique is the use of IRS-PCR-
painting probes that show an R-band pattern simultaneous with the combinatorial labelling.
Another major advantage of these probes is their capacity to detect the telomeric ends of the
chromosomes that are rich in ALU sequences. The IPM-FISH technique is thus a valuable tool for
identification of translocations involving the subtelomeric chromosome ends, which often remain
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undetected upon conventional cytogenetic analysis. IPM-FISH has been developed by Genset
Corporation (Evry, France), and its power for detecting cryptic translocations has been illustrated
in a recent publication by Helias et al. (2002).
The molecular cytogenetic resolution of the other established multi-colour systems is often
insufficient to detect subtelomeric translocations and deletions. To this end, Granzow and co-
workers developed a multi-colour FISH that visualises the telomeres of 8 chromosomes
simultaneously, and thus requires 3 hybridisation reactions to screen the integrity of all the
telomeres (Granzow et al., 2000).
More recently, a 12-colour M-FISH assay for subtelomeric rearrangements (M-TEL) to identify
hidden chromosome rearrangements in apparently normal karyotypes has been described (Brown
et al., 2001).
A third approach is based on two hybridisations with different probe sets. A first 24 colour assay
consists of combinatorial labelled subtelomeric probes using 7 different fluorochromes. Together
with a second set of subtelomeric probes, in which p- and q-arms are stained in different colours,
deletions or interchromosomal exchanges can be determined for all telomeric ends (Fauth et al.,
2001).
5.3. Multi-colour applications
The applications of multi-colour FISH have been explored in pre- and postnatal research and in
cancer cytogenetics. Initially, most publications reporting 24 colour FISH applications used the
first commercial available system, SKY (spectral karyotyping) (Cohen et al., 1997; Coleman et al.,
1997; Schröck et al., 1997; Veldman et al., 1997; Haddad et al., 1998; Rao et al., 1998; Sawyer
et al., 1998; Rowley et al., 1999; Schröck and Padilla-Nash, 2000; Abdel-Rahman et al., 2001;
Bayani and Squire, 2001; Nanjangud et al., 2002). Due to successful introduction of commercially
available probes and software for M-FISH, this 24 colour FISH approach has now also become
more widely implemented (Jalal and Law, 1999; Uhrig et al., 1999; Speicher et al., 2000; Jalal et
al., 2001a; Jalal et al., 2001b; Van Roy et al., 2001; Van Gele et al., in press; this study).
Multiple colour karyotyping provides the means to directly examine the entire metaphases in a
single experiment and to assign all chromosomal abnormalities. Differential staining of all 24
chromosomes in a single experiment is especially useful in the fully and accurate description of
complex chromosomal rearrangements, that could not or only partially be resolved using G-
banding. Complex rearrangements are frequently observed in tumour cells and leukaemias, but
can also be present in patients with mental retardation.
M-FISH can also be used to identify the origin of unknown amplified chromosomal material,
present as homogeneously stained regions ‘hsr’ or double minute chromosomes ‘dmin’. This is
illustrated in our study that used M-FISH analysis to identify the chromosomal origin of a dmin in
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the neuroblastoma cell line SJNB-12. Combining M-FISH results with comparative genome
hybridisation and reverse painting, showed that these amplicons contain 8q24 and 16q22-23
chromosomal material, and further study revealed that the genes MYC and ATBF1 were amplified
(Van Roy et al., 2001). This example clearly illustrates that M-FISH can also help to identify novel
genes involved in cancer.
M-FISH has enabled the elucidation of several examples of hidden or ‘cryptic’ structural
abnormalities in leukaemias, that may otherwise have been left undetected by classical
cytogenetic methods (Veldman et al., 1997; Mohr et al., 2000; Elghezal et al., 2001; Hilgenfeld et
al., 2001; Jalal et al., 2001b; Mathew et al., 2001; Nordgren et al., 2001; this study).
Furthermore, M-FISH can be used to screen for novel tumour-specific chromosome aberrations.
The detection of new chromosomal aberrations also greatly facilitates the identification of
activated oncogenes or fusion genes of pathological importance.
M-FISH studies further provide insights into the classification systems of tumours/leukaemias
when correlated with clinical data, treatment regimens, and prognosis. This is exemplified in our
M-FISH study on AML and MDS with complex karyotypes, in which a subgroup with extremely
poor prognosis could be evidenced, based on the presence of MLL copy gain in combination with
deletion of 5q.
Multi-colour FISH thus clearly provides multiple applications in pre- and postnatal research and
cancer cytogenetics. However, M-FISH will not and should not replace traditional banding
analysis. M-FISH using chromosome-painting probes could be used as a screening test to identify
gross abnormalities. A comparison of M-FISH results with conventional cytogenetic analysis
should define observed abnormalities more precisely and should maximise cytogenetic
information. Further information obtained from comparative genome hybridisation or the more
sensitive micro-array technology, helps to an accurate and detailed description of the karyotype.
We can conclude that M-FISH has become an indispensable FISH technology, not only for
chromosome analysis in basic research, but also for diagnostic tools.
5.4. Implementation of ’24 XCyte mFISH’ multi-colour FISH technology
The description of two strategies for 24 colour FISH, multiplex-FISH (M-FISH) and spectral
karyotyping (SKY) (Speicher et al., 1996; Schröck et al., 1996), raised high expectations for
detection and characterisation of chromosome rearrangements with improved sensitivity.
However, due to the high costs for the interferometer for SKY and the lack of commercial
software and probe sets for M-FISH, relatively few laboratoria were able to implement this new
technology. In October 1998, MetaSystems (Altlussheim, Germany), with whom our laboratory
has a longstanding collaboration, provided us with a new software program (ISIS mFISH)
designed for M-FISH image analysis. This particular software is used in cooperation with an
Chapter 1 23
Axioplan epifluorescence microscope from ZEISS. A precommercial ’24 XCyte mFISH’ 24 colour
probe kit from MetaSystems (Altlussheim, Germany) was evaluated on cell lines, which were
previously investigated in detail by cytogenetics, standard FISH and CGH (Van Roy et al., 2000;
Van Roy et al., 2001). This probe kit contains combinatorially labelled chromosome paints
obtained from DOP-PCR amplified microdissected chromosomes. Fluoresceine isothiocyanate
(FITC), SpectrumOrangeTM, TexasRed® and diethylcoumarine (DEAC) were used for direct
detection, whereas biotin was indirectly visualised with StreptavidinCyTM5.
The aim of this collaboration was to evaluate the user-feasibility of the combination of
MetaSystems ISIS mFISH software, the adapted ZEISS Axioplan and the 24 colour probe set.
Based on our observations, the probe kit and software were further optimised for commercial
use. Further updates of the ISIS software to a Microsoft Windows enabled version and the
extension of the 5-position filter wheel to an 8-position filter wheel in the ZEISS Axioplan
epifluorescence microscope, resulted in a more user-friendly M-FISH system. Overall, the
implementation of M-FISH using the ‘24 XCyte mFISH’ probe kit (Altlussheim, Germany) thus
requires only few adaptations with regard to equipment and software for laboratories with
previous FISH experience.
This successful introduction in our lab resulted in various publications (Van Roy et al., 2000; Van
Roy et al., 2001; Van Gele et al., in press; Vermeulen et al., submitted; this study)
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Identification of Cytogenetic Subclasses and
Recurring Chromosomal Aberrations in AML and
MDS With Complex Karyotypes Using M-FISH
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Complex chromosomal aberrations (CCAs) can be detected in a substantial proportion of AML and MDS patients, de novo
as well as secondary or therapy-related, and are associated with an adverse prognosis. Comprehensive analysis of the
chromosomal rearrangements in these complex karyotypes has been hampered by the limitations of conventional cytoge-
netics. As a result, our knowledge concerning the cytogenetics of these malignancies is sparse. Here we describe a
multiplex-FISH (M-FISH) study of CCAs in 36 patients with AML and MDS. M-FISH generated a genome-wide analysis of
chromosomal aberrations in CCAs, establishing several cytogenetic subgroups. -5/5q- was demonstrated in the majority of
patients (86%). Other rearrangements (present with or without -5/5q-) included: deletion of 7q (47%), 3q rearrangements
(19%), and MLL copy gain or amplification (17%). These genetic subgroups seem to display biological heterogeneity: MLL copy
gain or amplification in association with 5q- was detected only in AML patients and was significantly associated with extremely
short survival (median overall survival: 30 days, P 5 0.0102). A partially cryptic t(4;5)(q31;q31), a balanced t(1;8)(p31;q22), and
an unbalanced der(7)t(7;14)(q21;q13) were detected as possible new recurrent rearrangements in association with CCAs.
Novel reciprocal translocations included t(5;11)(q33;p15)del(5)(q13q31) and t(3;6)(q26;q25). We conclude that AML and MDS
with CCAs can be subdivided into molecular cytogenetic subclasses, which could reflect different clinical behavior and
prognosis, and that three recurrent chromosomal aberrations are associated with karyotype complexity.
© 2002 Wiley-Liss, Inc.
INTRODUCTION
Cytogenetic analysis provides essential informa-
tion of diagnostic and prognostic importance in
patients with hematological malignancies (Grim-
wade et al., 1998). Moreover, identification of the
genes, whose expression is affected by chromo-
somal rearrangements, has led to fundamental in-
sights into the regulation of malignant and normal
hematopoiesis (Look, 1997). Karyotypic analysis,
however, has major limitations with respect to the
detection of subtle or cryptic chromosomal aberra-
tions and the analysis of highly rearranged chromo-
somes, particularly in poorly spread and/or con-
tracted metaphases. As a consequence, clonal
aberrations can be overlooked by conventional cy-
togenetics, the t(12;21) in pre-B-cell acute lympho-
blastic leukemia being a paradigm of these short-
comings (Romana et al., 1994). These limitations
are evident in complex chromosomal aberrations
(CCAs), in which it is often impossible to identify
the chromosomes and chromosome bands that are
involved in balanced or unbalanced chromosomal
exchanges.
CCAs (i.e., chromosomal aberrations involving
more than two chromosomes and/or more than
three breakpoints) (Huret et al., 2001) can be de-
tected in up to 10 and 30% of de novo acute
myeloid leukemias (AML) and myelodysplastic
syndromes (MDS), respectively, and in up to 50%
of therapy-related AML and MDS (Fenaux et al.,
1996; Grimwade et al., 1998). CCAs are a well-
recognized cytogenetic entity in AML as well as in
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MDS and are known to confer an adverse progno-
sis. Reported complete remission rates vary from
21–46%, with a median overall survival between
1–5 months (Grimwade et al., 1998; Schoch et al.,
2001). Therefore, new therapeutic strategies for
this important patient group are needed, possibly
tailored to specific genetic subsets of patients. Also,
the identification of the genes implicated in this
disease entity may provide targets for the develop-
ment of therapeutic intervention directly targeting
these molecular defects or signaling pathways. To
this purpose, improved characterization of these
CCAs is essential, and therefore comprehensive
description of CCAs remains an important chal-
lenge. Recently, several new molecular cytogenetic
approaches were described, including multiplex-
fluorescence in situ hybridization (M-FISH), spec-
tral karyotyping (SKY), and multicolor combined
binary ratio labeling FISH (COBRA-FISH)
(Schrock et al., 1996; Speicher et al., 1996; Tanke
et al., 1999). Using these techniques, a different
color can be assigned to each of the 24 human
chromosomes, overcoming some of the limitations
of conventional cytogenetics.
Here we describe an M-FISH study of complex
karyotypic aberrations in 36 patients with AML
and MDS, thus representing the largest M-FISH
study of complex cytogenetic aberrations in pa-
tients with myeloid neoplasms to date. We aimed
to provide a comprehensive analysis of CCAs in
AML and MDS, to detect recurrent (balanced or
otherwise) chromosomal aberrations in myeloid
malignancies with CCAs, and to investigate
whether unbalanced rearrangements lead to recur-
rent chromosomal gains or losses.
MATERIALS AND METHODS
Patients
Patient samples were collected retrospectively
from three genetic centers in Belgium. Selection
criteria were: diagnosis of AML or MDS, according
to the FAB criteria (Bennett et al., 1982, 1985), and
the presence of chromosomal aberrations involving
more than two chromosomes and/or more than
three breakpoints.
Cytogenetic Analysis
Cytogenetic studies were performed on met-
aphases G-banded by Wright staining or Q-banded
by quinacrine staining using standard procedures.
Karyotypes were described according to the ISCN
(1995) guidelines. All patients had a complex
karyotype with the presence of marker chromo-
somes, additional material of unknown origin,
and/or ring chromosomes of unidentified origin.
M-FISH Analysis
The ’24XCyte’ probe kit was purchased from
MetaSystems (Altlussheim, Germany) and contains
combinatorially labeled chromosome paints ob-
tained from degenerated oligonucleotide primer
polymerase chain reaction (DOP-PCR) amplified
microdissected chromosomes. Fluorescein isothio-
cyanate (FITC), SpectrumOrange™, TexasRedt,
and diethylcoumarine (DEAC) were used for direct
detection, whereas biotin was indirectly visualized
with streptavidinCy™5. Metaphase slides were
pretreated with RNase and pepsin. Slides were
denatured with 70% formamide/2 3 SSCP at 80°C
for 5 min. Probe mix was denatured at 75°C for 5
min, incubated at 37°C for 30 min, and subse-
quently applied to the slides under an 18 3 18 mm
coverslip. After 2–4 days of hybridization, slides
were washed with 50% formamide/2 3 SSC (pH
7.3–7.5) at 42°C (3 3 5 min), followed by three
washes in 2 3 SSC (42°C). Biotin-labeled probes
were detected with streptavidinCy™5. Slides were
mounted in Vectashield (Vector Laboratories, Bur-
lingame, CA) containing 49,6-Diamidine-29-phe-
nylindole dihydrochloride (DAPI) (Roche Molecu-
lar Biochemicals, Brussels, Belgium) counterstain.
Fluorescent images were captured with a Zeiss
axioplan epifluorescence microscope (Carl Zeiss,
Zaventem, Brussels) (eight position filter wheel)
equipped with a CCD camera (739 3 575, pixel
size 11 3 11 mm). All six fluorochromes including
the DAPI counterstain were captured sequentially
using single-bandpass filters. Color composite im-
ages were constructed from the separate mono-
chrome images. At least five metaphase cells from
each patient were analyzed by M-FISH.
FISH With Whole Chromosome Paints and
Region-Specific Probes
Subsequent to M-FISH analysis, additional
FISH with whole chromosome plasmid libraries
(kindly provided by Dr. Collin Collins, Livermore,
CA) (Collins et al., 1991) or region-specific probes
was performed for confirmation or characterization
of chromosomal rearrangements. Probe-labeling
and FISH procedures were performed as described
according to standard procedures (Van Roy et al.,
1994; Jaju et al., 1999). For multiple-color FISH, a
combination of three or four different fluoro-
chromes was used following the procedure de-
scribed (Van Limbergen et al., 2001). Region-spe-
cific probes used were: LSI EGR1 (5q31), LSI
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D7S522 (7q31), LSI D13S25 (13q14.3), LSI
D20S108 (20q12), LSI CEP12 (cen12), (Vysis,
Downers Grove, IL), and RPCI PAC and BAC
clones: RP5-932F4, RP11-79I13, RP4-662P1 and
RP11-190I11 located at 1p31-32 and RP11-45O11,
RP11-204D12, RP11-203J07, RP11-252I13, RP11-
13O21, RP11-58G19, RP11-81C5, RP11-73N22,
RP11-15P5, RP11-47L19, RP11-265M23, RP11-
209F21, and RP11-45L19 located at 5q21-23.
Gene-specific probes used were: LSI p53 (encom-
passing TP53), LSI MLL dual-color probe (span-
ning the MLL gene) (Vysis, Downers Grove, IL),
ETV6 cosmid clones: 179A6, 50F4, 132B11, 163E7,
54D5, 148B6, and 167A6 (a kind gift from Dr. Peter
Marynen, Leuven, Belgium) (Baens et al., 1996),
AML1 cosmid clones: Y3, Y8, and YR4 (a kind gift
from Dr. Kimiko Shimizu, Tokyo, Japan) (Tanaka
et al., 1999), MDS1 RPCI-11 library BAC clones:
264D15 and 328P24 (kindly provided by Dr. Peter
Marynen, Leuven, Belgium) (Peeters et al., 1997),
EVI1 BAC clones: RP11-33A1, RP11-627P8, and
RP11-250A4, and ETO flanking BAC clones RP11-
89F14 and RP11-3J21 (identified by searching the
High Throughput Genomic Sequences (HTGS)
database using the Basic local alignment search tool
(BLAST) algorithm, with EVI1 or ETO mRNA at
http://www.ncbi.nlm.nih.gov/BLAST/) (Altschul et
al., 1997), and NUP98 PAC clone 1173K1 (a kind
gift from Dr. Peter Aplan, Gaithersburg, MD)
(Raza-Egilmez et al., 1998).
Statistical Analysis
Statistical analysis was performed using the
SPSS Software v. 10.0 (SPSS, Chicago, IL).
Kaplan-Meier plots were used to estimate the over-
all survival (Kaplan and Meier, 1958). Comparison
of survival between different cytogenetic sub-
classes was performed using the log-rank test.
RESULTS
Patient Characteristics
Twenty-three patients had AML and 13 were
diagnosed with MDS. For patient details, see Ta-
ble 1. The sex ratio was 17/19 (F/M); mean age at
diagnosis was 69 years (range: 89–42 years). The
median overall survival of all patients was 142 days
(range: 1 day to 1 year). Only two patients were still
alive at 6 months and 1 year of follow-up.
FISH Analyses
Initial karyotype descriptions based on G- or
Q-banding were revised according to information
obtained with M-FISH analysis. Additional FISH
with region- or gene-specific probes was performed
when a chromosomal rearrangement was sugges-
tive for a gene- or locus-specific rearrangement
(probes: see Materials and Methods). In cases
where two or more clones were present, only the
dominant clone was included in the analyses.
M-FISH allowed improved characterization of
the CCAs identified by conventional cytogenetics
(Table 1, Fig. 1). These included: 82 marker chro-
mosomes (mar), 51 chromosomes with material of
unknown origin (add), and 3 dicentric chromo-
somes (dic). Moreover, often chromosomal rear-
rangements were identified which were completely
or partially unnoticed upon chromosome banding
analysis (cryptic and partially cryptic rearrange-
ments). Conventional cytogenetics was largely con-
cordant for chromosomal rearrangements involving
large chromosomes, but rearrangements of the
smaller E, F, and G group chromosomes were
largely underestimated. Chromosome breakpoints
which could be unequivocally assigned by compar-
ison of M-FISH data with banding analysis are
depicted in Figure 2.
Unbalanced rearrangements
Unbalanced chromosomal translocations were
the most frequently observed rearrangements in
our series (n 5 146), often resulting in losses of
chromosomes 5/5q and 7/7q. Although interstitial
and terminal deletions were found (del(5q) n 5 14
and del(7q) n 5 1), loss of the long arm of chro-
mosomes 5 and 7 (5q- and 7q-) was more often the
result of unbalanced rearrangements which were
unnoticed in most instances (der(5q) n 5 16 and
der(7q) n 5 6) (Fig. 1E). These rearrangements
resulted in loss of regions 5q31 and 7q22-q31, re-
spectively, and had been classified by conventional
cytogenetics as marker chromosomes (9-5,1mar9
n 5 10; 9-7,1mar9 n 5 1), as chromosomes with
additional material of unknown origin (add(5q) n 5
6, add(7q) n 5 2), or as pure deletions (del(5q) n 5
3, del(7q) n 5 1) (Fig. 1E). In these patients, FISH
with probes for the critical regions at 5q31 and 7q22
confirmed suspected 5q and 7q loss (data not
shown). In only one patient (Patient 7), 5q- was
demonstrated with FISH without evidence for 5q-
deletion from the M-FISH karyotype.
Similar observations were made, to a lesser ex-
tent, for chromosomes 13 and 17, with 13q21-qter,
17p12-pter, and 17q24-qter as commonly deleted
regions (Fig. 3). Deletion of the TP53 gene encom-
passing chromosomal region 17p13 was found in 1
out of 3 patients (Patients 6, 16, and 36), whereas
the three patients with unbalanced 13q aberrations
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Figure 1.
65M-FISH ON COMPLEX KARYOTYPES IN AML AND MDS
all showed deletion of D13S25 (Patients 28, 34, and
36).
Balanced rearrangements
In total, 15 balanced translocation were detected.
Reciprocal translocations detected in these series
included: t(5;11)(q33;p15)del(5)(q13q31), t(4;
5)(q31;q31), t(3;6)(q26;q25), and t(1;8)(p31;q22)
(Patients 6, 16, 15, and 23, respectively, see Fig.
1E,F,I,J). An unbalanced rearrangement with the
same 4q31 and 5q31 breakpoints was observed in
one patient (Patient 29).
In order to delineate the breakpoints in these
translocations in further detail, FISH with region-
specific probes was performed. The 5q31 break-
point in the t(4;5)(q31;q31) was located between
markers D5S471 and D5S467, a region encompass-
ing ;1 Mb, whereas the 5q31 breakpoint in the
der(5)t(4;5)(q31;q31) was mapped approximately 3
Mb more telomeric, within an approximately
;4Mb interval, defined by markers D5S2059 and
D5S642. In the translocation t(1;8)(p31;q22), ETO
rearrangement was excluded, as the breakpoint was
located proximal to this gene. The 1p31 breakpoint
was subsequently mapped between stSG30407 and
D1S3389, a region of ;13 Mb containing at least 33
genes (Fig. 1J). The 11p15 breakpoint in the t(5;
11)(q33;p15)del(5)(q13q31) has also been impli-
cated in a recently reported recurrent translocation
in childhood AML that fuses NUP98 to the human
homolog of the mouse nsd1 gene (Jaju et al., 2000).
However, in the present case the breakpoint was
proximal to the NUP98 gene, thus excluding in-
volvement of this gene (Fig. 1E). Finally, for the
t(3;6)(q26;q25), FISH analysis with EVI1- and
MDS1-specific BAC clones showed that the 3q26
breakpoint was located between EVI1 and MDS1,
consistent with an EVI1 rearrangement (Fig. 1I).
Chromosomal gains and losses
In a previous study, we showed that M-FISH,
when compared with comparative genomic hybrid-
ization (CGH) data, is largely concordant with re-
spect to the detection of chromosomal gains and
losses due to unbalanced translocations occurring
in the observed karyotypes (Van Roy et al., 2001).
Recurrent aberrations were defined arbitrarily as
gains or losses that were demonstrated in at least
five independent observations. In this study, recur-
rent losses were noted for 5q, 7q, 12p, 13q, 16q,
17p, and 17q, whereas gain or amplification was
observed for 11q23 in six patients and 21q22 in one
patient (Fig. 3).
12p13 rearrangements were investigated with
ETV6 cosmid clones. In all patients, the ETV6
allele was shown to be deleted on the rearranged
chromosome 12 (Patients 7, 10, 22, 31, and 33).
11q23 rearrangements or multiple chromosome
11 derivative chromosomes were investigated using
probes spanning the MLL gene. In three of the six
patients, the MLL gene was shown to be amplified
(Patients 20, 26, and 35). In three patients with
multiple der(11) chromosomes, MLL was shown to
be retained on the derivatives, leading to 4 (Pa-
tients 9 and 30) or 9 (Patient 12) copies of MLL. In
one case, however, only the signal for the 39 MLL
was present on two derivatives (Patient 9; Fig. 1H).
In one patient, multiple chromosome 21 frag-
ments were located on chromosome 6. FISH using
AML1 cosmid clones revealed the presence of four
copies of the AML1 gene (Patient 24; Fig. 1G).
Analysis of marker chromosomes
Marker chromosomes were shown to represent a
heterogeneous group of rearrangements with re-
spect to the involved chromosomal regions and the
type of aberrations. Marker chromosomes were
predominantly the result of unbalanced transloca-
tions and, less frequently, deletions, insertions, and
rings, and contained segments of up to four differ-
ent chromosomes (Fig. 1B,C).
Figure 1. Representative M-FISH images (right) and G-banded chro-
mosomes (left) illustrating the various types of rearrangements de-
tected. A: Additional material of unknown origin (from top to bottom):
chromosome 19 with additional material of chromosome 22 in Patient
15; chromosome 19 additional material on chromosome 1 in Patient 35;
and chromosome 22 with additional chromosome 3 material in Patient
16. B: M-FISH image of a complex karyotype in Patient 25. C: Various
marker chromosomes in Patient 34. D: Cryptic translocations (from
top to bottom): der(1)t(1;20)(p34;q?) in Patient 30; partially cryptic
der(16)t(16;17) in Patient 16. E: Chromosome 5 and 7 long arm
deletions due to unbalanced translocations (from top to bottom):
unbalanced translocation der(5)t(5;17)(q13;q11.2;22) classified by
conventional cytogenetics as add(5)(q14) in Patient 35; complex chro-
mosome 5 and 7 rearrangements initially described as –5 in Patient 23
and –7 in Patient 6, respectively; complex chromosome 5 rearrange-
ments cytogenetically classified as del(5)(q12q34) in Patient 6 revised as
cryptic balanced t(5;11)(q33;p15)del(5)(q13q31), der(5)(5pter3
5q11::16q?), der(17)(17qter317p11.2::16q::5q1335qter). F: Cryptic
balanced t(4;5)(q31;q31) and unbalanced der(5)t(4;5)(q31;q31) found in
Patients 16 and 29, respectively. G: Complex chromosomes 6, 14, and
21 rearrangement with multiple copies of the AML1 gene in Patient 24.
H: M-FISH and FISH with MLL flanking probes in patients with chro-
mosome 11 abnormalities (from top to bottom): presence of only the
39 MLL (red) on two derivatives in Patient 9; nine copies of MLL in
Patient 12 with multiple der(11) chromosomes; segmental amplifications of
MLL within an elongated 11q arm in Patients 20, 26, and 35; four copies of
the MLL gene on multiple der(11) chromosome in Patient 30. I: Patient 15
with balanced partially cryptic translocation t(3;6)(q26;q25) analyzed in
detail with locus specific probes for centromere of 3 (red) and EVI1 gene
(green) and FISH with locus specific probes for centromere of 3 (red) and
MDS1 gene (green). J: Balanced translocations (from top to bottom):
t(9;15)(q34;q13) in Patient 6, t(1;8)(p31;q22) in Patient 23.
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Survival Analysis
Patients were subdivided according to the pres-
ence or absence of one or more of the following
cytogenetic aberrations: -5/5q-, -7/7q-, 3q rear-
rangements, and MLL amplification or copy gain
(Table 2). There was a trend towards shorter over-
all survival associated with the presence of one vs.
two or more of these chromosomal aberrations (me-
Figure 2. Overview of chromosomal breakpoints assigned by M-FISH analysis and G-banding. Breakpoints identified by G-banding are indicated by
open circles, whereas the refined breakpoints after M-FISH analysis are represented by filled circles.
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dian overall survival 180 days vs. 70 days, P 5
0.2503). Kaplan-Meier estimates showed that MLL
copy gain or amplification in association with 5q-
was associated with extremely poor overall survival
(median overall survival 30 days vs. 165 days in the
remainder of the patients, P 5 0.0102) (Fig. 4).
Figure 3. Overview of chromosomal gains and losses based on banding and M-FISH data. Chromosomal losses are represented by red bars to the
left of the chromosome, whereas chromosomal gains are indicated by a green bar to the right of each ideogram. Recurrent gains and losses were
arbitrarily defined as changes that were identified in at least five independent observations. The commonly deleted or gained regions are indicated by
arrows.
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DISCUSSION
CCAs are present in a substantial portion of de
novo as well as therapy-related AML and MDS
patients. Patients in whom these chromosomal ab-
errations are diagnosed have an adverse prognosis
under currently used treatment protocols (Grim-
wade et al., 1998; Schoch et al., 2001). Alternative
therapeutic strategies are therefore needed. Be-
cause (pre)leukemia is caused by genetic alter-
ations, new therapeutic interventions are likely ei-
ther to be based on genetic risk stratification or to
interfere with the underlying molecular defects or
altered signaling pathways or, most likely, both.
Furthermore, evaluation of response to therapy and
the detection of minimal residual disease depends
on the identification of recurrent genetic aberra-
tions. An important step in identifying disease
markers or therapeutic targets is an accurate iden-
tification of disease-associated genetic aberrations.
Until the advent of the multicolor FISH tech-
niques, this was impossible in CCAs due to the
limitations of conventional cytogenetics. There-
fore, we performed M-FISH on 36 patients with
AML or MDS with complex karyotypes, thus ob-
taining a genome-wide comprehensive analysis of
CCAs.
Analysis of these characterized complex karyo-
types revealed the presence of cytogenetic sub-
classes based on the pattern of different combina-
tions of genetic aberrations. As expected, the
majority of patients (31 out of 36; 86%) showed loss
of 5q material, due to monosomy 5, deletion, or
unbalanced rearrangements. The major recurrent
additional chromosomal aberrations were: deletion
TABLE 2. Occurrence of the Four Major Cytogenetic Abnormalities in the Investigated Patients*
No. Type Subtype 25/5q2 27/7q2 11q23 3q
2 MDS RAEB
4 MDS RARS
5 MDS RA
7 AML M6
8 AML M2
14 AML M6
16 MDS NA
24 MDS RAEBt
27 AML NA
34 AML M4
1 MDS RAEB
3 AML M2
6 MDS RAEB
11 AML NA
18 AML M1
25 AML M2
28 MDS RAEB
29 AML M6
31 MDS RAEBt
32 AML M2
33 AML M0
36 AML M2
12 AML M2
20 AML M2
26 AML M0
35 AML M2
13 AML M1
21 AML M2
10 MDS RAEB
19 MDS NA
22 MDS RAEB
15 AML M1
30 MDS RAEB
9 AML M2
17 AML M1
23 AML M2
*Presence of a cytogenetic aberration is indicated by a filled box, absence by an open one. No. 5 patient number (see also Table 1), 11q23 5 MLL copy
gain or amplification, 3q 5 presence of rearrangements with breakpoints at 3q21 and/or 3q26, NA 5 not available.
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of 7q (42%), 3q rearrangements (19%), and MLL
copy gain or amplification (17%). These three re-
arrangements were also observed in CCAs in ab-
sence of -5/5q, allowing a subclassification of all but
one of the patients. In that patient (Case 23), a
t(1;8)(p31;q22) was detected which was initially
described as a t(1;8)(p10;p10) based on G-banding
only. Other rearrangements always occurring in the
presence of -5/5q- were: del(17p) or del(17q) (14%
each), del(16q) (25%), 13q deletion (8%), and 12p
deletion (8%). These results suggest that AML and
MDS with CCAs display molecular cytogenetic
heterogeneity with respect to the acquisition of
specific aberrations, which in turn could reflect a
biological heterogeneity, possibly revealing differ-
ent prognostic subgroups. The retrospective design
of our study has hampered a thorough survival
analysis. However, we did find that MLL copy gain
or amplification in association with -5/5q- was an
indicator of an extremely poor prognosis. Although
these findings need further validation, we suggest
that cytogenetic evaluation of AML and MDS pa-
tients with CCA should always include MLL copy
number evaluation.
The role of MLL amplification or copy gain in
myeloid malignancies was only recently appreci-
ated (Michaux et al., 2000). In this study, MLL
amplification typically resulted from multiple cop-
ies on a derivative chromosome 11. In three addi-
tional patients, 2–4 marker chromosomes, which
were shown to be derived from chromosome 11
material only, led to MLL copy number gain. The
latter chromosome abnormality has not been re-
ported thus far. Here we provide evidence that
MLL amplification or copy gain can be detected in
a substantial proportion of patients with CCA
(17%) and that association with -5q is associated
with extremely poor survival. Although MLL am-
plification has been shown not to be restricted to a
particular disease phenotype, our results suggest
that the association with 5q- is primarily, if not
exclusively, found in AML, particularly M2.
The present study also allowed the identification
of translocations that may play a role in the devel-
opment and/or aggressive behavior of AML and
MDS with CCAs. The identification of gene rear-
rangements in these balanced aberrations could
provide a molecular target for detection of minimal
residual disease in some patients. Moreover, since
some of these rearrangements can be overlooked
by conventional cytogenetics, these balanced trans-
locations may also be present in other, less complex
karyotypes. A partially cryptic t(4;5)(q31;q31) was
present in two patients, diagnosed with AML-M6
and MDS, respectively. Remarkably, a similar
translocation has been reported previously in a SKY
study in a patient with MDS and CCAs (Veldman
et al., 1997). FISH with region-specific probes re-
vealed that the 5q31 breakpoints were located in
two distinct regions. These two intervals are ap-
proximately 3 Mb apart and contain four known
genes, to which no apparent oncogenic or tumor
suppressor function has been attributed.
Translocation t(1;8)(p31;q22) was detected in a
patient with MDS-RAEBt. Three translocations
involving chromosomes 1 and 8 with possibly sim-
ilar breakpoints, a der(1)t(1;8)(p32;q2?3), t(1;
8)(p?31;q24), and t(1;8)(p22;q22), were previously
reported in association with complex karyotypic
changes in patients with AML (Moertel and Miser,
1990; Calabrese et al., 1996; Kerndrup et al., 2001).
In the present case, we were able to exclude ETO
as candidate gene and to map the 1p breakpoint
between stSG30407 and D1S3389, a region of ;13
Mb containing at least 33 genes.
A der(7)t(7;14)(q21;q13), described as 9der(7),–149
by G-banding, was found in a patient with AML-M2.
This same derivative was also shown to be present in
two other cases, identified in two different SKY stud-
ies in AML patients with CCAs (Veldman et al.,
1997; Mohr et al., 2000). We suggest that these three
translocations are recurrent aberrations associated
with CCAs. Two previously unreported reciprocal
translocations detected in this study were further an-
alyzed using region-specific probes. The first, a t(5;
11)(q33;p15)del(5)(q13q31), was reminiscent of a
cryptic t(5;11)(q35;p15) found in childhood AML,
which results in rearrangement of the NUP98 gene
Figure 4. Kaplan-Meier plots for overall survival of patients accord-
ing to the chromosomal subgroup. MLL gain or amplification in associ-
ation with 5q- is associated with shorter overall survival (P 5 0.0102).
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(Jaju et al., 2000). In the present case, however, in-
volvement of NUP98 was excluded, indicating that
those translocations are distinct at the molecular
level. In a second translocation, t(3;6)(q26;q25), the
breakpoint was shown to map 59 of EVI1 and 39 of
MDS1, consistent with an EVI1 rearrangement by
translocation (Nucifora, 1997). Identification of a
putative partner gene on 6q25 is currently ongoing.
In this study, recurring chromosomal imbalances
leading to del(13)(q14), del(16)(q22), and del(17)
(q24) were detected in addition to the previously
reported del(5)(q31), del(7)(q22), del(12)(p13),
del(17)(p13), and gain or amplification of 11q23 and
21q22 (Kaneko et al., 1995; Fenaux et al., 1996;
Kakazu et al., 1999; Michaux et al., 2000; Streubel et
al., 2000, 2001). The current report suggests that
del(13)(q14), del(16)(q22), and del(17)(q24) also con-
tribute to the etiopathogenesis and the malignant
phenotype of AML and MDS with CCAs.
In conclusion, we have provided a comprehen-
sive molecular cytogenetic profile of the chromo-
somal alterations in complex karyotypes. Our study
revealed a molecular cytogenetic heterogeneity in
CCAs, in which unbalanced chromosomal ex-
changes play a central role. We suggest that this
molecular heterogeneity could be associated with a
different disease phenotype. We also detected
novel and recurring balanced translocations, which
are currently being characterized at the molecular
level. These translocations may also be present in
less complex karyotypes and could provide a mo-
lecular target for minimal residual disease detec-
tion in some patients.
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Chapter 2 53
Novel chromosome rearrangements in childhood ALL detected by combined
cytogenetic and M-FISH analysis
Heidi Van Limbergen, Bruce Poppe, Nurten Yigit, Jan Philippé, Bruno Verhasselt, Anne De Paepe,
Yves Benoit, Frank Speleman
Abstract
In this study we describe the findings of 4 previously not reported translocations through
combined use of cytogenetic and M-FISH analysis in eight childhood ALLs. A t(14;20)(q32;q11.2)
was observed in a 3-year old girl with T-ALL. FISH with an IGH locus specific probe provided
evidence for unusual rearrangement of the IGH gene, in the variable gene segment region. A
cryptic t(7;11)(q35;q24) was found in association with a t(1;14)(p32;q32) in a patient with T-
ALL. FISH indicated rearrangement of the TCRB locus at 7q35. We therefore assume that this
t(7;11) leads to overexpression of an as yet unidentified gene at 11q24. In order to determine
whether this t(7;11) might be a new recurrent cryptic translocation in childhood T-ALL, such as
the recently discovered t(5;14)(q35;q32), screening of additional patients is underway. Of further
notice were two translocations possibly involving the same 6q26 region on the distal end of the
long arm of chromosome 6. Finally, M-FISH and FISH with region specific probes revealed cryptic
insertions of AF4 and ETV6 in combination with complex rearrangements, leading to MLL/AF4
and ETV6/AML1 gene fusions.
Introduction
Acute lymphoblastic leukaemia (ALL) represents about 85% of childhood leukaemias. The current
cure rate is nearly 80 percent, reflecting the remarkable progress in identifying and treating
resistant subtypes of the disease (Pui & Evans, 1998; Harrison, 2001). The classification of ALL
into therapeutically relevant risk categories relies on both clinical parameters, including age,
leukocyte count, immunophenotype, central nervous system (CNS) involvement, as well as on the
blast cell karyotypes (Pui & Evans, 1998). Conventional cytogenetic analysis of ALL is often
hampered by the difficulty in obtaining good quality chromosomes for analysis. Improvements in
cytogenetic techniques and the complementation with interphase and multiple colour
fluorescence in situ hybridisation have increased the success rate in detection of recurrent
chromosome changes in ALL. A large number of chromosomal rearrangements have now been
described for which the genetic alterations and effect on prognosis are well known (reviews see:
Ferrando & Look, 2000; Harrison, 2001). These include ETV6/AML1 fusion and hyperdiploidy,
associated with a favourable outcome, and hypodiploidy, BCR/ABL1, and MLL rearrangements
associated with a poor prognosis in ALL. Recurrent genetic changes in T-cell ALL have also been
identified, but their effect on outcome is less pronounced (Heerema et al, 1998; Uckun et al,
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1998). Translocations observed among T-lineage ALL preferentially involve the TCRAD locus at
14q11 and the TCRB locus at 7q35, and are present in 20-25% of these patients (Ferrando &
Look, 2000). Despite the significant progress which has been made in identifying the molecular
defects occurring in childhood ALL, no known recurrent chromosomal changes are found in a
considerable number of (near)-diploid ALLs. Recent reports describing the finding of cryptic
translocations, e.g. the t(5;14)(q35;q32) in 22% of children with T-ALL (Bernard et al, 2001),
and the recurrent t(7;12)(q36;p13) (Beverloo et al, 2001; Slater et al, 2001) and
t(5;11)(q35;p15.5) (Brown et al, 2002) in childhood AML, encouraged us to perform further M-
FISH analysis on a series of 8 selected childhood ALLs.
Patients
A total of 8 cases of 66 childhood ALLs diagnosed between 1998 and 2001 at the Ghent
University Hospital (Belgium) were selected based on the presence of complex karyotypes and
the availability of sufficient well-spread metaphases (Table I). All but two patients are still alive
and in remission. Patient 3 and patient 4 died 30 months and 11 months post-diagnosis,
respectively.
Materials and methods
Cytogenetic analysis
Metaphase chromosome spreads from diagnostic bone marrow samples were prepared and G-
banded according to standard procedures. Karyotypes were described according to the ISCN
guidelines (ISCN, 1995).
M-FISH analysis
The ‘24Xcyte’ probe kit was purchased from MetaSystems (Altlussheim, Germany) and contains
combinatorially labelled chromosome paints obtained from degenerated oligonucleotide primer
polymerase chain reaction (DOP-PCR) amplified microdissected chromosomes. Fluoresceine
isothiocyanate (FITC), SpectrumOrangeTM, TexasRed® and diethylcoumarine (DEAC) were used
for direct detection, whereas biotin was indirectly visualised with StreptavidinCyTM5. M-FISH
procedure was performed as previously described (Van Limbergen et al, 2002). All six
fluorochromes including the DAPI counterstain were sequentially captured with a Zeiss axioplan
epifluorescence microscope (Carl Zeiss, Zaventem, Brussels) using single-bandpass filters. The M-
FISH ISIS software (MetaSystems, Altlussheim, Germany) for image captures and false colours
modification was used. At least 5 metaphase cells from each patient were analysed by M-FISH.
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FISH with whole chromosome paints and region-specific probes
Subsequent to M-FISH analysis, some results were confirmed or further characterised with whole
chromosome plasmid libraries (kindly provided by Dr. Collins, Livermore, CA) (Collins et al, 1991)
or region-specific probes. Probe-labelling and FISH was performed according to Van Roy et al
(1994). For multiple colour FISH, a combination of three or four different fluorochromes was
used following the procedure described (Van Limbergen et al, 2001). Routine FISH for the
detection of BCR/ABL1 fusion, ETV6/AML1 fusion, and MLL rearrangements, respectively, was
performed using commercial probes: LSI® ABL/BCR ES probe, LSI® TEL/AML1 ES probe, and
LSI® MLL dual color probe (Vysis, Downers Grove, IL). Additional region specific probes used in
this study were: BAC clones RP11-362J18, RP11-64A1, RP11-397E7, RP11-168E22, RP11-711J3,
and RP11-476C8 covering the AF4 locus; BAC clones RP11-556I13, RP11-282G13, RP11-1160C9,
RP11-1220K2, and RP11-17D6 covering the TCRB locus; the subtelomeric 21q probe GS-63-H24,
and commercial probes LSI® IGH/CCND1, LSI® IGH dual color and LSI® D20S108 (Vysis,
Downers Grove, IL).
RT-PCR analysis
Total RNA was extracted from bone marrow using Trizol (Gibco-BRL, Gaithersburg, MD) or the
RNeasy Mini kit (Qiagen, Hilden, Germany) according to the protocol of the manufacturer.
Routine screening of acute leukaemias at diagnosis, for the presence of 28 different
translocations or chromosomal rearrangements was performed with a multiplex PCR (mDX
HemaVision, DNA Technology A/S, Aarhus, Denmak), according to the manufactures
instructions. Screening of HOX11L2 overexpression in T-ALL, was performed with a standard PCR
using primers HOX11L2-F and HOX11L2-R as described previously by Bernard et al (2001).
Results
Cytogenetic analysis
Details of the cytogenetic findings are summarised in Table I. High hyperdiploid karyotypes (> 50
chromosomes) were observed in three patients, whereas the remaining patients were
pseudodiploid. Structural abnormalities included multiple marker chromosomes and unidentified
additional material, 5 deletions, 2 duplications, a novel balanced translocation t(6;12)(q27;q13),
and a recurrent t(1;14)(p32;q11).
Routine FISH and RT-PCR
FISH was routinely performed for detection of ETV6/AML1 and BCR/ABL1 gene fusion and MLL
rearrangement. MLL rearrangement was observed in patient 4 whereas patient 5 was positive for
the ETV6/AML1 gene fusion. Multiplex RT-PCR at diagnosis identified an MLL/AF4 fusion in
Chapter 2 56
patient 4, and confirmed the presence of ETV6/AML1 in patient 5. Both fusion transcripts were
confirmed by single specific RT-PCR analysis.
M-FISH and FISH with locus specific probes
Following M-FISH, revision of the G-banded karyotypes was possible in all the selected cases
(Table I).
FISH allowed confirmation and/or correction of observed numerical changes, identification of the
chromosomal origin of marker chromosomes and small translocated segments (adds), to unravel
the nature of complex chromosome rearrangements, and identification of novel/cryptic
rearrangements.
Novel reciprocal rearrangements
In total, 4 novel reciprocal translocations were detected: t(14;20)(q32;q11), t(6;12)(q26;q13),
t(6;10)(q26;q24), t(7;11)(q35;q24).
In patient 1, M-FISH confirmed the presence of translocated 20q material on the
derivative chromosome 14 and a partial deletion of the long arm of chromosome 6. FISH with
LSI IGH dual color probe showed a split of the IGH probe covering the variable gene segments.
Subsequent FISH analysis using the LSI IGH/CCND1 (Vysis) and the LSI D20S108 (Vysis) probe
showed the presence of one signal for IGH on chromosome 20 (Fig 1A), thus providing evidence
for the reciprocal nature of this translocation t(14;20)(q32;q11.2).
In patient 2, in addition to the recurrent t(1;14)(p32;q11), two novel cryptic translocation
t(7;11)(q35;q24) and t(6;10)(q26;q24) were found. The possible involvement of the TCRB gene
at 7q35 was investigated using BAC clones covering the TCRB locus in combination with a
chromosome 11 specific library. The combined BAC clones covering the TCRB locus were found
to be split: one signal was retained on the der(7), whereas the other signal was translocated to
the derivative chromosome 11 (Fig 1B). The LSI MLL dual color probe was retained on the
der(11).
In patient 3, we identified a reciprocal t(6;12)(q26;q13) with an apparently similar 6q26
breakpoint as the cryptic t(6;10)(q26;q24) in patient 8. Additional complex rearrangements
involving chromosomes 13, 14, 15, and 16 were observed (Fig 1C).
Cryptic insertions leading to MLL/AF4 and ETV6/AML1 gene fusion
Routine RT-PCR revealed the presence of an MLL/AF4 fusion gene in patient 4. However,
G-banding analysis and M-FISH showed the presence of a complex rearrangement involving
chromosome 1, 11, and 17, but provided no evidence for the involvement of chromosome 4 (Fig
1D). Triple colour FISH with the clones spanning AF4 in combination with LSI MLL dual color
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probe (Vysis), revealed a fusion signal on the der(11). This was further evidenced by triple colour
FISH using LSI MLL dual color probe (Vysis) and a chromosome 11 specific library. The 3’MLL
probe moved to the der(1) (Fig 1D). Therefore, we can conclude that MLL/AF4 fusion results
from a complex chromosomal mechanism. We assume that an insertion of 3’AF4 into 11q23 was
coincided by complex translocations involving chromosomes 1, 11, and 17.
Patient 5 was positive for ETV6/AML1 by PCR and FISH analysis. Triple colour FISH with
LSI TEL/AML1 ES probe (Vysis) and a chromosome 21 specific library, showed the ETV6/AML1
fusion signal on the der(21) (not shown). Results from triple colour FISH using LSI TEL/AML1 ES
(Vysis) and probe GS-63-H24 located at 21qter (Fig 1E), demonstrated that the ETV6/AML1
fusion on the der(21) most probably resulted from an insertion of 5’ETV6 into the AML1 gene on
21q22.
Chromosomal material of unidentified origin
In patient 6, M-FISH showed the additional material on the der(11) to be derived of
chromosome 1, whereas the marker chromosome was shown to result from a complex
rearrangement involving chromosomes X, 15, and 18 (Fig 1F).
In patient 5, the chromosome changes observed by banding analysis (including several
‘adds’) were revised as der(5)(5pter5q13::21q2221qter),der(8)(8pter8q24::
5q?),der(12)(12qter12p13::5q?::8q248qter),der(15)(Xp?q?::15p1215qter),der(11)
(11pter11q23::Xp?q?) (Fig 1E).
Discussion
Encouraged by the discovery of new and/or hidden translocations in previous multi-colour FISH
studies in ALL (Elghezal et al, 2001; Mathew et al, 2001a; Nordgren et al, 2002), we decided to
investigate eight childhood ALLs, selected for presence of only partially characterised, well-spread
metaphases, with combined cytogenetic and M-FISH analysis. Four novel balanced translocations
were identified in three patients: t(14;20)(q32;p11), t(7;11)(q35;q24), t(6;10)(q26;q24), and
t(6;12)(q26;q13).
A cryptic translocation t(7;11)(q35;q24) was detected in a patient with T-ALL in association with
a recurrent t(1;14)(p32;q11), a second cryptic translocation t(6;10)(q25;q24), and an
ins(9;10)(p22;?). FISH analysis showed rearrangement of a BAC clone spanning the TCRB locus
and led us to assume that this translocation, in analogy to other translocations involving TCR and
IGH loci, has led to juxtaposition of a proto-oncogene to the TCRB locus resulting in aberrant
expression of this gene. The finding of this translocation is reminiscent to the recently detected
cryptic t(5;14)(q35;q32) in T-ALL, which has now been shown to be present in as much as 22%
of T-ALL patients (Bernard et al, 2001). HOX11L2, an orphan homeobox gene located close to
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the chromosome 5 breakpoints was found to be transcriptionally activated as a result of this
translocation (Bernard et al, 2001). The t(7;11) also involves distal chromosome arm ends and
cannot be detected upon banding analysis only, and thus can be considered to be truly cryptic.
Further characterisation of this translocation, in particular the search for involvement of
candidate gene on 11q24 is currently ongoing. Also, screening of a large series of T-ALL patients
is underway in order to find whether this translocation is recurrent, and if so, to determine its
frequency of occurrence.
A novel reciprocal translocation t(14;20)(q32;q11) was detected upon banding analysis and FISH
with IGH spanning probes, and confirmed by M-FISH in a patient with T-ALL. The involvement of
the IGH locus in T-ALL is unusual. However, the breakpoint within the IGH gene was located in
the variable gene segments, distal to the typically involved ‘J’ or ‘switch region’ segments.
Mapping of the 20q11.2 breakpoint is ongoing in order to identify possible candidate genes.
Two reciprocal translocations, of which one was cryptic in nature, appeared to involve the same
chromosome band, 6q26. Further mapping is required to determine whether the same locus is
involved in both cases. When proven, this gene/locus may, as observed for other genes located
at the distal ends of chromosome arms (e.g. MLL and ETV6), lead to formation of hidden
translocations, as exemplified by one of the two 6q26 translocations observed here.
In addition to the above-described reciprocal translocations, we also identified insertions of AF4
and ETV6 in combination with complex chromosomal rearrangements, leading to formation of
MLL/AF4 and ETV6/AML1.
The classical translocation t(4;11)(q21;q23) and resulting MLL/AF4 fusion is strongly associated
with infant leukaemia and topoisomerase inhibitor-induced secondary leukaemias, and displays a
poor prognosis (Heerema et al, 1999). Despite the demonstration of presence of an MLL/AF4
fusion by FISH with locus specific probes and RT-PCR; G-banding nor M-FISH could evidence
involvement of chromosome 4 in patient 4. A complex rearrangement involving chromosomes 1,
11, and 17 was apparent from this analysis. Further analysis showed that MLL/AF4 fusion on the
derivative 11 resulted from an insertion of 3’ AF4 sequences into the MLL gene on the der(11),
thus indicating further complexity of the translocation. A cryptic MLL/AF4 fusion, as a result of
insertion of the 5’ MLL sequences in chromosome 4q21, has been recently demonstrated, but in
this report a normal karyotype was observed by G-banding (von Bergh et al, 2001). The current
observation clearly demonstrates the need for systematic screening of MLL/AF4 (either with FISH
or RT-PCR) in ALLs.
A similar insertion event was observed in a ETV6/AML1 positive ALL patient with complex
karyotypic changes i.e. the 5’ part of ETV6 being inserted into the AML1 gene on a derivative
chromosome 21, the latter being implicated in a complex translocation involving chromosomes 5,
8, and 12. A similar observation of insertion of AML1 into ETV6 on 12p13 was reported in an ALL
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with normal karyotype (Reddy et al, 2000). Cryptic insertions of 5’ AML1 have been observed in
complex karyotypes (Mathew et al, 2001b).
The latter reports and the present observation further document the occurrence of cryptic
insertions as an alternative mechanism for formation of fusion genes in leukaemia cells.
To date, only a limited number of studies have used 24-colour FISH to identify chromosomal
abnormalities in childhood ALL (Rowley et al, 1999; Elghezal et al, 2001; Kerndrup & Kjeldsen,
2001; Mathew et al, 2001a; Nordgren et al, 2001a; Nordgren et al, 2001b; Stark et al, 2001;
Nordgren et al, 2002). These studies evaluated the efficiency of SKY and M-FISH in the detection
of chromosome aberrations previously diagnosed using chromosome banding and/or RT-PCR,
and attempted to identify complex or novel rearrangements. Three novel, cryptic rearrangements
have been observed in a study of 20 patients whose leukaemia blast cells were normal by
conventional cytogenetics (Mathew et al, 2001a). Other novel translocations have been found in
patients with multiple chromosome rearrangements (Elghezal et al, 2001; Mathew et al, 2001a;
Nordgren et al, 2002). Using the IPM-FISH technology, a novel multi-colour approach that
obtains stronger hybridisation signals at the telomeric ends of the chromosome, Helias et al.
(2001) observed the novel recurring t(5;14)(q35;q32) in T-ALL. The finding of a possible
recurrent cryptic t(7;11)(q35;q24) involving the TCRB locus in our study offers new venues for
further research to characterise the involvement of candidate genes on 11q24 and to determine
its frequency of occurrence. This study thus demonstrates the great potential of M-FISH in
detecting previously unidentified translocations.
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Figure 1A: From left to right: partial G-banding and M-FISH identified a t(14;20)(q32;q11) in
patient 1. FISH using LSI IGH dual color probe revealed a split of the probe spanning the IGH
variable gene segment (green) (arrowhead). Dual colour FISH revealed a split of the IGH
spanning probe (green), and the fusion of one signal with LSI D20S108 (red) located at 20q12
(arrowhead). 1B: Partial G-banding and M-FISH analysis in patient 2 revealed a recurrent
t(1;14)(p32;q11), and 2 cryptic translocations. Dual colour FISH with chromosome 11 library
(red) and TCRB locus spanning probes (green) showing a split of the probe spanning TCRB and
the probe signal has moved to the der(11). 1C: Karyotype and M-FISH analysis in patient 3
showed the presence of a complex chromosome 13, 14, 15, and 16, a dup(1)(q12q43) and a
balanced translocation t(6;12)(q26;q13). 1D: G-banding, M-FISH analysis and FISH using locus-
specific probes to unravel a complex chromosome 1, 11, 17 rearrangement leading the MLL/AF4
fusion in patient 4. Triple colour FISH using LSI MLL dual color (distal probe red, proximal probe
green), and AF4 spanning probes (yellow) revealed a fusion signal (arrowhead). Triple colour
FISH using LSI MLL dual color probe and a chromosome 11 specific library (yellow) showed the
proximal MLL probe (green) on the der(11) (arrowhead) and the distal MLL probe (red) on the
der(1). 1E: Partial G-banding and M-FISH figure, showing a complex chromosome 5, 8, 12, 21
rearrangement in patient 5. Triple colour FISH using LSI TEL/AML1 ES probe (5’ ETV6 in green,
AML1 spanning probe in red) and GS-63-H24 probe located at 21qtel (yellow), showed that the
ETV6/AML1 fusion is inserted in the derivative chromosome 21. 1F: G-banding and M-FISH image
of complex chromosome change involving chromosomes X, 15, 18 in patient 6.
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Abstract
The IGH/PAX5 rearrangement resulting from the t(9;14)(p13;q32) has been mainly observed in
patients with lymphoplasmocytic lymphoma and diffuse large cell lymphoma, but has also been
described in other B-cell malignancies including splenic marginal zone lymphoma and plasma cell
leukaemia. Cytogenetic and molecular cytogenetic analyses revealed the presence of a t(9;14) in
two patients with respectively splenic marginal zone lymphoma and diffuse large cell lymphoma.
The presence of the t(9;14) in the presence of additional karyotypic changes was confirmed by
multi-colour FISH. In order to facilitate the screening for the IGH/PAX5 rearrangements, we
designed a two and three colour interphase FISH assay with probes spanning the IGH and PAX5
loci and validated their application in both patients. This interphase cytogenetics assay
overcomes the present limitations in reliably detecting IGH/PAX5 rearrangements. This assay now
offers the possiblity for reliable retrospective and prospective screening of large series of B-cell
proliferations which should allow more accurate assessment of the clinical spectrum of IGH/PAX5
positive B-NHL and related survival.
Introduction
B-cell non-Hodgkin’s lymphomas represent a heterogeneous group of neoplastic
lymphoproliferative disorders. Early classification systems were based on morphological features
of the neoplastic cells. Ancillary studies such as immunohistochemistry and cytogenetics have led
to the recognition of several distinct clinicopathological entities which were further defined in the
REAL classification (Harris et al., 1994), which was largely adopted by the WHO classification
(Harris et al., 1999; Jaffe et al., 2001). Prominent examples of recurring genetic aberrations
associated with B-NHL subtypes are rearrangements of MYC at 8q24 in Burkitt's lymphoma
(Diebold et al., 2001), the t(11;14)(q13;q32) leading to BCL1 overexpression in the recently
recognised entity of mantle cell lymphoma (MCL) (Velders et al., 1996), and the
t(14;18)(q32;q21) typically present in follicular lymphomas (FL) (Rowley, 1988; Horsman et al.,
1995).
The translocation t(9;14)(p13;q32) is a rare but recurrent chromosome rearrangement in B-NHL.
The t(9;14) was initially detected in single cases of alpha heavy chain disease and T-cell
leukaemia/lymphoma (Berger et al., 1986; Brito-Babapulle et al., 1987; Pellet et al., 1989) and
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was subsequently shown to occur in ~2% of karyotypically abnormal B-NHL (Offit et al., 1993).
This translocation results in juxtaposition of the PAX5 gene to the IGH gene in divergent
orientation on the der(14)t(9;14)(p13;q32) (Busslinger et al., 1996; Iida et al., 1996) and leads
to elevated expression of the PAX5 gene. The latter gene encodes a B-cell specific transcription
factor (BSAP) which is expressed throughout B-cell development and is involved in the control of
B-cell proliferation and differentiation (Urbanek et al., 1994; Nutt et al., 1999).
The total number of reported t(9;14) positive cases is presently still limited and predominantly
includes lymphoplasmacytic lymphoma (LPL) or diffuse large cell lymphoma (DLCL) with previous
history of LPL (Dascalescu et al., 1999; Ohno et al., 2000). The t(9;14) has also been reported in
single cases of other B-NHLs and more recently the 9;14 rearrangement was detected by SKY-
analysis in 4 patients with DLCL and complex karyotypes (Nanjangud et al., 2002). This
translocation has also been reported in other entities such as alpha heavy chain disease (Berger
et al., 1986; Pellet et al., 1989), follicular mixed-cell type lymphoma (Offit et al., 1992), primary
effusion lymphoma (Ichinohasama et al., 1998), splenic marginal zone lymphoma (MZL)
(Morrison et al., 1998) and plasma cell leukaemia (Avet-Loiseau et al., 1999; Avet-Loiseau et al.,
2001). Given the limited number of reported 9;14 positive cases and the difficulty to detect the
PAX5 rearrangement in the absence of metaphases or in complex karyotypes, further efforts are
needed to (1) improve the detection rate for this translocation, (2) obtain an accurate delineation
of the clinical, morphological and immunophenotypical spectrum, (3) determine the incidence and
prognostic value of this translocation in B-NHL subtypes more accurately. In this context, we
report two new cases of B-NHL with IGH/PAX5 rearrangement, together with a sensitive
interphase molecular cytogenetic assay for detection of this particular rearrangement.
Case Reports
Patient 1
In October 1999, a 77-year-old woman presented with acute hemi-abdominal pain. Clinical
examination showed marked leukocytosis and splenomegaly, but there was no hepatomegaly or
adenopathy. The white blood cell count was 32 x 109/L with 84% lymphocytes, which were
positive for CD19, CD20, CD23, FMC7, and , and negative for CD5, CD10, CD25, CD11c, and
CD103 excluding chronic lymphocytic leukaemia (CLL score: 1/5), follicular lymphoma or mantle
cell lymphoma. The abnormal lymphocytes were larger than the small cells of CLL with extensive
cytoplasm and some had lymphoplasmacytic features. Bone marrow examination revealed a
hyperplastic marrow with infiltration of abnormal lymphocytes (28%). Based on these data no
conclusive diagnosis could be made. Characteristics of both atypical CLL with
lymphoplasmacytoid features but more from splenic marginal zone lymphoma (MZL) were
observed. The patient was treated with standard chemotherapy with cyclophosphamide,
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vincristine and prednisone (CVP) every three weeks. However, she remained in bad condition
with night-sweating and persistent splenomegaly and leukocytosis. Therefore, she underwent a
splenectomy after the second course of CVP. The spleen was markedly enlarged and weighed
more than 1800 gram. The cut surface was homogeneously brown-red without the presence of
tumour nodules. Histological examination revealed a diffuse infiltration of the white and red pulp
by a neoplastic population of small lymphocytes with round nuclei and inconspicuous nucleoli.
There was only little lymphoplasmacytic differentiation. Immunohistochemical analysis confirmed
the flowcytometric findings of a CD5-, CD10-, CD20+ B-cell infiltration. After splenectomy the
treatment was adjusted and Fludarabine as monotherapy was started which resulted in an
improvement of the blood-cell count and general condition of the patient. After three courses of
Fludarabine and 4 months post-diagnosis the patient died of non-related disease.
Patient 2
A 54-year-old man was hospitalised in January 2002 because of weight loss, asthenia, fever and
night sweating. Clinical examination showed multiple adenopathies and hepatosplenomegaly.
Histological examination of the cervical lymph node showed complete effacement of the nodal
architecture by a diffuse lymphomatous infiltrate with a starry-sky pattern. The tumour cells were
large to medium, moderately pleomorphic with a round to vesicular nucleus containing one to
several prominent nucleoli and a rim of basophilic cytoplasm. Mitotic figures were numerous and
there was a high degree of apoptosis. Based on morphology, the differential diagnosis was
between a DLCL and an atypical Burkitt's lymphoma (BL). The tumour cells expressed membrane
IgM with  light chain and were positive for CD20. The cells were negative for CD10 and positive
for BCL2. Ki67 labelling showed 80-90% proliferating cells. These immunophenotypic features
were inconsistent with BL, and a diagnosis of DLCL was made. The absence of MYC
rearrangement was further confirmed by FISH analysis. EBV in situ hybridisation was performed
because of the history of renal transplantation and was negative. A light cytoplasmic IgM
staining was noted.
The patient was treated with a combination of cyclophosphamide, adriamycine, vincristine every
3 weeks. A marked improvement of the general condition of the patient was noted after the first
cure with disappearance of all of the adenopathies, the splenomegaly and the associated clinical
signs. The patient is actually well.
Materials and Methods
Cytogenetic analysis
G-banding and Q-banding were performed according to standard procedures on metaphases
from patient 1 and 2, respectively. Karyotypes were described according to the ISCN guidelines
(ISCN, 1995).
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M-FISH analysis
M-FISH was performed using the ‘24Xcyte’ probe kit (MetaSystems, Altlussheim, Germany)
following the manufacturer's instructions with minor modifications (Van Limbergen et al., 2002).
Briefly, to this purpose we applied combinatorially labelled chromosome paints obtained from
DOP-PCR amplified microdissected chromosomes. Fluoresceine isothiocyanate (FITC),
SpectrumOrangeTM, TexasRed® and diethylcoumarine (DEAC) were used for direct detection,
whereas biotin was indirectly visualised with streptavidinCyTM5. Separate images for all six
fluorochromes including the DAPI counterstain were captured sequentially with a Zeiss axioplan
epifluorescence microscope (Carl Zeiss, Zaventem, Belgium) using single-bandpass filters. Images
were captured and processed using the M-FISH ISIS software program from MetaSystems
(Altlussheim, Germany). Distinct pseudo-colours were assigned to each pair of chromosomes
based upon the colour signature for each pixel.
FISH analysis with region-specific probes
To confirm the presence of IGH/PAX5 rearrangements, we designed a dual and triple colour
interphase FISH assay.
For the triple colour detection of IGH/PAX5 we used a combination of BAC clones RP11-12P15,
RP11-344B23, RP11-297B17, RP11-220I1 containing the PAX5 gene and ~200 Kb of 5’ sequences
(http://genome.ucsc.edu/) and LSI® IGH dual color probe (Vysis, Downers Grove, IL). The latter
probe consists of a SpectrumGreen labelled 900 Kb probe, spanning the IGH variable region, and
a SpectrumOrange labelled 250 Kb probe located just 3’ of the IGH constant locus. The BAC
clones are indirectly labelled and visualised using avidin-Cy5, the commercial LSI® IGH dual color
probe is directly labelled with SpectrumGreen and SpectrumOrange.
For the dual colour interphase detection of IGH/PAX5 we used BAC clones RP11-47P23 and
RP11-12F16 located in the IGH constant region segment, PAC clone RP5-998D24 located in the
IGH variable region segment (indirectly labelled with digoxigenin) (Poulsen et al., 2001), and the
4 BAC clones described above containing the PAX5 gene (indirectly labelled with biotin).
Standard diagnostic FISH to investigate the presence of 13q14 deletion, trisomy 12 and deletion
of the TP53 gene was performed with LSI® D13S25 (13q14) probe, CEP® 12 probe kit and LSI®
p53 (17p13.1) probe (Vysis, Downers Grove, IL) respectively. BCL6 and MYC gene
rearrangements were investigated with the LSI® BCL6 dual color and LSI® MYC dual color probe
(Vysis, Downers Grove, IL).
BAC clone RP11-174I10, located at 13q14, was used in multiple colour FISH experiments.
Probe-labelling and FISH was performed according to Van Roy et al. (Van Roy et al., 1994).
Triple colour FISH, hybridisation and detection were performed as described by Van Limbergen et
al. (2001).
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Results
Cytogenetic analysis
In patient 1, cytogenetic studies on a bone marrow sample at diagnosis revealed a complex
karyotype: 47,XX,dup(1)(q21q24),t(9;14)(p13;q32),-13,+18,+mar[4]/46,XX[23] (Fig. 1A).
In the second patient the composite karyotype could be written as:
47,XY,+add(X)(p21),der(2)t(2;14)(q35;q21),inv(3)(p14q27),-7,del(9)(p13),t(9;14)(p13;q32),-14,
add(14)(q32),add(16)(p13),+2mar[cp13]/47,XY,idem,add(1)(p36)[cp9](Fig. 1F).
M-FISH analysis
Patient 1
M-FISH analysis showed the marker chromosome to be derived from chromosome 13 as a result
of an interstitial deletion, and confirmed the presence of the t(9;14)(p13;q32), dup(1)(q21q24)
and trisomy 18. As expected, the small distal 14q32qter segment on the der(9) could not be
detected with the chromosome 14 probe (Fig. 1B). The karyotype was revised as:
47,XX,dup(1)(q21q24),t(9;14)(p13;q32),del(13)(q12q31),+18[4]/46,XX[23].
Patient 2
M-FISH analysis identified multiple chromosome aberrations in this patient. Chromosome 14
material was observed on derivative chromosomes 1 and 2. Additionally, the der(1) was shown to
contain chromosome 14 and 9 material, whereas chromosome 3 material was found on the
der(9). Other rearrangements observed by M-FISH were abnormal chromosomes 7, 16, and X.
(Fig. 1G). Based on the M-FISH results the karyotype could be revised as:
47,XY,+der(X)(19::Xp21Xqter),der(1)(9pter9p13::14q3214q13::1p361qter),der(2)(2pter
2q35::14q2114qter),inv(3)(p14q27),der(7)(21qter21q21::7p147q22),der(9)(3qter
3q27::9p139qter),der(14)(14pter14q13::7?q7?q),der(14)(14pter14q32::?),der(16)
(21qter21q21::16p1316qter).
FISH with region-specific probes
Patient 1
Triple colour FISH with the BAC clones spanning the PAX5 gene and flanking sequences and LSI®
IGH dual color probe (Vysis, Downers Grove, IL) revealed a split of the PAX5 BAC clones, and co-
localisation with the SpectrumOrange labelled probe 5’ of IGH on the der(14). The probe
spanning the IGH variable region was located on the der(9) and co-localised with the probes for
PAX5 that remained on the der(9) (Fig. 1C,D).
Dual colour FISH for IGH/PAX5 detection revealed a signal for the IGH and PAX5 locus and the
presence of two fusion signals (Fig. 1E).
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Routine diagnostic examination on interphase nuclei from the diagnostic bone marrow revealed
deletion of 13q14 in 62% of the cells examined. There was no evidence for trisomy 12 or deletion
of 17p. Dual colour FISH using the BAC clones spanning the PAX5 gene and flanking sequences,
and the BAC clone located at 13q14 revealed that PAX5 rearrangements and del(13)(q12q31)
were present together in the same cells (not shown).
Patient 2
The presence of a PAX5/IGH rearrangement was confirmed by triple colour FISH using the IGH
double color probe (Vysis) in combination with the Cy5-labelled PAX5 probes. The PAX5 probes
yielded three signals and fusion with the probe 5’ of IGH (SpectrumOrange) on the der(1). The
probe covering the IGH variable region hybridised to the apparently normal chromosome 3, and a
IGH fusion signal was present on the der(2) (Fig. 1H,I). BCL6 rearrangement was observed using
the LSI® BCL6 dual color probe (Fig. 1J). The 5' BCL6 probe moved to the der(9), whereas the 3'
BCL6 probe was retained on the der(3) and co-hybridised with the probe covering the IGH
variable region. These observations are in keeping with a complex 1;3;9;14 translocation
resulting in IGH/PAX5 and IGH/BCL6 rearrangement.
Dual colour FISH using the IGH variable and constant probes (biotin) and PAX5 clones
(digoxigenin) revealed a split of both probes and 1 fusion signal (Fig. 1K).
Discussion
Using standard karyotyping, in combination with M-FISH and FISH with region-specific probes,
we investigated two new patients with IGH/PAX5-positive B-NHL.
The first patient was diagnosed with MZL. Cytogenetic analysis indicated the presence of a
classical t(9;14)(p13;q32) in the presence of additional karyotypic changes. M-FISH analysis
confirmed the presence of the t(9;14)(p13;q32) and defined the nature of the additional
chromosomal changes. MZL is a recently individualised lymphoma that encompasses extra-nodal
MALT-type lymphomas, splenic MZL and nodal monocytoid MZL (Maes & De Wolf-Peeters, 2002).
MZL displays a broad morphological spectrum and is associated with recurrent chromosomal
changes including trisomy 3, trisomy 18, and structural abnormalities of chromosome 1
(Dierlamm et al., 1996). Thus far the t(9;14) was reported in only one case of splenic MZL
(Morrison et al., 1998).
Cytogenetic analysis in the second patient with DLCL without prior history of LPL revealed a
complex karyotype, with two related clones: a first with a simple t(9;14)(p13;q32) and a second
clone with a complex t(1;3;9;14). FISH with region-specific clones confirmed the expected
IGH/PAX5 rearrangement as well as involvement of BCL6 rearrangement in the complex
t(1;3;9;14).
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Figure 1 A-E (patient 1): A: Partial karyotype of the G-banded chromosomes 1, 9, 13, 14, 18.
Normal chromosomes are placed on the left. B: M-FISH image illustrating the abnormal
chromosomes 1 and 13, the der(14) with additional chromosome 9 material and the additional
chromosome 18. C,D: Partial metaphase and interphase cell co-hybridised with BAC clones
containing the PAX5 gene and ~200 Kb of 5’ sequences (yellow) and LSI® IGH dual color probe
(IGH variable region (green), 5’ region flanking IGH (red)), illustrating a split signal for the PAX5
and IGH probes and double fusion signals on the der(9) and der(14) (arrowheads). E: Dual color
FISH with BAC clones spanning IGH constant segment and variable segment locus (red) and BAC
clones containing PAX5 gene and ~200 Kb of 5’ sequences (green) showed double fusion signal.
F-K (patient 2) F,G: Q-banding and M-FISH image of abnormal chromosomes 1, 2, 3, 7, 9, 14,
16, X. H,I: Partial metaphase and interphase cell co-hybridised with PAX5 BAC clones (yellow)
and LSI® IGH dual color probe (IGH variable region (green), 5’ region flanking IGH (red)),
illustrating split of PAX5 probes and fusion with the probe hybridising to the IGH constant region
on der(1) (arrowhead), probe of the IGH variable region (green) is located on chromosomes 3,
and 14, whereas the normal IGH dual color (red-green) signal is observed on the der(2). J: Dual
colour FISH with LSI BCL6 probe (Vysis) showing a split and localisation of the 5' part of the
probe on the der(9). K: Dual colour FISH on interphase with BAC clones spanning IGH constant
segment and variable segment locus (red) and PAX5 BAC clones (green) showed one fusion
signal and two signals of each probe.
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Involvement of a third locus, IG, was also noted in a t(2;9;14)(p12;p13;q32) (Morrison et al.,
1998), whereas BCL6/PAX5 rearrangement was previously detected in a t(3;9)(q27;p13) (Iida et
al., 1996). 3q27 translocations affecting the BCL6 gene are observed in 20% to 40% of DLCL,
and can involve either one of the 3 immunoglobulin genes or another non-IG partner (Ohno &
Fukuhara, 1997; Akasaka et al., 2000). This is the first report on simultaneous deregulation of
PAX5 and BCL6 by juxtaposition of the IGH gene locus in a patient with DLCL. Similarly,
deregulation of BCL2 and BCL6 has been reported to coexist in FL at diagnosis and is even more
common at relapse (Yonetani et al., 1998; Macintyre et al., 2000).
Thus far, assessment of the occurrence of the t(9;14)(p13;q32) in various B-cell NHL subtypes
was based on classical cytogenetic analysis, and thus only relies on those cases for which
metaphases were available. Moreover, a considerable number of B-NHL cases present with
complex rearrangements which may mask the 9;14 rearrangement. Also, the IGH/PAX5
rearrangement may be part of a variant translocation with involvement of additional translocation
partners as illustrated by the t(2;9;14)(p12;p13;q32) and our case. Due to the scattering of the
breakpoints proximal to PAX5 over a large distance, classical PCR assays are inappropriate and
provide no alternative for cytogenetic analysis. Also, PAX5 overexpression cannot be used for
screening as PAX5 is highly expressed in various B-NHL. Previous studies have shown that
interphase cytogenetics can be a valuable alternative for the detection of this type of gene
rearrangements. For the detection of IGH/PAX5 rearrangements, Iida and co-workers reported
the use of YAC clone (CEPH 788_C_3) in a single colour detection assay, yielding three instead of
two signals in t(9;14) positive cells (Iida et al., 1996). Although this approach is useful in some
cases, it is not applicable when the der(9) is lost, and consequently leads to some false negative
results. Here, we validated a 2 and 3 colour approach interphase FISH assay for sensitive and
reliable detection of IGH/PAX5 rearrangements, using BAC clones spanning PAX5 and flanking
sequences combined with either a commercial dual colour probe for detection of IGH
rearrangement or selected BAC clones for the IGH locus (Poulsen et al., 2001). In both patients,
the applied probe sets spanned the 9p13 as well as the 14q32 breakpoint. In patient 2, only one
fusion signal was observed due to the absence of the derivative chromosome 14 in the complex
rearrangement. Therefore, in patients carrying the reciprocal t(9;14)(p13;q32), the PAX5/IGH
gene rearrangement can readily be identified, with low false positive rate, because of the
presence of two fusion signals.
This interphase FISH assay may allow retrospective and prospective analysis of large series of B-
NHL in order to assess the frequency and distribution in different B-NHL subsets of the 9;14
translocation.
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Rearrangements of 12p, resulting from deletions or translocations, are common findings in hematologic malignancies. In many
cases, these rearrangements target the ETV6 gene (previously called TEL) located at 12p13. Various partner genes have been
implicated in the formation of fusion genes with ETV6. These include PDGFRB, JAK2, NTRK3, ABL2, and ABL1, each of which
encodes for proteins with tyrosine kinase activity. To date, ETV6/ABL1 transcripts have been detected in only four patients with
a leukemic disorder. Here, we describe one adult with chronic myeloid leukemia and a child with T-cell acute lymphocytic
leukemia with ETV6/ABL1. Molecular cytogenetic analysis confirmed that formation of an ETV6/ABL1 fusion in these patients
required at least three chromosomal breaks and showed that each of these translocations is the result of a complex
chromosomal rearrangement. Molecular analysis showed the presence of two fusion transcripts in both patients as the result
of alternative splicing, questioning the suggested role of these transcripts in the lineage specificity. Clinical findings of these
patients were compared to those of previously reported cases, and the possible clinical and biological similarities between
ETV6/ABL1 and other fusion genes leading to increased tyrosine kinase activity are discussed. © 2001 Wiley-Liss, Inc.
INTRODUCTION
A large number of recurrent chromosomal trans-
locations in hematologic malignancies have been
identified. The specific association of certain trans-
locations with distinct subtypes of leukemias with
characteristic morphologic and prognostic features
have stimulated efforts directed toward the unrav-
eling of the molecular consequences of these trans-
locations. For several genes, fusion to various part-
ner genes has been observed. A key example is the
ETV6 gene, located at 12p13, which is involved in
rearrangements with 41 different chromosome
bands, making it the most promiscuous gene in-
volved in human leukemia to date. Fourteen of
these breakpoints and the corresponding partner
genes have been cloned (Knezevich et al., 1998;
Rowley, 1999; Iijima et al., 2000; Salomon-Nguyen
et al., 2000). These partner genes may encode
transcription regulators, tyrosine kinases, or genes
with an as yet unknown function. ABL1, one of the
genes encoding a protein with tyrosine kinase ac-
tivity, is typically found as fusion partner of BCR in
most cases of chronic myeloid leukemia (CML)
and 20% of adult acute lymphocytic leukemia
(ALL) patients. The ETV6 gene was found to be
fused with ABL1 in single cases of ALL (Papado-
poulos et al., 1995), acute myeloid leukemia
(AML) (Golub et al., 1996), and two CMLs (Brunel
et al., 1996; Andreasson et al., 1997). Because of the
difficulty of detecting the 9;12 rearrangements by
conventional cytogenetic analysis, further molecu-
lar (cytogenetic) investigations have been per-
formed to determine the frequency of this fusion
gene in leukemic disorders. RT-PCR screening for
the ETV6/ABL1 fusion transcript in 186 adult ALLs
and 30 childhood ALLs was negative (Janssen et
al., 1995), and FISH analysis of 12 Ph-negative
CMLs, 22 chronic myeloproliferative disorders,
and 33 chronic myelomonocytic leukemias re-
vealed no new cases of ETV6/ABL1 fusion (Nilsson
et al., 1998). The apparent low incidence of ETV6/
ABL1 gene fusion in leukemia has been explained
by the opposite orientation of both genes (Andre-
asson et al., 1997), which requires at least three
chromosomal breaks to generate a functional ETV6/
ABL1 fusion.
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Here we report an ETV6/ABL1 gene fusion in an
adult patient with CML and in a 4-year-old child
with T-cell ALL. Molecular cytogenetic investiga-
tions with chromosome 9- and 12-specific probes
were performed to elucidate the nature of the chro-
mosomal rearrangement in each of the cases. Ad-
ditional clinical details from the previously re-
ported patients were collected and compared with
those of the present patients.
CASE REPORTS
Case 1
Peripheral blood analysis of a 59-year-old Cau-
casian male revealed a marked leukocytosis, with
an increase in granulocytes and left shift in differ-
entiation. His medical history included mental re-
tardation, seizures after a stroke, and colitis ulcer-
osa. At the time of diagnosis, the patient was
asymptomatic. Clinical examination revealed a
prominent spleen, with a craniocaudal axis of 20
cm, as measured by ultrasonography. Laboratory
tests showed a leukocyte count of 27 3 109/l, with
5% myeloblasts, 9% promyelocytes, 21% myelo-
cytes, 14% metamyelocytes, 2% stabs, 23% neutro-
phils, 5% lymphocytes, 4% monocytes, 5% ba-
sophils, and 15% eosinophils, with the presence of
young forms, a platelet count of 344 3 109/l, a
hemoglobin of 66 g/l, and hematocrit of 21.9%.
Lactate dehydrogenase (LDH) was 1,973 U/l; vit
B12 . 20 g/l. The leukocyte alkaline phosphatase
(LAP) score was very low.
Bone marrow examination revealed a hypercel-
lular marrow, with a poor erythroid cell line, a
hyperplastic granulocytic cell line with a left shift
in differentiation, and no excess of blasts. A high
amount of megakaryocytes with some dysplastic
features was noted. Reticulin staining was referred
to as grade 2.
Based on the guidelines of the FAB group for
distinguishing chronic myeloid leukemias, the pa-
tient was diagnosed as having typical CML (Ben-
nett et al., 1994). He was treated with oral hy-
droxyurea to control leukocytosis. a-Interferon was
not considered as a therapeutic option because of
unstable gait, due to his mental handicap that had
worsened after his stroke. Morphological investiga-
tion of bone marrow and blood samples taken dur-
ing therapy showed that no remission was ob-
tained.
One year after diagnosis, under treatment with
hydroxyurea, a marked increase in white blood
cells (up to 100 3 109/l), with 60% eosinophils and
young eosinophilic precursors, was noted in associ-
ation with fever and increasing LDH. Therapy was
changed to corticosteroids and thioguanine, with
good control of the leukocytosis, but with little
effect on the anemia and thrombocytopenia. Two
months later, 13 months after diagnosis, the patient
died due to sepsis.
Case 2
A 4-year-old boy was originally referred to a local
hospital complaining of a sore throat and fever that
partially responded to high-dose antibiotic treatment.
A week later, lymph nodes in the submandibular
region and groin were found to be swollen, and ab-
normal cells were present in the peripheral blood.
The initial physical examination confirmed the orig-
inal lymphadenopathy and, in addition, found en-
larged nodes in the neck and superclavicular regions;
the spleen was also enlarged. Additional tests showed
mediastinal and abdominal involvement. Laboratory
investigations revealed a hemoglobin of 104 g/l, a
leukocyte count of 67 3 109/l, and a platelet count of
286 3 109/l. Peripheral blood smears showed 49%
blasts, 5% metamyelocytes, 5% stabs, 10% seg-
mented neutrophils, 2% monocytes, 22% leukocytes,
1% basophils, and 6% eosinophils. The bone marrow
was hypercellular with 1% metamyelocytes, 1% stabs,
1% segmented neutrophils, 4% normoblasts, 4% lym-
phocytes, 1% myelocytes, 1% eosinophils, and 83%
blasts, which were acid phosphatase-positive. There
were two abnormal cell populations present in the
bone marrow, one consisting of smaller cells with few
nuclear clefts, a small amount of cytoplasm, and a
dense chromatin structure in the nucleus, and an-
other consisting of larger cells with large amounts of
basophilic cytoplasm, and lobulated nuclei with nu-
cleoli and a fine chromatin structure. Immunological
studies revealed a monoclonal cell population with
the following immunophenotype: SmCD3-,
CyCD31, CD51, CD71, and CD451. A diagnosis
of T-cell ALL was made.
The patient was treated with medium-risk che-
motherapy and entered complete remission, but
relapsed under treatment 15 months after diagno-
sis. Treatment with a relapse protocol resulted in
some improvement, but the child died of leukemia
7 months later.
MATERIALS AND METHODS
Cytogenetic Investigations
Bone marrow and peripheral blood cells were
cultured and harvested according to standard pro-
cedures. The constitutional karyotype was deter-
mined on PHA-stimulated peripheral blood lym-
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phocytes. Karyotypic analysis was performed on
G-banded or R-banded metaphase chromosomes.
Karyotypes were described according to the ISCN
(1995).
RT-PCR, Cloning, and Sequencing
Total RNA was extracted from bone marrow
using Trizol (Gibco-BRL, Gaithersburg, MD) ac-
cording to the protocol of the manufacturer. cDNA
was prepared from 1-mg RNA using random hex-
amers (100 ng) and the Superscript II reverse tran-
scriptase kit (Gibco-BRL); 2 ml of the reverse tran-
scription reaction was used for PCR in a total
volume of 25 ml using 10 3 Boehringer buffer
(Roche Diagnostics Belgium, Brussels, Belgium),
200 mM of each dNTP, 25 mM of each primer, and
1 U of Platinum Taq DNA polymerase (Gibco-
BRL). Primers are listed in Table 1. The primers
described by Papadopoulos et al. (1995) were used
in a nested PCR reaction (both patients). The first
PCR round used primers NZ5 (TEL out) and abl-
minus (ABL1 out) for 30 cycles (denaturation, 94°C
for 1 min; annealing, 55°C for 1 min; elongation,
72°C for 1 min). The second round used 1/10th of
the first reaction, and primers NZ7 (inner TEL) and
IP-abl-minus (inner ABL1) for 20 cycles and an-
nealing at 60°C. The other primer combinations
were used in single-step PCR reactions. Samples
were cycled in a Biozym PTC-200 for 35 cycles
(denaturation, 92°C for 20 sec; annealing, 57°C for
20 sec; elongation, 72°C for 1 min). Agarose gel-
sized and purified PCR products were cloned into
pCR2.1-TOPO using the TOPO TA Cloning kit
(Invitrogen BV, Groningen, The Netherlands). In-
serts were sequenced on an ABI PRISM 377 se-
quencer (PE Biosystems Europe, Lennik, Bel-
gium) using specific M13 forward and reverse
primers (Invitrogen BV) and the Big Dye Termi-
nator Sequencing Kit (PE Biosystems Europe).
Fluorescence In Situ Hybridization (FISH)
Probe labeling and FISH were performed as
described according to standard procedures (Van
Roy et al., 1994; Hagemeijer et al., 1998). Biotin
and digoxigenin were indirectly visualized using
Neutralite-Avidin-FITC (Eurogentec Belgium,
Seraing, Belgium) and Sheep-antidigoxigenine-
TRITC (Roche Diagnostics Belgium, Brussels,
Belgium) or using FluoroLink Cy5-labeled avidin
(Amersham Life Science, Little Chalfont, Buck-
inghamshire, U.K.). Additional fluorochromes were
TexasRed, SpectrumGreen, and SpectrumOrange
of the directly labeled commercial probes (Oncor,
Gaithersburg, MD; Vysis, Downers Grove, IL). For
multiple-color FISH, a combination of three or four
different fluorochromes was used. Each fluoro-
chrome and counterstain were captured sequen-
tially, using single-bandpass filters. The M-FISH
ISIS software (MetaSystems, Altlussheim, Ger-
many) for image capture and false color modifica-
tion was used for simultaneous visualization of the
different fluorochromes and for assignment of false
colors to each of the fluorochromes.
Probes used were chromosome plasmid libraries
pBS-6, pBS-9, pBS-12 (Collins et al., 1991), a chro-
mosome 12 centromere-specific probe LSI CEP12
(Vysis). Chromosome 12 region-specific probes
were YAC clone 958-b-8 covering the ETV6 gene
(Kobayashi et al., 1994), ETV6-specific cosmid
clones 179A6, 50F4, 132B11, 163E7, 54D5, 148B6,
and 167A6 (Baens et al., 1996), 12p subtelomeric
PAC clones 483G12 (Baens et al., 1996) and 9015
(National Institutes of Health and Institute of Mo-
lecular Medicine collaboration, 1996), and ETV6
flanking probes MLF2 (Kuefer et al., 1996) and
l5.1 (a gift from Dr. R. Gemmill, Denver, CO).
Chromosome 9-specific probes were commercial
probes BCR/ABL D-FISH (Oncor), LSI BCR/ABL
ES (Vysis), both hybridizing to the entire ABL1 gene,
ABL1-specific probes for exon 11 (PAC 835J22) and
TABLE 1. Primers Used for Detecting ETV6/ABL1 mRNA
Primer Reference Exon Sequence Nucleotide position
NZ5 Papadopoulos et al. (1995) 1 59-TCCTGATCTCTCTCGCTG-39 ETV6 1–19
NZ7 Papadopoulos et al. (1995) 2 59-ACTCGATCCGCCTGCCTGCG-39 ETV6 161–180
TEL-143F Andreasson et al. (1996) 4 59-GCCGGAGGTCATACTGCATCAG-39 ETV6 452–474
Oligo-20S Romana et al. (1995) 5 59-CGTGGAATTCAAACAGTCCA-39 ETV6 876–895
Abl-minus Papadopoulos et al. (1995) 3 59-CATTGTGATTATAGCCTAAGACCCGGAG-39 ABL1 409–437
IP-Abl-minus Papadopoulos et al. (1995) 2 59-TCTCCACTGGCCACAAAATCATACAG-39 ABL1 354–378
ABL-3R Andreasson et al. (1996) 3 59-GCATTTTTGGTTTGGGCTTCACACCATTCC-39 ABL1 438–468
Oligo-4 Martiat et al. (1990) 2 59-TCCACTGGCCACAAAATCATACAGT-39 ABL1 351–376
Oligo-1 Martiat et al. (1990) 2–3 59-GACCCGGAGCTTTTCACCTTTAGTT-39 ABL1 393–418
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intron 1 (PAC 1132H12, PAC 913J14, and PAC
888H11) (kind gift from Dr. M. Rocchi), 9q subtelo-
meric probe TelVysion 9q (Vysis) and cosmid
2241C1 (National Institutes of Health and Institute
of Molecular Medicine collaboration, 1996), and
NOTCH1 cosmid clone A-11 hybridizing telomeric to
ABL1 (Larsson et al., 1994). The chromosomal posi-
tion of the probes is shown in Figure 1.
FISH images were recorded on a Zeiss epifluores-
cence microscope using a black-and-white CCD cam-
era and the ISIS software program from MetaSystems
(Altlussheim, Germany) for image capture and digi-
tization or the MacProbe software from PSI.
RESULTS
Cytogenetic Investigations
Case 1
Cytogenetic analysis of peripheral blood (unstimu-
lated) performed at diagnosis revealed a partial
deletion of the short arm of chromosome 6 in the 16
metaphase cells analyzed. In addition, extra mate-
rial on the long arm of chromosome 9 and a small
distal deletion of the short arm of chromosome 12
were noted (Fig. 2). The karyotype was hence
46,XY,del(6)(p21),?t(9;12)(q34;p12)[16]. Cytogenetic
and molecular cytogenetic follow-up was per-
formed on bone marrow samples 33, 63, and 119
days after diagnosis and on blood samples 7, 63,
and 119 days after diagnosis. In all instances, only
abnormal cells were found. The constitutional
karyotype was normal.
Case 2
Cytogenetic studies on a bone marrow sample at
diagnosis revealed the following karyotype: 47,XY,
1X,del(6)(q?21)[35]/47,XY,1X[7]. Fifteen months
later, examination of a relapse bone marrow sample
provided metaphase cells of better quality and per-
mitted better definition of the del(6). No additional
chromosome abnormalities were found. The addi-
tional X chromosome was confirmed to be of consti-
tutional origin, indicating Klinefelter’s syndrome in
this patient. The karyotype was revised to 47,XXYc,
del(6)(q15q23)[4]/47,XXYc[21]. An identical clone
was found to be present in a lymph node biopsy
taken at the same time. Three months later, during
Figure 2. Partial karyotype of the G-banded chromosomes 9 and 12
in patient 1. Normal chromosomes are to the left.
Figure 1. Chromosomal position of chromosome 9 and 12 region-specific probes used for FISH.
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relapse therapy, the same clone was identified in a
second lymph node biopsy.
RT-PCR Analysis
Using the primers described by Papadopoulos et
al. (1995), nested RT-PCR analysis of case 2 re-
vealed an ETV6 exon 5-ABL1 exon 2 fusion tran-
script (Fig. 3A). The same fusion has been identi-
fied as type B in the previously described AML and
CML patients (Golub et al., 1996; Andreasson et
al., 1997). A second form (type A), resulting in the
fusion of the first four exons of ETV6 and exon 2 of
ABL1, was identified in case 1 (Fig. 3A) and in the
previously reported ALL patient (Papadopoulos et
al., 1995). The primer combination Oligo-20S/
oligo-4 and Oligo-20S/Oligo-1 can only be used to
detect type B. This PCR reaction was positive in
both cases and revealed the correct breakpoint af-
ter sequencing analysis (Fig. 3B). Single-step PCR
analysis using the primer combinations TEL143F/
ABL-3R (Andreasson et al., 1997), TEL143F/
Oligo-4, and TEL143F/Oligo-1 showed two bands
on agarose gel electrophoresis in both cases (Fig.
3C). Sequence analysis showed the larger, more
abundant product to result from the splicing of
ETV6 exon 5 to ABL1 exon 2, while the shorter
product spliced ETV6 exon 4 to exon 2 of ABL1.
Both fusion proteins consist of the Pointed (PNT)
or helix-loop-helix domain of ETV6 fused to the
kinase domain of ABL1.
Fluorescence In Situ Hybridization (FISH)
Case 1
Using the chromosome 6 library, only the two
chromosomes 6 were stained, excluding the possi-
bility of translocation of chromosome 6 material to
other chromosomes at this level of detection. Dual-
color FISH with chromosome 9 and 12 libraries
demonstrated a translocation of chromosome 12
material to distal 9q, but no chromosome 9 material
on chromosome 12 (data not shown). Triple-color
FISH with the LSI CEP12, LSI BCR/ABL ES
probe, and a YAC clone spanning the ETV6 gene
(YAC 958-b-8) showed that part of the ETV6 YAC
hybridization signal was translocated to the der(9)
and colocalized with ABL1 (Fig. 4A). Using the LSI
ABL/BCR ES probe, there was no evidence for a
translocation involving ABL1 (data not shown). Hy-
bridization with ETV6 cosmid clones (50F4,
Figure 3. A: Agarose gel showing the results of RT-PCR. Lane 1:
468-bp fragment of nested PCR with primers NZ7 and PI-ABL-minus in
patient 1; lane 2: 1,023-bp fragment of nested PCR with primers NZ7
and PI-ABL-minus in patient 2; lane 3: 100-bp ladder. B: Agarose gel
showing the results of RT-PCR. Lane 1: 348-bp fragment with primers
B12S20 and Oligo-1 for patient 1; lane 2: 306-bp fragment with primers
B12S20 and Oligo-4 for patient 1; lane 3: internal control; lane 4: 348-bp
fragment with primers B12S20 and Oligo-1 for patient 2; lane 5: 306-bp
fragment with primers B12S20 and Oligo-4 for patient 2; lane 6: internal
control; lane 7: 100-bp ladder. C: Agarose gel showing the results of
RT-PCR. Lane 1: 100-bp ladder; lanes 2 and 3: 267-bp and 822-bp
fragments with primers TEL143F and ABL-3R for patient 1 (lane 2) and
2 (lane 3); lanes 4 and 5: 175-bp and 730-bp fragments with primers
TEL143F and Oligo-4 for patient 1 (lane 4) and 2 (lane 5); lanes 6 and
7: 217-bp and 772-bp fragments with primers TEL143F and Oligo-1 for
patients 1 (lane 6) and 2 (lane 7).
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Figure 4. A: A metaphase cell from patient 1 cohybridized with the
BCR/ABL ES probe (staining the BCR gene on 22q11 (green) and the ABL1
gene on 9q34 (red)), centromeric probe for chromosome 12 (red) and
a YAC clone covering the ETV6 gene (YAC 958-b-8; yellow), which is
split, resulting in a signal on both normal and der(12) and a fusion signal
at the der(9) (arrowhead). B: A partial metaphase from patient 1
cohybridized with a subtelomeric probe for chromosome 9 TelVysion
9q (red), a subtelomeric PAC 483G12 for chromosome 12 (blue),
Oncor ABL/BCR D-FISH probe (ABL1 (green), BCR (yellow)) and Vysis
LSI CEP12 (red), revealed a translocation of both distal parts of chro-
mosome 12 and chromosome 9. C: Schematic representation of the
first possible chromosomal mechanism leading to ETV6/ABL1 rearrange-
ment in patient 1. D: Schematic representation of the second possible
chromosomal mechanism leading to ETV6/ABL1 rearrangement in pa-
tient 1. E: A metaphase cell from patient 2 cohybridized with an
ETV6-specific clones 54D5 (red) and 163E7 (green) revealed three
fusion signals, one of which located on der(9). F: Interphase FISH on
patient 2 with ETV6 clone 50F4 (green) and ABL1 39 probe (red).
132B11, 54D5, and 148B6) localized the 12p break-
point within cosmid 54D5, which spans exon 4 to
exon 8, and thus is in agreement with the RT-PCR
results. The normal chromosome 12 was shown to
carry an intact copy of the ETV6 gene. To deter-
mine the position of the distal chromosomal ends
of the respective derivative chromosomes 9 and 12,
four-color FISH was performed using a subtelo-
meric probe for chromosome 9 (Spectrum Orange),
a subtelomeric PAC clone for chromosome 12
(483G12) (Cy5), Oncor ABL/BCR D-FISH probe
(ABL1-labeled Spectrum Green, BCR-labeled
Texas Red), and Vysis LSI CEP12 (Spectrum Or-
ange). This probe combination revealed a translo-
cation of the distal ends of 12p and 9q, which was
not demonstrated with chromosome libraries (Fig.
4B). The NOTCH1 cosmid clone A-11, located te-
lomeric to ABL1, was shown to be translocated to
der(12), further confirming the rearrangement of 9q
distal to the ABL1 gene. Cohybridizations of the
ABL1-specific PAC clones (1132H12, 913J14,
888H11, and 835J22) with ABL/BCR ES and the
YAC clone for ETV6 showed that both the 59 and
the 39 parts of ABL1 were retained on the der(9),
thus excluding the possibility of deletion of the 59
part of ABL1 on the der(9). Based on these find-
ings, we propose two possible mechanisms for this
9;12 rearrangement. One possibility is a paracentric
inversion of 9q material distal to ABL1 exon 2,
followed by translocation of the distal part of chro-
mosome 12 (12pter to ETV6 exons 4–5) and 9qter
(distal to ABL1) (Fig. 4C). A second possibility
(perhaps more likely) is insertion of the 59 part of
ETV6 into ABL1, followed or coinciding with ex-
change of the distal ends of 9q and 12p (Fig. 4D).
The karyotype is therefore either 46,XY,del(6)
(p21),der(9)inv(9)(q34q34)t(9;12)(q34;p13) or 46,XY,
del(6)(p21),der(9)ins(9;12)(q34;p13p13)t(9;12)
(q34;p13).
Case 2
Routine diagnostic examination of ETV6/AML1
and BCR/ABL1 rearrangements in childhood ALL
on interphase nuclei from the diagnostic bone mar-
row revealed three instead of two signals of the
ETV6-specific probe 50F4. However, the quality of
the metaphase cells was insufficient to determine
the chromosomal localization of the signals. Meta-
phase cells of better quality were obtained from a
lymph node biopsy at relapse. Dual-color FISH
experiments with the ETV6-specific probes 54D5/
163E7 and 50F4/132B11 showed for each combi-
nation three fusion signals (Fig. 4E). FISH with
the ETV6 probes 50F4, 148B6, 167A6, and 179A6
and the 59 and 39 ABL1-specific PAC clones
835J22, 1132H12, 913J14, and PAC 888H11
showed colocalization at 9q34 (Fig. 4F). Metaphase
studies showed that each ETV6 probe was located
at 9q34 and on both chromosomes 12, indicating
that a copy of the entire ETV6 gene was inserted
into 9q34. Because both 59 and 39 PAC clones for
ABL1 were retained on the der(9), there was nei-
ther an apparent partial deletion, nor were any
ABL1 sequences translocated to chromosome 12.
FISH with the subtelomeric cosmid 2241C1 and
PAC 9015 clone for 9q and 12p, respectively,
showed no exchange of either chromosome ends
(not shown). Furthermore, probes located on either
side of ETV6 (MLF2 telomeric and l5.1 centro-
meric) hybridized only to both normal chromosome
12 homologues, limiting the inserted segment to a
region mainly involving ETV6. However, in order
to generate an ETV6/ABL1 fusion transcript, a sec-
ond rearrangement on the der(9) in addition to the
insertion must have occurred. One possibility is
that the entire ETV6 gene was inserted immedi-
ately distal to ABL1, followed by an inversion with
breakpoints in ABL1 exon 2 and ETV6 exon 5. The
revised karyotype could therefore be written as
47,XXYc,del(6)(q15q23),der(9)ins(9;12)(q34;p13p13)
inv(9)(q34q34).
DISCUSSION
Using molecular and cytogenetic analyses, we
observed ETV6/ABL1 fusion in an adult patient
with CML and in a child with T-cell ALL. Until
the present time, despite both PCR and FISH
strategies, only four additional ETV6/ABL1-posi-
tive leukemias have been detected (Papadopoulos
et al., 1995; Brunel et al., 1996; Golub et al., 1996;
Andreasson et al., 1997). The rare occurrence of
this fusion transcript has been explained by the
opposite orientation of both genes. Consequently,
an in-frame fusion cannot result from a simple
translocation but requires a more complex mecha-
nism, including at least three breaks. Detailed mo-
lecular cytogenetic analyses of the present cases
provided further evidence for the complex nature
of the rearrangements leading to ETV6/ABL1 gene
fusion. Moreover, we demonstrated that in each
case distinct mechanisms lead to a similar gene
fusion. In both patients, the ETV6/ABL1 fusion
gene is located on the der(9). In patient 1, we
assume that the 9;12 rearrangement resulted from a
paracentric inversion of ABL1 followed by a recip-
rocal translocation of both the distal parts of 12p
and 9q. Another possible mechanism to form an
ETV6/ABL1 fusion gene on the der(9) is insertion
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of 59 part of ETV6 into ABL1, followed or coincid-
ing with exchange of the distal ends of 9q and 12p.
In patient 2, a complex rearrangement also oc-
curred. The entire ETV6 sequence was present on
the der(9) but a second rearrangement must have
taken place, e.g., a paracentric inversion, in order to
create the ETV6/ABL1 fusion gene. This rearrange-
ment is unusual in that an intact copy of the ETV6
gene was found to be present on both chromo-
somes 12. Similar complex rearrangements have
also been observed for the MLL/AF10 fusion, in
which both fusion partners also have opposite ori-
entations (Beverloo et al., 1995; data not shown).
The present report further illustrates that these
complex 9;12 rearrangements are impossible or dif-
ficult to detect on banding analysis. Also, FISH
with BCR/ABL1 probes (e.g., ABL/BCR ES Vysis
probe) does not allow detection of the rearrange-
ment in all cases. Indeed, in both patients, no split
of the probe spanning the ABL1 gene was ob-
served. In patient 2, the ETV6 involvement was
first recognized by FISH probes used for routine
analysis of ETV6/AML1 rearrangements in child-
hood ALL. Therefore, FISH detection of the
ETV6/ABL1 rearrangement should be performed
using DNA probes spanning both the ETV6 and
ABL1 genes.
Investigations of the biological activity of the
ETV6/ABL1 and BCR/ABL1 fusion products by
Okuda et al. (1996) and Voss et al. (2000) showed a
striking degree of overlap in the substrates and
signaling pathways activated by the two fusion pro-
teins, with ABL1 rather than BCR or ETV6 orches-
trating the pathways involved in the transformation
process. BCR and ETV6 might play a similar role
in the dimerization or oligomerization necessary for
the activation of ABL1. This biological similarity
between both fusion genes may also be partly re-
flected in the clinical features of BCR/ABL1- and
ETV6/ABL1-positive leukemias. BCR/ABL1 is
present in more than 95% of CML and in 20% of
adult ALLs and more rarely in AML (; 5%).
ETV6/ABL1 fusions have been observed in three
patients with CML, two patients with ALL, and
one patient with AML. One of the ETV6/ABL1-
positive CML patients also displayed trisomy 8 and
t(3;21) chromosomal alterations that are known to
occur in CML as recurrent secondary changes.
The addition of the two present cases of ETV6/
ABL1-positive leukemias allows a preliminary at-
tempt toward a phenotype-genotype correlation of
this particular gene fusion. For this purpose, we
also obtained additional clinical data on the previ-
ously reported patients with ETV6/ABL1 rearrange-
ments. The 32-year-old CML patient described by
Andreasson et al. (1997) underwent allogenic bone
marrow transplantation in 1997 and is still in com-
plete remission (B. Johansson, personal communi-
cation). The present two cases as well as the 22-
month-old patient with cALL (L1) (Papadopoulos
et al., 1995), the 82-year-old patient with AML-M6
(Golub et al., 1996), and the 49-year-old patient
with CML (Brunel et al., 1996) had a very rapid
disease progression and died shortly after diagnosis
(L. Wiedemann, personal communication; J. D.
Rowley, personal communication). Although the
number of patients is still small, these data may
suggest a more aggressive disease phenotype.
Two different transcripts were detected in the
previously reported cases. Fusion of ETV6 exon 4
to ABL1 exon 2 (type A) was detected in the ALL
patient reported by Papadopoulos et al. (1995),
while fusion of ETV6 exon 5 to ABL1 exon 2 (type
B) was present in patients with AML and CML
(Golub et al., 1996; Andreasson et al., 1997). Inter-
estingly, using the primer combination described
by Andreasson et al. (1997), both transcripts A and
B were detected in the present patients. However,
nested RT-PCR, as described by Papadopoulos et
al. (1995), revealed only one of the fusion tran-
scripts in these two cases. Possibly, both the choice
of primers and the ratio of both fusion transcripts
will determine the possibility to detect either one
or both transcripts. The finding of both fusion tran-
scripts in both patients with CML and ALL ques-
tions the suggested role of these transcripts in lin-
eage specificity.
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Molecular cytogenetic analysis of 10;11 rearrangements in acute myeloid leukemia
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MLLT10 (previously called AF10) is a moderately common MLL
fusion partner predominantly occurring in acute monoblastic
leukemia (AML-M5). 10;11 rearrangements require at least three
breaks in order to generate an in-frame MLL-MLLT10 fusion as
a result of the opposite orientations of both genes on the
respective chromosome arms. In this study, we describe a
detailed molecular cytogenetic analysis of MLL-MLLT10 posi-
tive 10;11 rearrangements in two patients. We observed an as
yet unreported chromosomal mechanism with at least four
breakpoints, leading to MLL-MLLT10 gene fusion in a 24-year-
old male. An inversion of 11q13-q23 with a breakpoint in the
MLL gene was followed by an additional break 3′ of MLL prior
to insertion of the 11q segment into MLLT10. In a second
patient, a 37-year-old male with AML-M5b, molecular cytog-
enetic analysis of an apparent 10;11 reciprocal translocation
showed an intrachromosomal inversion of 3′MLLT10 followed
by a reciprocal translocation between 10p12 and 11q23. Review
of the literature showed that all cases were the result of an
inversion of either 10p or 11q followed by translocation 10p;11q
or insertion of the inverted segment into MLLT10 or MLL.
Leukemia (2002) 16, 344–351. DOI: 10.1038/sj/leu/2402397
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Introduction
MLL rearrangements occur in approximately 5–10% of acute
lymphoid and myeloid leukemias, poorly differentiated or
biphenotypic leukemias and myelodysplastic syndromes, and
are typically associated with a poor prognosis, both in chil-
dren and adults. The MLL gene is highly promiscuous with
more than 20 partner genes now identiﬁed.1–3 MLL rearrange-
ments may be readily detectable by cytogenetic analysis, eg
in the case of the t(4;11)(q21;q23), but can be easily over-
looked when partner genes are located at distal ends of chro-
mosomes, eg in the t(9;11)(p22;q23) and t(11;19)(q23;p13).4–6
The majority of MLL abnormalities are the result of reciprocal
translocations. An exception is the MLL rearrangement with
MLLT10,7 a moderately common partner gene, which is found
in different types of chromosomal 10;11 rearrangements.8–11
Non-random chromosomal rearrangements involving chro-
mosomes 10 and 11 were identiﬁed by cytogenetic analysis,
but with the type of rearrangements and breakpoints being
variable. A signiﬁcant proportion of these 10;11 abnormalities
was shown to result in MLL-MLLT10 fusion,8–17 although the
occurrence of two other possible transcripts, CALM-MLLT10
and MLL-ABI1 has been described.10,18–20 The nature and
complexity of these 10;11 rearrangements was ﬁrst described
by Beverloo et al8 and explained by the opposite orientation
of both genes on the respective chromosome arms. In this
study, we performed a detailed molecular cytogenetic analysis
of 10;11 rearrangements in two patients. We describe a new
chromosomal mechanism leading to MLL-MLLT10 fusion and
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observed alternative splicing of an as yet unreported MLL-
exon-8-MLLT10 fusion, resulting in three different isoforms.
Furthermore, we present an overview of the different
chromosomal mechanisms leading to MLL-MLLT10-positive
10;11 rearrangements described in 16 leukemia patients
which were investigated with FISH.
Case report
Patient 1
Patient 1 was a 24-year-old Caucasian male who presented
with persistent fatigue, weight loss and night sweating. Blood
analysis revealed pancytopenia. The bone marrow was hyper-
cellular with 98% blast cells. These cells with plentiful cyto-
plasm were strongly basophilic, and one or more large promi-
nent nucleoli and ﬁne chromatin structure were present.
Cytochemical staining showed a strong naphtol AS-D acetate
esterase (NASDA) activity, inhibited by NaF. This is character-
istic for monocytic leukemia. Immunophenotyping of the blast
cells was positive for CD33, HLA-DR and CD11C, which pro-
vides further evidence for the nature of the malignant cells.
Based on the guidelines of the FAB group for distinguishing
acute myeloid leukemias, a diagnosis of AML-M5a was
made.21,22
Induction chemotherapy type IVA I with Ara-C, idarubicin
and VP16 was started. After a second round of chemotherapy
with amsacrine and Ara-C, the patient reached complete
remission. He received two additional rounds of chemo-
therapy and complete remission was sustained. Bone marrow
transplantation was suggested, but no HLA-identical donor
could be found. The patient is still doing well 50 months
after diagnosis.
Patient 2
A 37-year-old male was originally presented at the hospital
with loss of weight and swollen lymph nodes. Bone marrow
biopsy revealed a hypercellular marrow largely replaced by
an extensive population of monocytic precursors (monoblasts
and promonocytes) and abnormal monocytes. Cytochemical
analysis was positive for Sudan black B (SBB) and -naphtyla-
cetate esterase (ANAE), which was inhibited by NaF. Immuno-
phenotyping of the blast cells was CD45, CD33, CD34,
CD15, CD13, HLA-DR, CD11c and CD11b positive. Thus the
bone marrow aspirate was consistent with AML-M5b.
The patient was treated according to the EORTC-protocol
06991 and achieved a complete remission. Following induc-
tion and consolidation therapy, progression of the disease was
observed. Therefore, the patient entered a second treatment
with idarubicin and ﬂudarabine and attained complete
remission. He then underwent an allogenic bone marrow
transplantation from a HLA-compatible donor. Four months
post-transplantation the patient is doing well.
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Materials and methods
Cytogenetic investigations
Bone marrow and peripheral blood cells were cultured and
harvested according to standard procedures. Karyotypic
analysis was performed on G-banded metaphases. The karyo-
type was described according to the recommendations of
ISCN.23
Fluorescence in situ hybridization (FISH)
Probe labelling and FISH was performed as described accord-
ing to standard procedures.24 Biotin and digoxigenin-modiﬁed
probes were visualized using avidin-FITC and sheep-anti-
digoxigenin-TRITC or using avidin-Cy5 and sheep-anti-digoxi-
genin-TexasRed.25 The MLL spanning dual color probe (Vysis,
Downers Grove, IL, USA) is a commercially available directly
labelled probe (SpectrumOrange and SpectrumGreen). For
multiple-color FISH, a combination of four different ﬂuoroch-
romes was used. Sequential images for each ﬂuorochrome
and the DAPI counterstain were captured on a Zeiss Axioplan
microscope using the appropriate single-bandpass ﬁlters. The
M-FISH ISIS software program from MetaSystems (Altlussheim,
Germany) for image capture and false color modiﬁcation was
used for simultaneous visualization of each ﬂuorochrome and
for assignment of false colors for each of the ﬂuorochromes.
The following probes were used: chromosome plasmid
libraries pBS-10 and pBS-11,26 YAC 807 b 3 containing
MLLT10,18 RP11–418C1 located telomeric to MLLT10 and
also containing the 5′ part of the gene, RP11-177H22 located
within the MLLT10 gene, RP11-249M6 and RP11-399C16
almost completely overlapping and located centromeric to
MLLT10 and also containing the 3′ part of the gene, RP11-
251H5 (10p11.21), subtelomeric 10p YAC TYAC95 (a kind
gift from Dr A Jauch, Institute of Human Genetics, Heidelberg,
Germany),27 YACs 742 f 9 and 856 b 9 spanning the MLL
gene and 1.0 Mb of sequences located distal to MLL,8,19 MLL
spanning probes (Vysis), YACs 946 f 4 (11q14) and 932 f 8
(11q21).28 The relative positions of the 10p12 clones as indi-
cated at the Human Genome Project working draft at UCSC
(http://genome.ucsc.edu/) were veriﬁed by ﬁber-FISH.29
RT-PCR, cloning and sequencing
Total RNA was extracted from bone marrow using Trizol
(Gibco BRL, Paisley, UK) according to the protocol of the
manufacturer. cDNA was prepared from 1 g RNA using ran-
dom hexamers (100 ng) and the Superscript II reverse tran-
scriptase kit (Life Technologies, Paisley, UK). Two l of the
reverse transcription reaction was used for PCR in a total vol-
ume of 50 l using 10 × Boehringer buffer (Roche Diagnos-
tics, Brussels, Belgium), 200 m of each dNTP, 25 m of each
primer and 1 U of Platinum Taq polymerase (Gibco BRL). The
primers AF10 pmr 29, AF10 pmr 18, AF10 pmr 41 and MLL
exon5(b) for the detection of MLL/MLLT10 were described
previously.14 For the identiﬁcation of CALM/MLLT10 and
MLLT10/CALM the primer combinations C-S1/A-A1, C-S1/A-
A2 and C-A1/A-S1 were used.30 Samples were cycled in a
Biozym PTC-200 for 40 cycles (denaturation, 92°C for 30 s;
annealing, 57°C for 30 s; elongation, 72°C for 1 min). Agarose
gel-sized and puriﬁed PCR products were cloned into pCR2.1-
TOPO using the TOPO TA Cloning kit (Invitrogen, Paisley,
Leukemia
UK), and inserts were sequenced on an ABI PRISM 377
sequencer (PE Biosystems Europe, Lennik, Belgium), using
speciﬁc M13 forward and reversed primers (Invitrogen) and
the Big Dye Terminator Sequencing Kit.
Results
Cytogenetic and FISH analysis
Patient 1: Cytogenetic analysis at diagnosis revealed tri-
somy 8 and a chromosome 10;11 rearrangement in all 30 cells
analysed (Figure 1a). The constitutional karyotype was nor-
mal. FISH analyses with chromosome 10 and 11 libraries and
a chromosome 11 library in combination with a subtelomeric
probe for 10p both demonstrated insertion of chromosome 11
material into the short arm of chromosome 10 (Figure 2a,b).
Dual-color FISH was performed using YACs 742 f 9 and
856 b 9 covering the MLL gene and YAC 807 b 3 spanning
the MLLT10 gene (Figure 2c). Hybridization signals for MLL
andMLLT10 probes were localized on two regions, one proxi-
mal and one distal on the short arm of chromosome 10. No
signals were observed for MLL on the derivative chromosome
11. Further characterization was done by four-color FISH
using the MLL dual-color probe (Vysis), MLLT10 YAC
807 b 3 and 2 YACs located at 11q14 and 11q21 region,
respectively (Figure 2d). The MLL spanning probes were split:
the probe proximal to MLL and covering the 5′ part of MLL
colocalized with the MLLT10 probe at the centromeric part of
the insertion, whereas the 3′ part of MLL colocalized with the
telomeric MLLT10 signal. One of the two proximal 11q YACs
was inserted into 10p. Triple-color FISH with MLL (Vysis) in
combination with YACs 946 f 4 and 932 f 8, showed that
the 11q14 YAC 946 f 4 was retained on the der(11), whereas
the 11q21 YAC 932 f 8 was inserted into 10p as expected
from the previous in situ hybridization experiment (not
shown). In order to generate the observed FISH data, we
assumed that an inversion of 11q14-q23 with a breakpoint
within the MLL gene occurred, followed by or accompanied
by insertion of a larger part of 11q material (including 3′ MLL)
into MLLT10 (Figure 3a).
Patient 2: Cytogenetic analysis at diagnosis revealed a
Figure 1 Partial G-banded karyogram in patients 1 and 2. Abnor-
mal chromosomes are on the right.
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Figure 2 Selected metaphase spreads of patient 1 (a–d) and patient 2 (e–i) following FISH with chromosome paints and locus speciﬁc probes,
and ﬁber-FISH images of the 10p12 BAC clones (j-k). (a) Insertion of chromosome 11 material (arrowhead) into the derivative chromosome 10
evidenced by co-hybridization of chromosome 10 (green) and chromosome 11 (red) libraries. (b) hybridization with chromosome 11 library
(red) and TYAC95 (green) showed subtelomeric probe retained on the der(10) (arrowhead). (c) Double fusion signal on der(10) (arrowheads) as
evidenced by double-color hybridization of YACs 856 b 9 and 742 f 9 (green) covering MLL and YAC 807 b 3 covering MLLT10, respectively.
(c) Split of MLL spanning probes (red and green are the probes telomeric and centromeric to the MLL breakpoint, respectively) and colocalization
of 5′ and 3′ MLL with MLLT10 YAC 807 b 3 (pink) at the centromeric and telomeric border, respectively, of the inserted 11q segment. YACs
946 f 4 (11q14) and 932 f 8 (11q21) (both in yellow) were present on the normal chromosome 11 and on both der(10) and der(11). (e) Triple-
color FISH with MLL (Vysis) and chromosome 10 library showing the presence of 5′ MLL (green) on the der(11) (arrowhead). (f) Hybridization
of chromosome 10 (green) and chromosome 11 (red) libraries showing an apparent reciprocal rearrangement. (g) Triple-color FISH with MLL
spanning probes (Vysis) (5′ part in green and 3′ part in red) and YAC 807 b 3 covering MLLT10 (yellow) showing fusion of 5′ MLL and MLLT10
at the der(11) (arrowhead). (h) Triple-color FISH with MLL spanning probes (Vysis) and a BAC clone RP11-418C1 located 5′ of the MLLT10
gene and containing part of 5′ MLLT10 (yellow) revealing that RP11-418C1 was translocated to the der(11) (arrowhead). (i) Split of BAC clone
RP11-249M6 (yellow) and colocalization with 5′ part (green) and 3′ part (red) of the MLL spanning probes (Vysis) (arrowheads). (j) Fiber-FISH
image of two partially overlapping clones RP11-177H22 (green) and RP11-418C1 (red), and clone RP11-249M6 (red and green) revealing that
RP11-418C1 and RP11-249M6 are located at either side of RP11-177H22. (k) Fiber-FISH image of two almost completely overlapping clones
RP11-249M6 (red) and RP11-399C16 (red and green), and RP11-177H22 (green). In the bottom image of both ﬁber-FISH ﬁgures, the green and
red ﬂuorescent signal were shifted in a vertical direction to allow more accurate assessment of the size of the overlapping fragments.
del(9)(q12q34) and a t(10;11)(p1213;q23) in all 18 meta-
phases analysed (Figure 1b). FISH with MLL spanning probes
revealed a split signal, with colocalization of the 5′ part of
MLL and MLLT10 YAC 807 b 3 (Figure 2g). FISH with chro-
mosome 10 and 11 libraries demonstrated an apparent
reciprocal translocation (Figure 2f). No involvement of chro-
mosome 9 could be demonstrated by dual-color FISH with
chromosome 9 and 10 speciﬁc libraries (not shown). Triple-
color FISH with a chromosome 10 speciﬁc library and MLL
spanning probes showed translocation of 3′ MLL to chromo-
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Figure 3 Proposed chromosomal mechanism leading to MLL-MLLT10 rearrangement in patients 1 (a) and 2 (b). (a) Inversion of 11q13-q23
with a breakpoint in the MLL gene, followed by an additional break 3′ of MLL prior to insertion of the 11q segment into MLLT10. (b) Paracentric
inversion involving MLLT10 with breakpoints in MLLT10 and immediately centromeric to MLLT10 within BAC clones RP11–249M6 and RP11–
399C16, followed by a reciprocal translocation between 10p12 and MLL at 11q23.
some 10p (Figure 2e). The MLLT10 YAC 807 b 3 was not
split, but entirely translocated and colocalized to the der(11)
5′MLL (Figure 2g). In order to characterize the translocation
in further detail, BAC clones RP11–418C1, RP11–177H22,
RP11–249M6 and RP11–399C16, located in the genomic
contig NT 008895 and covering MLLT10 and sequences
immediately proximal and distal to MLLT10, were tested (see
also Materials and methods). The relative positions of these
clones are indicated at the Human Genome Project working
draft at UCSC (http://genome.ucsc.edu/). Using ﬁber-FISH, we
conﬁrmed the positions as indicated (Figure 2j,k), and esti-
mated the overlap of RP11–418C1 with RP11–177H22 to be
less than 30 kb. RP11–418C1 and RP11–177H22 were trans-
located to the der(11) (Figure 2h). RP11–249M6 and RP11–
399C16 were split and colocalized with 5′ and 3′ part of MLL
dual-color probe (Figure 2i). RP11–251H5 located at
10p11.21 was retained on the der(10) as expected (not
shown). These ﬁndings suggest that this 10;11 rearrangement
resulted from an inversion of 3′ MLLT10 with breakpoints
within MLLT10 and immediately proximal to MLLT10, fol-
lowed by a reciprocal translocation involving MLL at 11q23
(Figure 3b).
RT-PCR, cloning and sequencing
Using primers AF10 pmr 29, AF10 pmr 18, AF10 pmr 41 and
MLL exon5(b), RT-PCR reactions were performed for the
detection of MLL/MLLT10 fusion transcripts, including posi-
tive controls. Using the AF10 pmr 29 and AF10 pmr 18 in
combination with the primer MLL exon5(b), three bands were
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observed on agarose gel for both patients (Figure 4). Cloning
and sequencing of these PCR products showed the presence
of three distinct isoforms for MLL/MLLT10 fusion gene as the
result of alternative splicing. The novel chromosomal break-
point was located at cDNA position 883 (base position corre-
sponding to the Genbank entry for MLLT10 accession number
U13948) in MLLT10 and exon 8 in MLL. The second splice
variant joined MLL exon7 and MLLT10-nt-883. In the third
transcript, which also joined MLL exon7 and MLLT10-nt-883,
exon 6 was spliced out. As expected, RT-PCR analyses for
MLLT10-CALM and CALM-MLLT10 were negative in both
patients.
Discussion
Due to the opposite orientation of MLLT10 and MLL on their
respective chromosome arms, MLL-MLLT10 gene fusion
requires complex rearrangements with three or more breaks.8–10
Similar observations were made for other chromosomal
abnormalities involving genes with opposite orientation,
including EWS-ERG31 and ETV6-ABL.32 For the latter, we
recently described two novel types of chromosomal rearrange-
ments leading to ETV6-ABL fusion.25 Although these complex
rearrangements may be readily visible at the cytogenetic level,
in some instances the chromosomal defect may be subtle or
even cryptic.13,25,33
Using multicolor FISH with locus-speciﬁc probes, we have
investigated the chromosomal nature of two MLL-MLLT10-
positive chromosome 10;11 rearrangements. In the ﬁrst
patient, at least four breakpoints must have occurred in order
to explain the observed FISH results. In this patient, cyto-
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Figure 4 Agarose gel showing the results of the ampliﬁcation of
the MLL-MLLT10 RT-PCR. 100 bp ladder (lane 1), three fragments of
PCR with primers MLL exon5(b) and AF10 pmr 29 in patient 1 (lane
2) and patient 2 (lane 3).
genetic and FISH results demonstrated insertion of 11q
material into 10p. More detailed analysis showed that in a ﬁrst
event an inversion with breakpoint in MLL and a proximal
breakpoint in 11q1421 occurred. As the 3′ MLL part was
present on the inserted 11q− material, we must however
assume that a third breakpoint occurred distal to MLL prior to
insertion of the 11q− segment into 10p12. This rearrangement
resembles the inversion–insertion reported in patient 8 by
Beverloo et al8 and the patient described by Tanabe et al10 In
patient 2, reversed orientation of 3′ part of MLLT10 resulted
from inversion on 10p with breakpoints within MLLT10 and
immediately proximal to MLLT10, followed by a reciprocal
translocation withMLL at 11q23. This alteration resembles the
chromosomal abnormality in patient 4 described by Beverloo
et al.8 This is the ﬁrst report which indicates that the proximal
inversion breakpoint is located immediately centromeric to
MLLT10 at a distance less than 100 kb. The breakpoint region
contains a predictive gene, DNAJL1. It remains to be eluci-
dated whether the same breakpoint region is involved in other
patients with this type of chromosomal rearrangement, leading
to MLL-MLLT10 fusion. Also, possible involvement of DNAJL1
in these rearrangements should be investigated. Cloning of
these breakpoints should also shed light on the mechanisms
leading to these complex chromosomal rearrangements.
Review of the literature yielded 27 patients with MLL
involved in 10;11 rearrangements, of which 20 had MLL-
MLLT10 rearrangement as detectable with FISH or RT-PCR.
In 13 patients, molecular cytogenetic analysis was performed
which provided information concerning the nature of the
chromosomal alteration (Table 1). These rearrangements can
be classiﬁed into four different types of chromosomal
rearrangements. In all types an inversion of the 5′ MLL or 3′
MLLT10 is required in order to allow an in-frame MLL-
MLLT10 fusion. In the ﬁrst two types, an inversion of the 11q−
segment including 5′ MLL is followed by either translocation
with (type 1) or insertion into (type 2) the short arm of chromo-
some 10 at 10p12. In the second two types a similar sequence
occurred but here the orientation of the 3′ MLLT10 segment
is inverted, followed by 11q23− translocation (type 3) or inser-
tion (type 4) (Figure 5). Until now, four 10;11 rearrangements
have been described in which a third chromosome is involved
in the translocation.8,9,14 These translocations could be con-
sidered as either type 1 or type 3 variants (Table 1, cases 3,
6, 9 and 11). The 10;11 rearrangement in patient 1 of this
report could be considered as a variant type 2 rearrangement,
as an additional breakpoint distal to MLL occurred, following
the inversion of 11q and prior to the insertion into MLLT10.
The rearrangement in patient 2 resembles a type 3 rearrange-
ment.
Yet another 10;11 chromosomal rearrangement has been
described by Sinclair et al34 resulting in translocation of the
entire MLL gene to distal 10p (10p15) followed by inversion
with breakpoints at 10p12 and the translocated MLL. This
could possibly be a ﬁfth chromosomal mechanism leading to
MLL-MLLT10. However, the fusion transcript has not been
conﬁrmed by FISH or RT-PCR in this patient.
Although molecular cytogenetic investigations provide
insight into the detailed nature of chromosomal abnormalities,
the mechanisms that trigger the formation of these alterations
remain unclear. For some MLL aberrations, evidence was
obtained that ALU repeat sequences, as well as topoisomerase
cleavage sites and DNase I hypersensitive sites were impli-
cated. It was demonstrated that the genomic breakpoints in
MLL were located preferentially in the 5′ half of the breakpoint
cluster region in de novo leukemia patients, whereas in ther-
apy-related and infant leukemia the break is more frequently
in the 3′ half of the breakpoint region containing the topoiso-
merase cleavage sites.35–39 Molecular analysis of the breakpo-
ints occurring in these 10;11 rearrangements is required to
understand how these complex rearrangements come about.
Only one study thus far reported additional breakpoint analy-
sis.17 FM3 sequences were cloned at the inversion breakpoint
distal to MLLT10 and some homology to the consensus
topoisomerase 2 binding site was found.
RT-PCR analysis for detection of MLL-MLLT10 fusion tran-
scripts revealed a previously unreported MLL-exon-8-MLLT10
fusion and two smaller isoforms due to alternative splicing. A
complex pattern of alternative splicing with exon scrambling
has been reported for the MLL gene in both normal and malig-
nant cells.40–42 Alternative splicing and cryptic splice site acti-
vation during RNA processing of MLL-AF4 chimeric tran-
scripts has been observed.43 Recently, splice variants for MLL-
MLLT10 fusion transcripts were also reported by Angioni et
al.11 Clearly, alternative splicing of the normal MLL gene may
result in increased complexity of the biological function of
MLL and possibly the same holds for the splice variants of the
hybrid transcripts.
In conclusion, multicolor FISH was successfully applied in
the characterization of MLL-MLLT10-positive 10;11 chromo-
somal rearrangements. We described an as yet unreported
chromosomal mechanism, leading to MLL-MLLT10 in-frame
fusion. We also investigated an apparent reciprocal 10;11
rearrangement in further detail and compared our results with
previously reported cases.
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Karyotype Diagnosis Age Type FISH PCR SB Ref.
1 47,XY,inv(11)(q14q23)t(10;11) AML-M5 9 years Type 1 MLL-MLLT10 + + 8,14
(p12;q23),+der(?)t(?;1q)[35]/46, fusion
XY
2 46,XY,inv(11)(q13q23)t(10,11) AML-M5 8 months Type 1 MLL-MLLT10 + + 8,14
(p12;q23),[28]/46,XX[2] fusion
3 46,XX,t(4;15)(q13;q22),inv(11) AML-M5a 6 months Type 1 variant MLL-MLLT10 + + 8,14
(q13q23)t(10;11;21)(p12;q23; fusion
q22)[20]
4 46,XY,t(10;11)(p12;q23)[9]/46, AML-M5 27 years Type 4 MLL-MLLT10 + ND 8,14,17
XY[3] fusion
5 46,XX,del(7)(q22),−10,inv(11) AML-M4 12 years Type 1 MLL-MLLT10 ND ND 8,14
(q13q23)t(10;11)(p12;q23),+der fusion
(10)inv(11)(q13q23)t(10;11)
(p12;q23)[5]/46,idem,add(5)
(q3?)[5]
6 46,XY,t(11;10;9)(q23;p12;q33), AML-M5 27 months Type 3 variant MLL-MLLT10 + + 8,14
add(12)(p13) fusion
7 46,XY,inv(11)(q13q23)t(10;11) AML-M5 41 years Type 1 MLL-MLLT10 + + 8,14
(p12;q23) fusion
8 46,XX,t(1;9)(q11;q34)/46,idem, AML-M5 21 months Type 2 MLL-MLLT10 ND ND 8
ins(10;11)Ip12;q23q13)/46,XX fusion
9 46,XY,inv(11)(q13q23)t(10;11;6) AML-M5 66 years Type 1 variant MLL-MLLT10 ND ND 8
(p12;q23;p23) fusion
10 47,XY,+der(1)t(1;?)(p13;?),inv AML-M5 69 years Type 1 MLL-MLLT10 ND ND 8
(11)(q13q23)t(10;11)(p11.2; fusion
q23)[12]/47,XY,inv(11)(q13q23)
t(10;11)(p11.2;q23),+19[8]
11 46,XY,t(10;11;4)(p12;q23;q26) AML-M5a 9 months Type 3 variant MLL-MLLT10 ND + 9
[8]/idem,add(14)(p13)[35]/46, fusion
XY
12 45,XY,del(1)(p34p36),−9,inv ins AML-M5 2 years Type 2 MLL-MLLT10 + + 12,10
(10;11)(p12;q23q12),t(11;15) fusion
(q13;q2?3)
13 46,XX,del(10)(p14) B-ALL 0 years Type 4 variant MLL-MLLT10 + + 11
fusion
14 46,XX,+der(1;21)(q10;q10),der AML-M4 2 years MLL split + + 16
(5)inv(5)(p15.1q12)ins(5)(q33.1;
q13.3q22)t(10;11)(q12;q23),−21
15 47,XY,der(10)t(10;11)(p12;q23) AML-M5a 8 years MLL split + + 16
inv(11)(q14q23),der(11)t(10;11)
(p12;q13),+?der(?)t(1;?)(q10;?)/
46,XY,der(10)t(10;11)(p12;q23)
inv(11),der(11)t(10;11),der(13)
t(1;13)(q10;q10)
16 46,XY,t(10;11)(p12;q23) AML-M5a 27 years MLL split + ND 16
17 46,XY,t(10;11)(q23;q25) AML-M5 9 years ND + ND 15
18 46,XX AML-M5a 4 months cryptic ND + + 13
19 51,XX,+6,+15,+17,+20,+21 AML-M7 23 months cryptic ND + + 13
20 51,XX,+3,+8,t(10;11)(p?1;q23), AML-M5 49 years ND + ND 14
+der(10),+19,+21
21 46,XX,der(10)(10qter→10p12:: AML-M5a 41 years Type 5 MLL split ND ND 34
11q23→11q23::10p15→10p12::
11q23→11qter),der(11)t(10;11)
(p1?5;q23)
22 46,XY,t(10;11)(p11;q23) AML-M4 3 months MLL split ND + 12
23 47,XX,+8,t(10;11)(p11;q23),del(20) AML-M4/M5 8 months ND ND + 44
(q11q13)
24 46,XX,t(10;11)(p12;q23) AML-M5a 3 months ND ND + 16
25 47,XX,der(1)?ins(1)(p13q2?3?) AML-M5a 3 years MLL split ND ND 16
t(1;11)(q21;q23),+8der(10)ins
(10;11)(p1?q23q2?)der(11)
t(1;11)(q?;q2?)
26 46,XY,t(10;11)(p13;q13) AML-M5 68 years ND ND + 45
27 47,XX,t(10;11)(p13;q23),+8,del AML-M5b 2.3 years cryptic MLL split ND ND 33
(9)(q?21)/47,XX,der(10)t(10;11)
(p13;q23),der(11)t(1;11),+8,del
(9)(q?21)/46,XX,der(7)t(3;7)(?;
p22),t(9;10)(p22;p?15),der(11)
t(10;11)(p13;q23),−13,+22
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Figure 5 Schematic overview of the four different types of MLL-MLLT10-positive chromosomal 10;11 rearrangements represented in the
literature thus far. Type 1 and 2 result from inversion of 11q13q14-q23 involving the MLL locus followed by translocation with or insertion
into 10p12. Type 3 and 4 result from inversion of the MLLT10 locus followed by translocation with or insertion into 11q23.
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Chapter 4: General Discussion
The studies included in this thesis were among the first to illustrate the new important
possibilities, which are offered by M-FISH in the study of genetic aberrations in leukaemia.
Three leukaemic disease entities with complex karyotypic changes were investigated.
Furthermore, the different chromosomal mechanisms leading to gene fusion for partner genes
with opposite orientation were investigated in the t(9;12)(q34;p12) and t(10;11)(p13;q23)
translocations.
PART I: M-FISH in the study of malignant haematological neoplasms with complex chromosomal
changes
M-FISH studies were performed on 36 patients with MDS or AML (paper 1), 8 paediatric patients
with ALL (paper 2) and 2 lymphoma patients with a suspected 9;14 translocation (paper 3).
These studies illustrated the resolving power of M-FISH as it allowed:
1. Identification of particular combinations of recurrent chromosomal changes in patients
with AML or MDS (paper 1)
2. Identification of MLL amplification in patients with AML or MDS with extreme poor
prognosis (paper 1)
3. Identification of hidden/novel chromosome alterations (paper 1,2,3)
4. Detection of recurrent chromosome rearrangements in complex karyotypes (paper 1,2,3)
5. The refinement/correction of translocation breakpoints (paper 1,2,3)
6. Identification of the chromosomal origin of marker chromosomes, additional material in
unbalanced translocations, and amplified material (paper 1,2,3)
As mentioned in the introduction, recurrent translocations have been identified in many
leukaemia disease subentities (Mitelman, 2002). The resulting gene defects can be used in
diagnosis and disease monitoring. Moreover, the discovery of these gene defects has lead in
many cases to detailed understanding of the molecular pathogenesis of these disorders and can
lead to rational targeted therapeutic interventions. Unfortunately, most molecular targets are
presently still unknown in a significant proportion of AML and MDS either because no karyotypic
changes can be found, or due to the presence of complex chromosomal changes. Although, SKY
and M-FISH studies revealed no new recurrent rearrangements in AML and MDS with normal
karyotypes, using the 12 colour FISH assay for telomeric rearrangements (M-TEL) Brown and co-
workers found a possible new recurrent t(5;11)(q35;p15.5) in 2 children with AML and an
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apparently normal karyotype (Brown et al., 2002). Therefore additional studies with adapted
probe sets are required to investigate the possibility of cryptic rearrangements in adults with AML
and MDS and a normal karyotype. Recent studies in this patient group revealed mutations of
FLT3, RAS and TP53 in some of them (Stirewalt et al., 2001), but in other AML and MDS patients
with a normal karyotype the molecular events implicated in the development of the disease
remains unclear.
In paper 1 we provided a detailed insight into the distribution of recurrent chromosome
abnormalities in AML and MDS patients with complex chromosomal changes. The latter are
present in 10 and 30% of de novo AML and MDS, respectively, and in up to 50% of therapy
related AML and MDS (Fenaux et al., 1996; Grimwade et al., 1998).
Genetic studies on AML and MDS with complex karyotypes have focussed on the occurrence and
clinical relevance of particular chromosome changes such as monosomy for chromosome 5 and 7
or partial deletion of the long arms of these two chromosomes, chromosome 3q26
rearrangements and 12p deletions (Ohyashiki et al., 1992; Streubel et al., 1998; Fenaux, 2001;
Grimwade et al., 2001; Schoch et al., 2001). In parallel with our M-FISH study on myeloid
disorders with complex karyotypes, a number of multi-colour analyses on similar but smaller
patient groups were performed (Kakazu et al., 1999; Mohr et al., 2000; Lindvall et al., 2001;
Odero et al., 2001). Observations emerging from all these studies were the overall
underestimation of the complexity of these karyotypes, the observation of hidden chromosome
rearrangements, and the possibility to identify the origin of all marker chromosomes and
additional material present in unbalanced translocations. Furthermore, a significant number of 5q
and 7q deletions were shown to result from unbalanced translocations, whereas presumed
chromosome 5 and chromosome 7 loss appeared to be due to hidden chromosome 5 and 7
rearrangements.
Due to the size of the investigated patient group in our study, we were the first to
describe the particular combinations of cytogenetic aberrations in detail. As expected, -5/5q- was
demonstrated in the majority of the patients (86%). Other major recurrent aberrations, also
observed in the absence of -5/5q- were deletion 7q (42%), 3q21-q26 chromosome aberrations
(22%), and MLL copy gain or amplification (17%). Based upon the presence of one or more of
these four recurrent chromosome changes, all but one patient could be placed into subgroups.
Other rearrangements frequently observed in our study were in order of frequency: del(17p) or
del(17q), del(16q), del(13q) and del(12p). However, these abnormalities were always occurring
in the presence of -5/5q-. Although with current treatment protocols prognosis is poor for
patients of this study group, the recognition of these cytogenetic subgroups may become
relevant in clinical trials for new therapeutic strategies as particular combinations of genetic
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changes may then become treatable and others not. Further studies in future clinical trials are
thus essential in order to assess the prognostic relevance of each of these combinations.
Possibly, these patients may benefit from treatment directed against two or even more genetic
defects (e.g. restoration of the function of tumor suppressor genes on 5q or 7q, and
downregulation of EVI1 or MLL)
One particular cytogenetic subgroup identified in our study was AML or MDS with MLL
amplification. MLL amplification typically resulted from multiple copies on the derivative 11 and
has recently been reported by several other groups (Avet-Loiseau et al., 1999; Kakazu et al.,
1999; Cuthbert et al., 2000; Michaux et al., 2000; Streubel et al., 2000; Andersen et al., 2001;
Lindvall et al., 2001). In view of the frequent involvement of MLL in gene fusions with numerous
partner genes, one could assume that both gain of function of MLL due to these gene fusions or
overexpression of the entire MLL gene as a result of amplification could be directly involved in
leukaemogenesis. As the amplicons are large and contain many genes the possibility of other
genes being co-amplified cannot be excluded. Poppe et al. (submitted) tested expression of
candidate proto-oncogenes on 11q23-24 in MLL amplified leukaemia, and found MLL to be the
single gene significantly expressed in all 11q23 amplified cases. Elevated expression of HOXA9, a
known downstream target of MLL, in MLL amplified leukaemias indicates that the amplified MLL
genes exert their normal biological function, i.e. to sustain expression of their target genes.
Further functional assays should investigate the role of the MLL gene in leukaemia in further
detail.
Interestingly, in three patients, 2 to 4 marker chromosomes derived from chromosome 11
material only, led to MLL copy number gain. The latter chromosome abnormality was reported in
recent studies in combination with other structural abnormalities (Michaux et al., 2000; Andersen
et al., 2001). In a third patient, 3 copies of the 3’ MLL were detected on two der(11), whereas
MLL was absent on the two other der(11). This particular MLL abnormality has not been reported
thus far.
Although the patient group with MLL amplification is very small, survival analysis showed that
these patients compared to those without MLL amplification or copy gain revealed a very short
survival.
Another major result obtained in both M-FISH studies on AML/MDS (paper 1) and ALL (paper 2)
was the identification of novel and cryptic chromosomal rearrangements. We have found 171
rearrangements that were only partially characterised or overlooked by conventional cytogenetics
of which 19 were balanced translocations.
A translocation t(1;8)(p32;q22) in an AML patient was investigated in further detail. The
1p32 breakpoint was located within a BAC clone that contains the 5’ part of the transcription
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factor NFIA. In the BAC clone spanning the 8q22 breakpoint however, no known genes were
present. The NFIA gene belongs to the nuclear factor I (NFI) gene family of site-specific DNA-
binding proteins, which function both in viral DNA replication and in the regulation of gene
expression. In addition, NFI proteins have been associated with a number of oncogenic processes
(Gronostajski, 2000). The NFI family is composed of four members in vertebrates (NFIA, NFIB,
NFIC, and NFIX) (Rupp et al., 1990; Kruse et al., 1991), of which the NFIB gene is a known
translocation partner of the HMGIC gene in human pleomorphic adenomas (Geurts et al., 1998).
In this translocation, the C-terminus of NFIB is fused to HMGIC, and the aberrant fusion product
is expressed in the affected tissue. Although the NFIB fusion is found in only a small percentage
of the tumours, its presence suggests that aberrant expression of this region of NFIB may play a
role in generation of the tumour. We are currently investigating whether the NFIA is upregulated
in this patient using quantitative PCR analysis.
Specific aberrations involving 3q21 or 3q26 were observed in 8 patients with myeloid
neoplasms and complex karyotypes. In three patients, 3q26 rearrangements involved other
chromosomal regions than the recurrent 3q21 breakpoint, including the first example of a half-
cryptic t(3;6)(q26;q25) leading to EVI1 overexpression. Overexpression of the transcription factor
EVI1 is considered to play a key role in the pathogenesis of myeloid leukaemias with 3q26
rearrangements (Nucifora, 1997), and is associated with dysmegakaryopoiesis and extremely
aggressive AML and MDS (Langabeer et al., 2001).
Two novel balanced translocations, a t(14;20)(q32;q12) and a t(7;11)(q35;q24), were
observed in paediatric patients with ALL. The t(7;11)(q35;q24) was observed in a patient with T-
ALL in combination with 4 other chromosome alterations, including a t(1;14)(p32;q11). Although
the latter is a recurrent, albeit rare translocation in T-ALL leading to TCRD-TAL1 rearrangement,
the t(7;11) was further investigated since the 7q35 band is known to harbour the TCRB locus and
thus might be of functional significance. The presence of the recurrent t(1;14) translocation does
not necessarily exclude the functional relevance of the t(7;11). This has been illustrated for e.g.
the t(9;22) which may occur together with other known recurrent translocation such as inv(3)
and t(15;17) (Johansson et al., 2002). FISH analysis confirmed involvement of the TCRB locus.
Activation of gene expression under the influence of the TCRB promotor is a well-known
mechanism in the development of T-ALL. Recently, another cryptic translocation was discovered
in T-ALL, t(5;14)(q35;q32) (Bernard et al., 2001). As in our case, this t(5;14)(q35;q32) could not
be detected by G-banding. Further FISH analysis showed that this translocation was present in 5
out of 23 (22%) children with T-ALL, and could not be detected in B-ALL. Presently we are
investigating possible upregulation of candidate genes located at 11q24 and FISH studies are
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underway to screen a large patients series in order to investigate the frequency of the t(7;11)
rearrangement.
Strengthened by the successes in our AML/MDS and ALL studies, M-FISH was introduced in
routine analysis of haematologic malignancies with complex karyotypes. The usefulness of this
approach was illustrated by the study of two patients with B-cell non-Hodgkin’s lymphoma (B-
NHL) and a complex karyotype. Karyotypic analysis in combination with M-FISH and FISH with
region-specific probes revealed a t(9;14)(p13;q32) with IGH/PAX5 rearrangement in one patient.
In a second patient a complex rearrangement involving chromosomes 1, 3, 9 and 14 resulted in
PAX5/IGH fusion. 9;14 translocations are known to cause PAX5 overexpression due to
juxtaposition of PAX5 to the IGH promotor (Iida et al., 1996; Hamada et al., 1998). The
t(9;14)(p13;q32) has been thus far predominantly observed in lymphoplasmacytoid lymphoma
(LPL) and diffuse large cell lymphoma (DLCL) (Offit et al., 1992; Iida et al., 1999; Ohno et al.,
2000) but has also been detected in single cases of other B-NHL. In order to assess the
frequency of this rearrangement, a sensitive test for detection of IGH/PAX5 rearrangement is
reported. As breakpoints can be located at a considerable distance 5' to PAX5, a simple PCR
approach is not possible. PAX5 overexpression occurs in other B-cell proliferations excluding the
possibility to detect PAX5 (over)expression by RT-PCR, as done for EVI1 rearrangements.
Consequently, in the absence of metaphases or in complex karyotypes masking the t(9;14), the
genetic diagnosis may be difficult. For these reasons we decided to develop a FISH interphase
assay for detection of the t(9;14).
PART II: Chromosomal mechanisms leading to gene fusion for partner genes with opposite
orientation were investigated in the t(9;12)(q34;p12) and t(10;11)(p13;q23)
In the second part of the thesis, multi-colour FISH was used to characterise the complex nature
of the recurrent t(9;12)(q34;p12) and t(10;11)(p13;q23), leading to ETV6/ABL1 and MLL/MLLT10
fusion, respectively. Both fusion products are characterised by opposite orientation of the partner
genes on the respective chromosome arms. Therefore, an in-frame fusion cannot be the result of
a simple reciprocal translocation, but requires complex rearrangements with 3 or more breaks.
The molecular data as well as the clinical observations of our patients were compared with other
reports.
Major findings of these studies were:
1. refined characterisation of the translocation breakpoints and identification of novel
chromosomal mechanisms leading to ETV6/ABL1 and MLL/MLLT10 fusion (paper 4,5)
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2. the evaluation of clinical findings in our patients in combination with those of previously
reported cases suggests an association of an aggressive disease phenotype with
t(9;12)(q34;p12) (paper 4)
3. proposal of four basic chromosomal mechanisms which lead to 10;11 rearrangements
and MLL/MLLT10  fusion, based upon data from this study and published cases (paper 5)
The nature of the chromosomal rearrangements leading to in frame ETV6/ABL1 fusion was
studied in detail in an adult with CML and a 4-year-old boy with ALL. This rare type of gene
fusion has only been reported in six other patients: one patient with ALL (Papadopoulos et al.,
1995), 4 patients with CML (Brunel et al., 1996; Andreasson et al., 1997; Lin et al., 2002) and 1
patient with AML (Golub et al., 1996). The low incidence of these 9;12 rearrangements has been
explained by the opposite orientation of both genes, which require at least three chromosomal
breaks, instead of two for the more common gene fusions. Moreover, as both fusion partners are
located at the subtelomeric ends on their respective chromosome arms, the t(9;12)(q34;p12) can
be easily missed by classical cytogenetic analysis.
The analysis of the two chromosome rearrangements leading to ETV6/ABL1 fusion
events was performed using a multi-colour approach with locus specific probes. Based upon the
molecular cytogenetic findings in the first patient, the formation of the ETV6/ABL1 is explained by
two possible mechanisms, (1) a paracentric inversion of a 9q segment immediately distal to ABL1
exon 2, followed by translocation of the distal part of chromosome 12 (12pter to ETV6 exon 4-5)
and 9qter (distal to ABL1), or (2) insertion of the 5’ part of ETV6 into ABL1, followed by or
coinciding with exchange of the distal ends of 12p and 9q. In the second patient we propose that
the entire ETV6 gene is inserted immediately distal to ABL1, followed by inversion with
breakpoints in ABL1 exon 2 and ETV6 exon 5. Comparison to other cases in literature showed us
that in each case distinct mechanisms lead to a similar gene fusion, the fusion product being
located on either the der(9) or der(12).
The detection of ETV6/ABL1 gene fusion is clearly of prognostic value. In our study we
compared clinical data of the two patients with previously reported cases. Apart from one patient
who underwent allogenic bone marrow transplantation and is still alive, the other patients
presented with a very rapid disease progression and died shortly after diagnosis (this study).
Although the number of patients is still small, these data suggest a more aggressive disease
compared to BCR/ABL1 positive leukaemia.
Investigations of the biological activity of the ETV6/ABL1 and BCR/ABL1 fusion products
revealed that both ETV6 and BCR might play similar roles in the oligomerisation necessary for the
activation of ABL1 (Okuda et al., 1996; Voss et al., 2000). This biological similarity between both
fusion genes is partly reflected in the clinical features of these two patient groups. BCR/ABL1 is
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present in 95% of CML, 20% of adult ALL, and in rare cases of AML. Although the number of
ETV6/ABL1 patients is too small to draw conclusions, a similar distribution of leukaemia types is
observed: 4 patients with CML, 2 patients with ALL, and one patient with AML. Interestingly,
recent studies report that ABL1 tyrosine kinase inhibitor STI571 also strongly inhibits growth of
the ETV6/ABL1 positive cells in vitro (Carroll et al., 1997; Lin et al., 2002). Responses to
treatment were however disappointing in the first ETV6/ABL1 positive CML patient (O’Brien et al.,
2002). Similarly, poor response to therapy has also been reported in single case of Philadelphia-
positive CML. Although the mechanism of resistance in this ETV6/ABL1 positive case is unknown,
the possibility that a higher dose of STI571 is needed, deserves further consideration (Mahon et
al., 2000). Obviously, further studies are required. These observations strengthen the importance
to detect this fusion transcript in BCR/ABL1 negative CML patients.
In this respect the difficulty to detect the 9;12 rearrangements cytogenetically has
already be mentioned. In this study we also showed that FISH with BCR/ABL1 specific probes,
such as the LSI BCR/ABL ES (Vysis) used in routine diagnosis of CML and ALL also may fail to
observe a split of the ABL1 probe in some cases. Indeed, in our two cases, no split of the LSI
ABL/BCR ES probe could be visualised. We suggest that at diagnosis patients with CML that are
negative for BCR/ABL1, should be screened for ETV6/ABL1 using probes spanning both the ETV6
and ABL1 gene. However, RT-PCR screening for the ETV6/ABL1 fusion transcript in 186 adult
ALLs and 30 childhood ALLs was negative, and FISH analysis of 12 Philadelphia-negative CMLs,
22 chronic myeloproliferative disorders, and 33 chronic myelomonocytic leukaemias also revealed
no new cases (Janssen et al., 1995; Nilsson et al., 1998).
Translocations involving the long arm of chromosome 11 (q14-q23) and the short arm of
chromosome 10 (p11-p13) occur in both ALL and AML and result in different gene fusion events.
Chaplin and co-workers originally cloned an MLL-MLLT10 fusion cDNA from a patient with AML
and t(10;11)(p12;q23) (Chaplin et al., 1995). The nature and complexity of these 10;11
rearrangements was first described by Beverloo and co-workers (Beverloo et al., 1995).
MLL/MLLT10 gene fusion most frequently occurs in the AML-M5 morphological subtype
(myelomonocytic leukaemia), but has also been reported in other AML subtypes and ALL (Gore et
al., 2000). A second type of rearrangement is the t(10;11)(p13;q21) which has been shown to
fuse MLLT10 to CALM  in U937, a cell line derived from a diffuse histiocytic lymphoma (Dreyling
et al., 1996). Subsequently, CALM-MLLT10 has been identified in both AML and ALL (Kobayashi
et al., 1997; Dreyling et al., 1998; Kumon et al., 1999; Bohlander et al., 2000; Carlson et al.,
2000; Jones et al., 2001). The t(10;11)(p11.2;q23) was also shown to fuse MLL to ABI1 in one
patient with AML-M4 (Taki et al., 1998). In view of this genetic heterogeneity, RT-PCR and/or
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detailed FISH studies are necessary to discriminate between the specific fusion events present in
each case.
In paper 5, we presented a multi-colour FISH analysis with region specific probes on two patients
with AML-M5 and 10;11 rearrangements leading to MLL/MLLT10  fusion.
Based upon our observations and previously reported cases, we provide a schematic
overview of four possible chromosomal mechanisms leading to MLL/MLLT10 gene fusion. In all
types an inversion of either 5’ MLL at 11q or 3’ MLLT10 at 10p is required, to allow in-frame
fusion. In the first two types, the MLL/MLLT10 fusion gene is located on the der(10) as result of a
translocation (type 1) or insertion (type 2) of the inverted 11q segment. In the other two types, a
similar event occurs, but here the inverted 10p segment is translocated with (type 3) or inserted
(type 4) into 11q23 to form an in-frame MLL/MLLT10 fusion. All MLL/MLLT10 rearrangements
described until now, result from one of these four chromosomal mechanisms or a variant of it. In
our first patient we observed a new chromosomal mechanism that is basically a variant of type 2.
The inversion event on 11q is coincided by another break 3’ of MLL prior to the insertion event.
In the second patient, a 37-year old male, MLL/MLLT10 fusion resulted from a type 3
rearrangement.
Some of these chromosome 10;11 rearrangements are difficult or impossible to detect by
G-banding. Moreover, in type 4, standard FISH analysis with MLL spanning probes will not detect
a split signal. Therefore, RT-PCR screening is necessary at diagnosis.
The study on chromosomal rearrangements leading to gene fusion for genes with opposite
orientation illustrates that alternative and more complex mechanisms can cause formation of
fusion genes. Similar mechanisms may also be involved in the formation of in frame fusion of
genes with similar orientation in the context of complex translocations, i.e. MLL/AF4 and
ETV6/AML1. Using multi-colour FISH analysis, we observed cryptic insertions of AF4 and ETV6 in
combination with complex rearrangements, leading to MLL/AF4 and ETV6/AML1 gene fusions
(paper 2). A similar cryptic MLL/AF4 fusion, as a result of insertion of the 5’ MLL sequences in
chromosome 4q21, has been recently demonstrated, but in this report a normal karyotype was
observed by G-banding (von Bergh et al., 2001). Also insertion of AML1 into ETV6 on 12p13 as in
combination with complex rearrangements has been described (Mathew et al., 2001).
However, to understand the mechanisms that trigger the formation of chromosome
alterations, molecular analysis of the genomic breakpoints is required. Until now, only one study
performed genomic breakpoint analysis at the inversion breakpoint distal to MLLT10, and found
that the cloned FM3 sequences show some homology with topoisomerase 2 binding site (Chaplin
et al., 2001). For other MLL aberrations, evidence was obtained that in addition to topoisomerase
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cleavage sites, ALU repeat sequences and DNase I hypersensitive sites were also implicated
(Broeker et al., 1996; Cimino et al., 1997; Super et al., 1997; Strissel et al., 1998; Strissel et al.,
2000). There is also evidence that some translocations occur due to an inappropriate use of DNA
recombination mechanisms (Finger et al., 1986; Rabbitts et al., 1988). However, for many
chromosomal aberrations involved in leukaemogenesis, the precise mechanisms have not yet
been determined.
In recent years a fascinating evolution of different multi-colour FISH technologies could be
witnessed, each providing new applications in the study and detection of constitutional and
acquired genetic changes. Colour karyotyping techniques hold the potential to facilitate the
identification of chromosomal aberrations without compromising one of the important features of
cytogenetic diagnosis, i.e. the analysis of the entire genome. However, multi-colour FISH will and
should be complemented by other techniques like conventional cytogenetics, CGH, micro-array,
interphase FISH and molecular analyses for the accurate and detailed description of the
karyotype.
Future developments of multi-colour FISH include specific diagnostic interphase probe-sets for
the identification of multiple specific chromosomal translocations in leukaemia and lymphoma.
Moreover, if transferred to 3D-interphase cytogenetics, multi-colour FISH should provide
important new insights into the architectural organisation and dynamics of chromosome structure
as a function of nuclear metabolic activity. In addition, future developments of new microscope
generations and imaging systems could again have a dramatic impact on the way we will analyse
chromosomes in the future.
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Summary
Information concerning presence or absence of particular genetic defects is often useful in the
diagnosis and classification of leukaemias and lymphomas and may offer important prognostic
information. Most often these genetic alterations, e.g. translocations, were first detected upon
classical cytogenetic analysis. Subsequently genes involved in these rearrangements were
identified thus providing the possibility for molecular diagnosis and detection of minimal residual
disease.
Despite this major contribution of cytogenetic analysis in unravelling genetic defects in malignant
cells, this method suffers from limited resolution (~10 Mb), even in good quality metaphases. As
a result, a substantial number of chromosomal aberrations can be overlooked or only partially
characterised. In addition, certain chromosomal aberrations can be masked due to their
involvement in complex rearrangements.
The limitations of classical chromosome studies have been overcome by the introduction of
fluorescence in situ hybridisation (FISH), which offers a molecular dimension to cytogenetic
analysis. Different new FISH technologies have emerged, each with their own particular
advantages and applications, e.g. interphase FISH, comparative genome hybridisation, and fibre-
FISH. Multi-colour FISH, which produces differential staining of all human chromosomes in 24
colours, offers a new level of sensitivity to cytogenetic analysis. In this thesis we described the
successful application of M-FISH as a method to explore the complex nature of particular
chromosomal rearrangements and in the characterisation of complex karyotypes in specific
leukaemia patient subsets.
In a first part of the thesis we used M-FISH in the study of 36 patients with myeloid malignancies
with complex karyotypic changes, 8 childhood acute lymphoblastic leukaemia and in the
characterisation of complex karyotypes of two B-cell non-Hodgkin’s lymphoma patients with a
recurring t(9;14)(p13;q32).
Acute myeloid leukaemia and myelodysplastic syndrome with complex karyotypes are mostly
observed in elderly patients and are associated with a poor outcome. The karyotypic patterns and
key genetic events in these pateints remain to be determined, mainly due to the difficulty to fully
describe these complex karyotypes by G-banding analysis. M-FISH technology was used to clarify
the complex aberrations more precisely and helped us to redefine the patients in subgroups
based on the presence of -5/5q-, -7/7q-, 3q21-26 rearrangements, and MLL copy number gain or
amplification. Extreme short survival times were noted for patients with MLL copy number gain in
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association with -5/5q-. The recognition of these particular genetic subgroups may be of
importance when assessing new therapeutic strategies for these elderly leukaemia patients.   
Using M-FISH, we identified 171 rearrangements of which 19 balanced translocations, that were
partially characterised or overlooked by conventional cytogenetics. One particular balanced
translocation t(1;8)(p32;q22) found in a patient with acute myeloid leukaemia was studied in
further detail using FISH with region-specific probes. The 1p32 breakpoint was located within a
BAC clone that contains the 5’ part of the transcription factor NFIA. Novel reciprocal
translocations that involve genes with known implication in leukaemia are a t(3;6)(q26;q25) in a
patient with acute myeloid leukaemia involving the EVI1 gene, a t(14;20)(q32;q12) and a
t(7;11)(q35;q24) in paediatric patients with acute lymphoblastic leukaemia that involve the IGH
and TCRB  locus, respectively.
Karyotypic analysis in combination with M-FISH and FISH with region-specific probes revealed
9;14 rearrangements in two patients with B-cell non-Hodgkin’s lymphoma (B-NHL) with complex
karyotypes. The t(9;14) is known to cause PAX5 overexpression due to juxtaposition of the PAX5
gene to the IGH locus and is considered as a typical hallmark for lymphoplasmacytic lymphoma
(LPL) and LPL derived large cell diffuse lymphoma (DLCL). Nevertheless, these t(9;14) has also
be detected in  other B-NHL subtypes. The present two cases further support the notion that the
t(9;14) may not be restricted to LPL and LPL derived DLCL. The incidence of the t(9;14) in
various disease entities may be underestimated due to limited possibilities to detect this
rearrangement by molecular methods. Therefore, we also developed a sensitive dual and triple
colour interphase assay for detection of the 9;14 rearrangement.
In a second part of the thesis, multi-colour FISH was used to unravel the complex nature of the
recurring translocations t(9;12)(q34;p12) and t(10;11)(p13;q23). In both translocations, the
genes have opposite orientations on the respective chromosome arms. Therefore, in frame fusion
cannot result from a simple reciprocal translocation. Multi-colour FISH using region-specific
probes, confirmed the complexity of these rearrangements and provided further insights into the
possible chromosomal mechanisms leading to these fusion transcripts.
In conclusion, we clearly illustrated the power of combining cytogenetic, molecular and multi-
colour FISH analysis in the identification and classification of chromosome rearrangements in
hematological malignancies.
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Samenvatting
Het opsporen van genetische afwijkingen is een essentieel onderdeel in de diagnostiek en
classificatie van leukemieën en lymfomen, en is vaak ook van prognostisch belang. Vele van deze
diagnostisch/prognotisch relevante genetische defecten zijn het gevolg van chromosomale
herschikkingen, voornamelijk translocaties, en werden voor het eerst gedetecteerd dankzij
klassiek chromosomenonderzoek. Dankzij de identificatie van de betrokken genen in deze
herschikkingen werd moleculaire diagnose van maligne aandoeningen en de bepaling van de
minimale ziekterest mogelijk en werden belangrijke nieuwe fundamentele inzichten verworven in
normale hematopoïese en leukemogenese.
Ondanks het belang van cytogenetisch onderzoek dient rekening gehouden te worden met de
beperkte resolutie tot 10 Mb, zelfs in goed-gespreide metafasen, waardoor een beduidend aantal
chromosoomherschikkingen kunnen worden gemist. Ook de ontrafeling van de aard van de
herschikkingen in karyotypes met multipele chromosomale afwijkingen is niet sluitend met
klassieke banderingsanalyse.
Fluorescentie in situ hybridisatie (FISH) biedt een moleculaire dimensie aan het cytogenetisch
onderzoek en kan aldus antwoord bieden op bepaalde tekortkomingen van het klassiek
chromosomenonderzoek. Verscheidene nieuwe FISH technologieën zoals interfase FISH,
vergelijkende genoomhybridisatie, en Fiber-FISH werden ontwikkeld, elk met hun specifieke
voordelen en toepassingsmogelijkheden. Meerkleuren FISH geeft een bijkomende gevoeligheid
aan het cytogenetisch onderzoek door alle 24 humane chromosomen differentieel aan te kleuren.
In deze thesis wordt de succesvolle toepassing van M-FISH geïllustreerd in de studie van
complexe chromosoomherschikkingen in specifieke subsets van leukemieen en in de analyse van
de aard van chromosomale herschikkingen die leiden tot fusiegenen uitgaande van genen met
tegengestelde chromosomale oriëntatie.
In het eerste deel van de thesis werd M-FISH toegepast in de studie van 36 volwassenen met
myeloïde aandoeningen met complexe karyotypische herschikkingen, in 8 kinderen met acute
lymfatische leukemie en in complexe chromosomale herschikkingen in twee patiënten met een
non-Hodgkin's lymfoma en een gekende t(9;14)(p13;q32).
Acute myeloïde leukemieën en myelodysplastische syndromen met complexe herschikkingen
worden doorgaans aangetroffen bij oudere patiënten en zijn geassocieerd met ongunstige
prognose. Ten gevolge van de complexiteit van de karyotypes is in tegenstelling tot andere
subtypes in leukemische aandoeningen, de precieze aard van de herschikkingen die causaal zijn
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voor deze aandoeningen slechts gedeeltelijk gekend. M-FISH analyse werd gebruikt om de
complexiteit van deze herschikkingen in detail te beschrijven en hielp ons om deze patiënten te
hergroeperen in subgroepen op basis van de aanwezigheid van -5/5q-, -7/7q-, 3q21-26
herschikkingen, en meerdere copijen of amplificatie van MLL. Bijkomend, werd een significant
slechtere overleving in patiënten met meerdere copijen van MLL in combinatie met -5/5q-
gedetecteerd. Deze herclassificatie van de patiënten op basis van deze subgroepen kan
belangrijk zijn in kader van nieuwe therapieën toegespitst op specifieke chromosomale
herschikkingen.
Dankzij M-FISH konden 171 herschikkingen waaronder 19 gebalanceerde translocaties
geïdentificeerd worden, die onvolledig of niet gedefinieerd werden met klassieke cytogenetica.
Verder onderzoek met regio-specifieke probes van een t(1;8)(p32;q22) in een patiënt met acute
myeloïde leukemie leidde tot de karakterisatie van het 1p32 breukpunt binnen een BAC kloon dat
het 5' einde van de transcriptiefactor NFIA bevat. Niet-eerder gerapporteerde translocaties met
betrokkenheid van leukemie-geassocieerde genen zijn een t(3;6)(q26;q25) in een patiënt met
acute myeloïde leukemie met betrokkenheid van het EVI1 gen, een t(14;20)(q32;q12) en een
t(7;11)(q35;q24) in pediatrische patiënten met acute lymfatische leukemieën met betrokkenheid
van respectievelijk de IGH  en TCRB  locus.
Een combinatie van G-bandering, M-FISH en FISH met regio-specifieke probes leidde tot de
gedetailleerde analyse van een 9;14 herschikking in twee patiënten met B-cel non-Hodgkin’s
lymfoom (B-NHL) met complexe karyotypes. Dergelijke  9;14 translocaties geven aanleiding tot
PAX5 overexpressie door een translocatie van het PAX5 gen naar de IGH locus en wordt
beschouwd als een typische herschikking in lymphoplasmacytair lymfoom (LPL). Nochtans
werden deze 9;14 herschikkingen ook teruggevonden in andere B-NHL subtypes wat bevestigd
wordt door de bevindingen in de door ons gerapporteerde patiënten. Om gevoeligere screening
van de t(9;14) in de diverse B-NHL subentiteiten mogelijk te maken werd een  gevoelige twee-
en driekleuren interfase FISH test ontwikkeld.
In een tweede deel van deze thesis werd meerkleuren FISH gebruikt om de complexiteit van de
gekende translocaties t(9;12)(q34;p12) en t(10;11)(p13;q23) te onderzoeken. Beide translocaties
worden gekarakteriseerd door een tegengestelde oriëntatie van de beide betrokken genen op de
respectievelijke chromosoomarmen, waardoor een 'in-frame' fusie niet het gevolg kan zijn van
een eenvoudige reciproke translocatie. Meerkleuren FISH met regio-specifieke probes bevestigde
de complexiteit van deze herschikkingen en gaf een beter inzicht in de mogelijke chromosomale
mechanismen die leiden tot deze fusietranscripten.
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Samengevat kunnen we stellen dat we geslaagd zijn in ons opzet om M-FISH toe te passen in de
studie van complexe karyotypische herschikkingen in maligne hematologische aandoeningen en
in het ontrafelen van de aard van de herschikkingen die optreden in het ontstaan van ETV6/ABL
en MLL/MLLT10 fusiegenen.
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La recherche d’aberrations génétiques particulières est d’une grande utilité pour le diagnostic et
la classification des leucémies et des lymphomes. Elle constitue souvent un outil pronostique
important. Ces anomalies génétiques ont été détectées pour la première fois en cytogénétique
conventionelle grâce à la mise à jour de remaniements chromosomiques récurrents, par exemple
de translocations. Les gènes impliqués ont pu être ainsi identifiés, fournissant la possibilité d’un
diagnostic moléculaire et d’une détection de la maladie résiduelle et contribuant aux progrès dans
l’élucidation des mécanismes de l’hématopoïèse et de la leucémogenèse
Vu la résolution limitée (environ 10Mb) de la cytogénétique, certains remaniements ne peuvent
être visualisés. Même en utilisant un banding de haute résolution, des réarrangements complexes
peuvent échapper à la détection ou être interprétés erronément.
Les limites de la cytogénétique conventionelle ont été améliorées lors de l’avènement de
l'hybridation in situ fluorescente (FISH), qui offre une dimension moléculaire à l'analyse
cytogénétique. Les techniques de FISH sont nombreuses et ont chacune leurs avantages et
applications propres, telles la FISH interphasique, l'hybridation génomique comparative et la FISH
sur fibres chromatiniennes. La multi-FISH, qui “peint” les chromosomes humains en 24 couleurs
différentes, offre un degré de sensibilité supérieur à l'analyse cytogénétique. Dans cette thèse,
nous décrivons l'application de la multi-FISH pour explorer la nature complexe de remaniements
chromosomiques particuliers et pour caractériser les caryotypes complexes dans des leucémies et
lymphomes humains.
Dans la première partie de la thèse, nous avons appliqué la multi-FISH à 36 patients atteints
d’affections myéloïdes et présentant des aberrations chromosomiques complexes, à 8 enfants
atteints de leucémie lymphoblastique aiguë (ALL) à caryotype complexe ainsi qu’à deux patients
atteints de lymphome non hodgkinien (B-NHL) avec t(9;14)(p13;q32) récurrente. Les leucémies
myéloblastiques aiguës (AML) et les syndromes myélodysplasiques (MDS) avec anomalies
cytogénétiques complexes sont le plus souvent observés chez des patients âgés et ont un
mauvais pronostic. Contrairement à ce qui s’observe dans d’autres sous-types de leucémie, les
mécanismes précis sous-tendant ces remaniements complexes demeurent non élucidés. La multi-
FISH a été appliquée pour clarifier avec précision les anomalies complexes et a permis de
regrouper les patients en différents sous-groupes cytogénétiques, en fonction de la présence de -
5/5q -, de -7/7q -, d'anomalies 3q21-26 et d'amplification ou de copies multiples du gène MLL.
L’existence de copies multiples du MLL en association avec un -5/5q- péjore particulièrement la
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survie. Cette reclassification pourrait être utile et permettre de proposer des thérapies nouvelles
adaptées à chaque aberration chromosomique spécifique.
Grâce à la multi-FISH, nous avons observé 171 anomalies chromosomiques qui avaient été non
détectées ou partiellement caractérisées par l’analyse cytogénétique conventionelle. Parmi celles-
ci, 19 étaient des translocations équilibrées. Nous avons étudié plus en détail la t(1;8)(p32;q22)
observée chez un patient atteint d’AML en appliquant la technique FISH à l’aide de sondes
spécifiques des régions d’intérêt et avons constaté que le point de cassure en 1p32 est situé dans
un clone BAC contenant la partie 5’ du gène de transcription NFIA. De nouvelles translocations
réciproques avec réarrangement de gènes intervenant dans la leucémie sont une t(3;6)(q26;q25)
impliquant le gène EVI1 chez un patient présentant une AML, une t(14;20)(q32;q12) et une
t(7;11)(q35;q24) impliquant les régions contenant respectivement les gènes IGH et TCRB dans
des cas d’ALL pédiatrique.
La combinaison de l'analyse cytogénétique conventionelle, de la multi-FISH et de la FISH avec
des sondes spécifiques de régions d’intérêt s'est avérée utile dans la détection de la translocation
9;14 chez deux patients atteints de B-NHL à caryotype complexe. Cette t(9;14) est associée à
l'hyperexpression de PAX5 résultant de la juxtaposition du gène PAX5 au locus IGH . Elle est
considérée comme marqueur typique de lymphomes lymphoplasmocytaires (LPL) et de
lymphomes diffus à grandes cellules (DLCL) dérivés du LPL. Néanmoins, cette t(9;14) a
également été détectée dans d’autres sous-types de B-NHL. Les deux cas décrits illustrent que la
t(9;14) n’est pas restreinte au LPL ou au DLCL dérivé du LPL. L'incidence de la t(9;14) dans les
diverses entités de lymphome est difficile à établir vu les possibilités limitées de détection
moléculaire. Nous avons donc mis au point une analyse par FISH interphasique en deux et trois
couleurs pour la détection de ce réarrangement.
Dans une deuxième partie de la thèse, la multi-FISH a été utilisée pour préciser la nature
complexe des translocations t(9;12)(q34;p12) et t(10;11)(p13;q23). Les gènes intervenant dans
ces deux translocations ont des orientations opposées sur les bras respectifs des chromosomes.
Par conséquent, la fusion avec maintien du cadre de lecture (in-frame) observée ne peut résulter
d'une simple translocation réciproque. La multi-FISH couplée à la FISH à l’aide de sondes
régionales confirme la complexité de ces changements et mène à une meilleure connaissance des
mécanismes chromosomiques possibles causant ces transcrits de fusion.
En conclusion, nous avons clairement illustré l'importance de combiner l'analyse cytogénétique,
moléculaire et la multi-FISH pour l'identification et pour la classification des remaniements
chromosomiques dans diverses maladies hématologiques.
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